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ABSTRACT 
The presence of flavonoids and isoflavonoids in foods and their addition as bioactives to 
food products can impart unpleasant bitterness. Therefore, debittering strategies are 
demanded. The aim of this research was to identify human bitter receptors (hTAS2Rs) 
sensing (iso)flavonoids and to determine the intrinsic bitterness and structure-activity 
relationships of soy isoflavones, tea catechins and a large set of structurally similar 
(iso)flavonoids by testing for activation of hTAS2Rs in vitro. A subsequent aim was to use 
the bitter receptor assay for investigation of different debittering strategies.  
Out of all 25 human bitter taste receptors, hTAS2R14 and hTAS2R39, were activated 
by soy isoflavones. hTAS2R14 was only activated by isoflavone aglycones, whereas 
hTAS2R39 was activated by isoflavone glucosides as well. Investigation of almost 100 
(iso)flavonoid aglycones for activation of hTAS2R14 and hTAS2R39 revealed that many 
(iso)flavonoids activated these receptors. The structural characteristics for an (iso)flavonoid 
to activate hTAS2R14 and hTAS2R39 were determined by 3D-pharmacophore models to 
be composed of two (for hTAS2R14) or three (for hTAS2R39) hydrogen bond donor sites, 
one hydrogen bond acceptor site, and two aromatic ring structures, of which one had to be 
hydrophobic. Three 6-methoxyflavanones were identified which reduced activation of 
hTAS2R39 by epicatechin gallate (ECG). These bitter receptor blockers were characterized 
as reversible insurmountable antagonists. Furthermore, complexation of epigallocatechin 
gallate (EGCG) with food proteins (mainly β-casein and Na-caseinates) reduced 
hTAS2R39 activation. A trained sensory panel confirmed reduced bitterness perception.  
The systematic investigation of (iso)flavonoid aglycones indicated that the substitution 
pattern of (iso)flavonoids is of higher importance for bitter receptor activation than the 
backbone structure. In case of bitter receptor antagonists, the substitution pattern as well as 
backbone structure revealed to be crucial for functionality. The bitter receptor assay was 
shown to be an appropriate tool not only for identification of bitter receptor agonists and 
antagonists, but also for identification of reduced receptor activation by complexing agents. 
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BITTER TASTE IN RELATION TO DIETARY COMPOUNDS 
Bitter taste in food is mostly disliked by consumers. On the other hand, bitter taste in food 
can be appreciated, as long as it is moderate, in products such as bitter lemon, coffee, beer, 
and dark chocolate (1). Bitter tasting compounds in food are mainly derived from plants 
(e.g. caffeine in coffee, naringin in grapefruit, sinigrin in cabbage, hop bitter acids in beer), 
but they can also occur in products from animal origin (e.g. bitter peptides in cheese), due 
to processing (e.g. the Maillard reaction products such as quinizolate or 
(bis)pyrrolidinohexose reductones) and upon storage (e.g. oxidized lipids) (2-4). In this 
thesis, dietary compounds are defined as compounds naturally present in food raw 
materials, food products, and compounds (natural or synthetic) added to food products. 
Drugs, herbal medicine, and synthetic or natural non-consumable bitter substances are 
considered as non-dietary.  
The biological function of bitter compounds in plants is to protect the plant against 
pathogens, parasites and predators. Especially toxins (e.g. strychnine) are often bitter. 
Therefore, it has been assumed that the ability to taste bitter compounds and rejection of 
bitter taste has long been crucial to survival. However, a correlation between toxicity and 
bitter taste thresholds has not been found (1).  
Numerous natural bitter compounds have been associated with putative health effects. 
Amongst them, isoflavonoids and flavonoids play a central role. Therefore, a trend in food 
product development is the design of functional foods, enriched in (iso)flavonoids. 
However, their incorporation in, or fortification of, foods can introduce or enhance 
bitterness, and, therefore, debittering strategies are demanded. Investigation of bitter taste 
and reduction of bitter taste by sensory tests is laborious and can be influenced by many 
factors. A fast and objective way of investigating bitterness is the measurement of intrinsic 
bitterness on bitter taste receptors by the use of a cell-based assay system. This method 
constitutes an important part of this thesis. 
Intrinsic bitterness is the capacity of a compound to activate a bitter taste receptor, 
uncoupled from other taste qualities (e.g. sweet), senses (e.g. smell), influences (e.g. 
hormone levels) and interactions (e.g. with saliva). Due to its high throughput character, 
many (potentially) bitter compounds (even of non-food quality) can be examined in a bitter 
receptor assay. In this way, sensory panels can be disburdened from tasting many aversive 
compounds, and their services can be minimized to confirm the impact of compounds of 
high interest.  
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STRUCTURAL CLASSIFICATION OF FLAVONOIDS AND ISOFLAVONOIDS 
Flavonoids are ubiquitously occurring secondary plant metabolites that play, besides their 
physiological role in plants as pigment and defence compounds, a role in the human diet 
(5). Isoflavonoids occur almost exclusively in the Leguminosae family (6). Flavonoids and 
isoflavonoids are classified as members of phenolic compounds. The non-(iso)flavonoid 
phenolics are e.g. hydroxycinnamic acids, coumarins, xanthones, stilbenes, ellagitannins, 
and lignans. 
(Iso)flavonoids consist of two aromatic rings, connected via a three-carbon bridge (C6-
C3-C6). In most cases, the three carbon bridge is part of a six member heterocyclic ring, 
including one oxygen atom (pyran ring) (7). In Table 1, an overview of the most important 
dietary (iso)flavonoid subclasses is shown, including their generic numbering pattern. 
(Iso)flavonoids belong to the super family of phenyl benzopyrans (6), and their 
nomenclature is based on the variation of the C-ring, and the connection between B- and C-
rings. The linkage of the B-ring to position 2 of the benzopyran describes the class of 
flavonoids (2-phenyl benzopyrans), whereas a linkage to position 3 describes the class of 
isoflavonoids (3-phenyl benzopyrans). The positions 2 and 3 are accentuated in the first 
structure of Table 1. In literature, isoflavonoids are often referred to as flavonoids, but due 
to their different substitution of the C-rings compared to flavonoids, this classification is 
controversial. In this thesis, a distinction between flavonoids and isoflavonoids is, therefore, 
made. Besides attachment to position 2 or 3, the B-ring can be connected to position 4, a 
class of compounds referred to as neoflavonoids (4-phenyl benzopyrans). Neoflavonoids 
hardly occur in the human diet. Furthermore, there are C6-C3-C6 compounds not containing 
the pyran C-ring, e.g. chalcones and aurones, which are referred to as minor or 
miscellaneous flavonoids. 
The backbone structures are mostly substituted by –OH, -OCH3 and O-glycoside 
groups, but also C-glycoside, prenylation and sulfonation are possible substitutions (5, 8). 
In foods, (iso)flavonoids occur as glycosides (e.g. in many fruits, seeds, and vegetables), as 
aglycones (e.g. in tea and in fermented soy products), or as oligomers (such as 
proanthocyanidins, e.g. in grapes and peanuts). This thesis focusses on the aglycones and 
takes two food products as examples: soybean-derived (Glycine max) products and tea 
(Camellia sinensis).  
1
  
Chapter 1 
 
4 
 
Table 1. Mostly described dietary (iso)flavonoid subclasses, with examples of compounds and their 
sensorial characteristics (combined from (1, 9) and adapted according to (3, 10-20)). n.i. no information 
found (21). 
Subclass Backbone 
structure 
Example Typical food 
source 
Sensorial 
characteristics 
Flavonoids 
Flavone Tangeretin 
Nobiletin 
Luteolin 
Apigenin 
orange juice 
orange juice 
green spices 
green spices 
bitter 
bitter 
n.i. 
n.i. 
Flavonol 
 
Quercetin 
Kaempferol 
Myricetin 
wine, onion 
capers 
wine 
bitter 
n.i. 
bitter 
Flavanone 
 
Naringin 
Eriodictyol 
grapefruit juice 
oregano 
bitter 
tasteless 
Flavanol 
 
Catechin (n=1, R=H) 
Procyanidin B2 (n=2, R=H) 
Epigallocatechin gallate 
(n=1, R=gallic acid) 
wine, chocolate 
wine, chocolate  
tea 
bitter, astringent 
astringent, bitter 
bitter, astringent 
Antho-
cyanidin 
 
Pelargonidin 
Cyanidin-3-O-glycoside 
strawberry 
blackberry 
n.i. 
n.i. 
Isoflavonoids 
Isoflavone 
 
Genistein 
Daidzein 
Biochanin A 
soy products 
soy products 
peanut 
bitter, astringent 
bitter, astringent 
n.i. 
Coumestan 
 
Coumestrol soy products n.i. 
Miscellaneous flavonoids 
Chalcone 
 
Xanthohumol 
Isoliquritigenin 
beer 
licorice 
bitter 
n.i. 
Dihydro-
chalcone 
 
Phloretin 
Neohesperidin-
dihydrochalcone 
apple juice 
artificial 
sweetener in 
chewing gum 
neutral - bitter 
sweet 
n
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PROPERTIES OF (ISO)FLAVONOIDS 
Sensorial effects 
(Iso)flavonoids can produce several sensorial responses, from sweet (dihydrochalcones) to 
astringent (proanthocyanidins, flavanols), and bitter (most subclasses) (9). For flavanols, it 
has been found that their degree of polymerization determines their sensorial properties. 
Monomeric flavanols (catechins) tend to be more bitter than astringent, whereas bitterness 
decreases and astringency increases upon increasing degree of polymerization 
(proanthocyanidins) (12). Sweet and bitter taste result from the activation of taste receptors 
on the tongue, whereas astringency is a puckering, rough or dry sensation in the mouth 
(22), caused by the interaction between phenolic compounds and proline-rich salivary 
proteins. This interaction leads to precipitation of salivary proteins and a loss of lubrication 
in the mouth (23). The mechanism underlying astringency is not fully understood yet. 
Sensory impressions by astringency and bitterness are easily confused and require training 
to be reliably distinguished. The majority of flavonoids with known sensorial properties is 
reported as tasting bitter. Examples of taste properties are given in Table 1. The following 
subchapters will go more into detail about taste, especially bitter taste.  
 
Effects on color and stability 
The name “flavonoids” is derived from the Latin word “flavus”, meaning yellow, due to the 
fact that many flavonoids are yellow. Additionally, flavonoids can be whitish, brownish, 
greenish, orange, red, purple, and blue. The latter three colors are the typical anthocyanin 
colors, which are responsible for the appearance of e.g. red wine and berries. 
Although of minor importance compared to taste, flavonoids can also be involved (24) 
in the stability of a food product, e.g. beer and wine, by changes of color (oxidation) or 
haze formation (interaction of haze-forming proteins and phenolics). 
 
Effects on health 
A large number of publications reports on potential health benefits of flavonoids and 
isoflavonoids. These are e.g. prevention of some cancers, cardiovascular disease, 
menopausal complaints and osteoporosis, and are ascribed to properties such as antioxidant, 
anti-inflammatory, anti-carcinogenic, anti-thrombotic, and binding to the human estrogen 
receptor (5, 9, 25). It should be mentioned that there are also contradictory studies on health 
effects of (iso)flavonoids, and the real effect on health has often not been established yet 
(26). Nevertheless, as the large majority of reports has proposed beneficial health effects of 
(iso)flavonoids, a trend in food product development is the design of functional foods, 
enriched in (iso)flavonoids. 
1
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DIETARY OCCURRENCE OF (ISO)FLAVONOIDS 
Consumption and content in food 
The (iso)flavonoid consumption in several Western countries has been calculated to vary 
between 20 mg / day and 220 mg / day (7, 27-30). Flavanols are often reported to be the 
most consumed flavonoids. The mean dietary intake of isoflavonoids accounts for a few mg 
/ day only in non-Asian countries (7, 31), whereas it can add up to 25-100 mg / day in 
Asian countries (31). 
Three databases list contents of (iso)flavonoids reported for various food sources: (i) 
USDA database for the flavonoid content of selected foods (32), (ii) USDA database for the 
isoflavonoid content of selected foods (33), and (iii) Phenol-Explorer (18-20). Flavonoid 
and isoflavonoid contents in food can vary largely. A complicating factor is the common 
practice to hydrolyze glycosides into aglycones before quantitative analysis (34). Therefore, 
the exact contents of individual (iso)flavonoid glycosides and aglycones are often not 
known. 
Soy products and tea are given as examples for the dietary occurrence of 
(iso)flavonoids in food products rich in aglycones. 
 
Soy 
In Western markets, soybean products have, despite their claimed health-promoting effects 
(35), limited acceptance due to undesirable tastes (1). Besides astringency and beany flavor, 
bitterness is regarded as one of the key off-tastes, probably evoked by the presence of 
isoflavones and saponins (36). It is unknown which of the two classes has the highest 
contribution to soy off-taste. Nevertheless, this thesis focusses on isoflavones. Furthermore, 
several soybean-derived peptides and oxidized fatty acids can taste bitter, but as they are 
usually removed during soy food production they are not considered important for bitter 
taste in soy products (1). Twelve different isoflavones (Table 2) commonly occur in 
soybeans and soybean-derived products (37). The composition of isoflavone forms depends 
on cultivar, growth conditions, and processing method (38-40). Examples of isoflavone 
compositions in unprocessed soybeans and soy products are shown in Figures 1 and 2. 
Commonly, genistein forms are most abundant in soybeans, followed by daidzein and 
glycitein forms (37, 40). Malonyl glucosides and unsubstituted glucosides are the 
predominant form in unprocessed soybeans, whereas acetyl glucosides and aglycones are 
present in very small amounts (37) (Figure 1). Processing can lead to the conversion of 
malonyl glucosides into acetyl glucosides (decarboxylation upon dry heating) and 
unsubstituted glucosides (mainly due to deesterification upon moist heating) (40, 41). 
During soaking of soybeans, aglycone formation is started due to action of β-glucosidases 
(prior to heating). Fermentation strongly increases the amount of aglycones (41). The 
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effects of processing are reflected in the change of isoflavone composition, as shown for 
selected soybean products in Figure 2. In literature, isoflavone aglycones (1, 36, 42), 
glucosides (36, 42), and malonyl glucosides (43) have been reported as bitter. Contradictory 
observations have been made about the taste of the aglycones genistein and daidzein and 
their glucosides genistin and daidzin. Whereas converting isoflavones enzymatically into 
their aglycones has been suggested as method to reduce bitterness and astringency by one 
author (44), another author reported an increased objectionable taste after β-glucosidase 
treatment, caused by aglycones (45). An objective tool to determine the intrinsic bitterness 
of isoflavones is needed to identify the target molecules for modifying bitter taste of soy 
products. 
 
Table 2. Generic structure of soy isoflavones. 
 
Isoflavone 
aglycones 
Unsubstituted 
isoflavone 
glucosides 
Acetyl 
isoflavone 
glucosides 
Malonyl 
isoflavone 
glucosides 
mainly 
obtained after 
fermentation 
native / formed 
upon moist 
heating 
formed 
upon dry 
heating 
native 
R1 = OH R2 = H Genistein Genistin Acetyl 
genistin 
Malonyl 
genistin 
R1 = H R2 = H Daidzein Daidzin Acetyl 
daidzin 
Malonyl 
daidzin 
R1 = H R2 = OCH3 Glycitein Glycitin Acetyl 
glycitin 
Malonyl 
glycitin 
 
 
Figure 1. Composition of isoflavone forms in unprocessed soybeans (adapted from (37)). 
 
1
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Figure 2. Composition of isoflavone forms in soy products (adapted from (46)). 
 
Tea 
Another example of a food product rich in flavonoids, and known for its bitter taste, is tea. 
In contrast to many other flavonoid-rich food products, flavonoids in green tea occur 
mainly in their aglycone forms. Green tea (unfermented) contains higher concentrations of 
catechins than oolong tea (semi-fermented) or black tea (fermented), and is also reported as 
the most bitter tasting tea (1). In total (on a dry weight basis), green tea consists of 30-42 % 
(w/w) phenolic compounds (47). Amongst them, the largest group consists of catechins 
(Figure 3), whereas smaller amounts of phenolic acids (e.g. 5-galloylquinic acid and 5-
caffeoylquinic acid) and flavonol glycosides (e.g. quercetin 3-O-rutinoside and kaempferol 
3-O-glucoside) are present. The compositions of phenolic compounds, flavanols in 
particular, in green tea is illustrated in Figure 4. Besides phenolic compounds, tea contains 
also the bitter alkaloids theobromine and caffeine (3-4 % w/w). During fermentation into 
oolong and black tea, a large number of different structures are formed upon oxidation of 
flavanols, resulting in thearubigins, theaflavins, and others. The exact composition of the 
high molecular weight compounds, thearubigins in particular, and their molecular structures 
are largely unknown (47, 48).  
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The flavanols in tea are commoly referred to as “catechins”. They consist mainly of the 
stereoisomers catechin (C) and epicatechin (EC), gallocatechin (GC) and epigallocatechin 
(EGC), and the galloylated epicatechin gallate (ECG) and epigallocatechin gallate (EGCG) 
(see Figure 3). With respect to their taste properties, they are known as bitter and 
astringent, the latter being less pronounced (12). Epicatechin is reported as more bitter than 
catechin (49), and the galloylated catechins ECG and EGCG are perceived as most bitter 
(11). The oxidation products theaflavins and thearubigins are to a large extent not 
commercially available, and their taste properties are not well-established. 
 
 
Figure 3. Structures of most abundant catechins in green tea (from (50)). 
 
 
Figure 4. Example of composition of phenolic compounds in green tea (adapted from (47, 50)). 
 
OHO
OH
OH
OH
OH
(+)-Catechin
(C)
(-)-Gallocatechin
(GC)
(-)-Epicatechin
(EC)
(-)-Epigallocatechin
(EGC)
(-)-Epigallocatechin gallate
(EGCG)
(-)-Epicatechin gallate
(ECG)
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TASTE RECEPTORS 
Taste perception 
The perception of food is to a large extent determined by its taste, but actually it results 
from a combination of all sensory senses: smell, taste, vision (e.g. color, appearance), touch 
(e.g. texture, temperature, pain, astringency), and even sound (e.g. breaking of textures). 
Interactions which may happen between senses are called “cross-modal interactions”, 
finally leading to the overall sensory perception (51). In this thesis, the focus lays 
exclusively on taste. 
There are five basic tastes: sweet, salty, sour, bitter, and umami. Debate is still ongoing 
regarding possible fat receptors. The function of taste is probably the evaluation of the 
nutritional content of food (sweet: carbohydrates, salt: minerals, umami: proteins), but it 
also acts as warning system against spoilage and toxicity (sour and bitter). Furthermore, it 
has an important role in creating enjoyment during food consumption (52). Taste is 
perceived via taste receptors activated by non-volatile compounds. These taste receptors are 
located on the surface of taste receptor cells, embedded in taste buds. A taste bud can 
contain taste receptor cells for all five taste qualities. Taste buds are located mainly in the 
papillae on the tongue, but also in other tissues of the mouth and throat. Sweet, bitter and 
umami receptors belong to the group of so-called G-protein coupled receptors (GPCRs), 
also known as seven-transmembrane domain receptors, whereas salt and sour receptors are 
ion channels (52). 
 
Bitter taste receptors 
In 2000, two research groups discovered bitter taste receptors in human and mouse (53-55). 
They were first called T2Rs (53), TRBs (55), or TAS2Rs (56). Recently, the Gene 
Nomenclature Committee of the Human Genome Organization (HUGO) adapted the human 
TAS2R nomenclature (57). Human bitter taste receptor genes comprise of ~ 25 full length 
members (58). Surprisingly, bitter taste receptors have not only been identified in oral 
tissues, but also in e.g. the respiratory system and the gastrointestinal tract. Their functions 
are not fully understood yet. Instead of contribution to taste perception, they might play a 
role in digestion and metabolism (gastrointestinal tract) and act as a warning system for 
inhalation of harmful substances (respiratory system) (59). 
The signal transduction mechanisms of bitter receptors, belonging to the GPCR family, 
have been characterized as follows. Upon activation of a bitter receptor by a bitter 
compound, heterotrimeric G-proteins, consisting of Gαgustducin, Gβ3 (or Gβ1), and Gγ13, 
couple to the receptor (60, 61). Subsequently, the G-proteins dissociate into Gαgustducin and 
the Gβγ-subunit. Two pathways (αgustducin-PDE- pathway and βγ-PLC-β2-IP3/DAG pathway) 
are described (Figure 5), which lead to the elevation of intracellular calcium levels, the  
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Figure 5. Proposed signal transduction mechanism in bitter receptor cells (adapted from (62, 65)). 
 
depolarization of the taste cell, and finally neurotransmitter release (62). In detail, the Gβγ-
subunit activates phospholipase Cβ2 (PLC-β2) (63), which cleaves phosphoinositol 
biphosphate (PIP2) into inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 
provokes the release of Ca2+ from the endoplasmatic reticulum (ER) into the cytoplasm 
(64). The other pathway via αgustducin-PDE is not entirely clear yet. Gαgustducin stimulates 
phosphodiesterase (PDE) to reduce the cyclic adenosine monophosphate (cAMP) levels. 
The decreased cAMP concentration may disinhibit cyclic nucleotide-inhibited (cNMP) 
channels and result in elevation of intracellular Ca2+ (62). Another suggested mechanism is 
that the decreased cAMP concentration leads to low activity of cAMP-dependent protein 
kinase (PKA). High PKA levels might lead to chronic inhibition of Ca2+ release. The role of 
αgustducin might thus be to maintain cAMP levels low to ensure adequate Ca2+ signaling (65). 
Ca2+ triggers the opening of the TRPM5 channel, influx of cations, resulting in taste cell 
depolarization, and subsequently neurotransmitter release, that activates the taste nerves, 
finally giving a signal to the brain (62, 66). 
 
Cell-based bitter receptor assays 
Native taste receptor cells from the human oral tissue are difficult to culture longer than a 
few days, and it is challenging to obtain large amounts of human material. Therefore, 
1
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heterologous expression systems in easy maintainable cells are used to study response of 
bitter receptors towards bitter tastants. To this end, almost exclusively human embryonic 
kidney (HEK)293 cells are used. As the native taste receptor specific G-proteins are lacking 
in HEK293 cells, an easy-measurable readout system was created by co-expression of one 
of the hTAS2Rs and Gα15 (54). This Gα subunit has been shown to couple to a wide range 
of receptors and can activate a Ca2+ signaling pathway (54, 67). Intracellular Ca2+ release is 
easily detectable by calcium-sensitive dyes in combination with fluorescence 
measurements. Gα15 was used in the early hTAS2R studies (54, 56), but later on, the 
sensitivity of the bitter receptor assay has been increased by the use of Gα16, containing the 
last 44 amino acids of the native Gαgustducin (68). An alternative way to measure bitter 
receptor activation has been reported for bitter receptors expressed in Spodoptera 
frugiperda SF9 insect membranes, measuring guanosine 5’-O-(gamma-thio)-triphosphate 
(GTPγS)-binding to α-gustducin (or its homolog, transducin) (54, 69). Despite the 
advantage of a higher resemblance to the transduction mechanism in native cells, the latter 
approach has the disadvantage of being a low throughput method. Hence the majority of 
bitter receptor studies have been conducted in the HEK293 Gα16gust44 system. 
For cell-based bitter receptor assays in HEK293 cells, stably expressing Gα16gust44, 
transient (70) as well as stable (71) expression of the hTAS2R gene has been reported. For 
this, HEK293 T cells and HEK293 T-REx Flp-In cells are used, respectively. With transient 
(temporary) transfection the receptor DNA is temporarily expressed. As most of the DNA 
is not integrated into the cell genome, it is degraded within a few days. Therefore, transient 
transfection is merely useful for rapid analysis or when only a few experiments are 
performed. On the other hand, stable cell lines, in which the receptor gene is stably 
integrated into the cell genome, are more practical for frequent analyses. They have the 
advantage that transfection only needs to be performed once and the expression level of the 
gene is constant over time. An accompanying advantage of the Flp-In system is that the 
integration side of the integrated gene is always the same, due to targeted recombination. In 
Figure 6, a simplified scheme of a bitter receptor assay in stable cell lines is shown. The 
DNA of the respective hTAS2R is integrated in the cell nucleus (in Figure 6 indicated in 
blue) and the receptor expression is induced by the addition of doxycycline. After 
incubation with calcium sensitive fluorescent dye, the bitter molecules are added. Upon 
activation of the bitter receptor, the heterotrimeric G-proteins couple to the receptor. 
Subsequently, the G-proteins dissociate into Gα16 and the Gβγ-subunit, which starts the 
signaling cascade resulting in intracellular calcium release. Due to the presence of a 
calcium-sensitive fluorescent dye, receptor activation can be recorded as fluorescent signal 
in a fluorescence plate reader. In order to establish dose-response behavior of a bitter 
receptor agonist, the activation of the respective hTAS2R is measured at different 
concentrations of the bitter compound. The maximum signal of activation for each 
concentration is subsequently plotted in a sigmoidal dose-response curve, from which  
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Figure 6. Simplified bitter taste receptor cell-assay, stably expressing the hTAS2R gene (partially 
adapted from (72)). 
 
 
1
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receptor activation threshold, half maximal activation concentration (EC50) and maximal 
receptor activation by the respective agonist can be obtained. 
 
Characteristics of bitter taste receptors 
Bitter receptors are the most diverse amongst the family of taste receptors. They can 
recognize structurally very diverse bitter compounds (e.g. salts, peptides, lactones, phenolic 
compounds, terpenes, alkaloids). Native bitter taste receptor cells can express multiple 
hTAS2Rs (73), and it has been shown, that they are able to form oligomers in HEK cells 
(74). However, no functional consequences seemed to result from this ability, and using 
single hTAS2Rs in HEK cells in order to identify agonists seems to be appropriate.  
Bitter receptors are seven-transmembrane receptors, as they contain seven α-helices 
passing through the cell membrane. Besides the seven transmembrane (TM) regions, they 
comprise of three extracellular loops (EL) and three intracellular loops (IL). Amongst the 
25 hTAS2Rs, the lengths of the loops, extracellular N-termini, and intracellular C-termini 
are quite variable (75). Figure 7 shows a snake plot of a generic bitter taste receptor. Most 
literature suggests the presence of a single ligand binding site. This binding pocket is most 
probably located within the transmembrane-region (76-81). Predicted or experimentally 
confirmed amino acid residues involved in agonist interaction are accumulated in TM III, 
VI, and VII (76). However, a possible influence of EL1 and EL2 in agonist selectivity has  
 
 
Figure 7. Snake plot of a generic hTAS2R. Amino acid positions involved in agonist interaction in the 
receptors hTAS2R1 (81, 82), -16 (77, 83), -30 (69), -38 (79), and -46 (78) are indicated by colors (red, 
predicted in four receptors, green, two hits, blue, one hit.) (adapted from (76)).  
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been reported as well (69, 80). So far, information on amino acid residues involved in 
ligand binding is limited to hTAS2R1, -16, -30, -31, -38, -43, and -46. 
A state-of-the-art overview of hTASRs and examples of their agonists, divided into 
dietary and non-dietary origin, is given in Table 3. Some bitter receptors are broadly tuned, 
meaning that they are activated by several classes of compounds (hTAS2R1, -4, -10, -14,    
-39, and -46), whereas others have, so far, a very limited agonist spectrum of one or two 
agonists only (hTAS2R3, -13, -41, -49, and -50). Two bitter taste receptors, hTAS2R16 and 
hTAS2R38, seem to respond quite specifically to almost exclusively one kind of chemical 
structure (mainly β-glucopyranosides for hTAS2R16 and mainly sulfur-containing 
compounds for hTAS2R38) (56, 84, 85). For some bitter receptors (hTAS2R3, -9, -13, -20, 
and -41), only non-dietary agonists have been identified so far. For four hTAS2Rs, no 
agonists have been identified yet. Such receptors are called “orphan receptors”. Also, not 
all compounds known as bitter have been assigned to hTAS2Rs yet, but the progress in the 
last years is enormous. In Figure 8 this progress is illustrated, showing that e.g. only half of 
all human bitter receptors were deorphanized in the beginning of this Ph.D. research (May 
2009), whereas at the time of writing (August 2013), only four receptors were not assigned 
to bitter compounds yet. Especially the number of compounds identified as agonists has 
risen enormously. 
The compounds known as most intensely bitter are the synthetic compound denatonium 
(86) and the natural compound amarogentin (87). Not only obviously bitter compounds are 
hTAS2R agonists. The sweet compounds acesulfame K, saccharin, and steviol glycosides 
exhibit bitter after taste. This observation has been explained by the identification of bitter 
receptors activated by these sweeteners (88, 89).  
Furthermore, in bitter receptors, a considerable number of single-nucleotide 
polymorphisms (SNPs) is known. The most prominent example is hTAS2R38, in which 
SNPs lead to “taster” and “non-taster” phenotypes. “Tasters” perceive 6-n-propylthiouracil 
(PROP) and phenylthiocarbamide (PTC) as bitter, whereas “non-tasters” do not. Likewise, 
at receptor level, the hTAS2R38-PAV (taster) variant is activated by both substances, 
whereas the hTAS2R38-AVI (non-taster) variant is not (84). This example shows also that 
in vitro measurements of bitter receptors expressed in HEK cells can resemble in vivo 
situations. Remarkably, the ratio of “tasters” versus “non-tasters” based on hTAS2R38 
polymorphisms in the human population is approximately 50 % / 50 %, though with 
regional differences (90). In contrast, for some other receptors, e.g. hTAS2R14, SNP ratios 
of 99 % / 1% in the human population are reported (75), and functional SNPs are unknown 
(91). Besides the SNP variants, also the density of taste buds seems to play a role in 
bitterness sensitivity (92).  
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Table 3. Overview of bitter taste receptors with examples of their respective agonists. Recently changed 
former receptor names and references are given in parentheses. 
Bitter 
receptor 
Example of agonist 
non-dietary 
Example of agonist 
dietary 
hTAS2R1 
 
Dextromethorphan (85) 
Tyr-Pro-Phe-Pro-Gly-Pro-Ile-His-Asn-Ser 
 
 
(93) 
hTAS2R3 
 
Chloroquine (85) unknown 
hTAS2R4 
 
Azathioprine (85) 
 
Stevioside (89) 
hTAS2R5 
 
1,10-Phenantroline (85) 
 
β-1,2,3,4,6-Penta-O-galloyl-D-
glucopyranose (94) 
hTAS2R7 
 
Papaverine (95) 
 
Caffeine (85) 
hTAS2R8 
 
Parthenolide (85) 
 
Saccharin (95) 
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Bitter 
receptor 
Example of agonist 
non-dietary 
Example of agonist 
dietary 
hTAS2R9 
 
Ofloxacin (96) unknown 
hTAS2R10 
 
Strychnine (56) 
 
 
Coumarin (85) 
hTAS2R13 
 
Diphenidol (85) unknown 
hTAS2R14 
 
 
1-Naphthoic acid (70) 
 
cis-Isohumulone (97) 
hTAS2R16 
 
Amygdalin (56) 
 
Arbutin (56) 
hTAS2R19 
(hTAS2R48) unknown unknown 
hTAS2R20 
(hTAS2R49) 
 
Cromolyn (85) unknown 
hTAS2R30 
(hTAS2R47) 
 
Denatonium benzoate (69) 
 
Quassin (85) 
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Bitter 
receptor 
Example of agonist 
non-dietary 
Example of agonist 
dietary 
hTAS2R31 
(hTAS2R44) 
 
Famotidine (85) 
 
Acesulfame K (88) 
hTAS2R38 
 
 
Phenylthiocarbamide (PTC) (84) 
 
Sinigrin (85) 
hTAS2R39 
 
Colchicine (85) 
 
 
Thiamine (85) 
hTAS2R40 
 
 
Dapsone (85) 
 
Cohumulone (97) 
hTAS2R41 
 
Chloramphenicol (98) unknown 
hTAS2R42 unknown unknown 
hTAS2R43 
 
Aristolochic acid (88) 
 
Aloin (99) 
hTAS2R45 unknown unknown 
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Bitter 
receptor 
Example of agonist 
non-dietary 
Example of agonist 
dietary 
hTAS2R46 
 
Artemisinin (100) 
 
Quinine (85) 
hTAS2R50 
 
Andrographolide (101) 
 
Amarogentin (101) 
hTAS2R60 unknown unknown 
 
Structure-activity relationships of bitter compounds that activate hTAS2Rs 
The correlation between the chemical structure of a compound and its biological activity is 
generally described as structure-activity relationship. The analysis of structure-activity 
relationships leads to the identification of chemical groups responsible for the activity of 
the compound. As bitter compounds can be very variable in structure, it is difficult to 
identify general molecular characteristics responsible for bitterness. It was reported that 
bitter compounds require one polar group and one hydrophobic group, and that the 
threshold of bitter compounds depended on the apolar moiety, but were also related to steric 
factors and charge distribution within the molecule (87). However, it has been shown that 
small structural variations can lead to large changes in activity, e.g. the amino acid L-
phenylalanin tastes bitter whereas D-phenylalanin tastes sweet, and isosakuranetin-7-O-
rutinoside tastes neutral, whereas isosakuranetin-7-O-neohesperidoside tastes bitter (3). At 
the receptor level, few studies have investigated structure-activity relationships. It has been 
shown that hTAS2R16 was activated by various β-glucopyranosides (hydrophobic residue 
attached to glucose by a β-glycosidic bond), but not by the corresponding α-
glucopyranosides or β-galactopyranosides. The potency of receptor activation was 
influenced by the hydrophobicity of the residue (56). Furthermore, steviol glycosides were 
identified as agonists of hTAS2R4 and hTAS2R14. They showed higher sensitivity towards 
hTAS2R4, and it was investigated that the length of the sugar chain, pyranose substitution, 
and the C16 double bond determined the taste of steviol glycosides (89). For most bitter 
receptors agonists, structure-activity relationships have not been investigated yet. 
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Figure 8. Number of ligands reported per hTAS2R (54, 56, 69-71, 80, 83-85, 88, 89, 93-110) in May 
2009 and August 2013. The dendrogram (top) illustrates the sequence relationship within the hTAS2R 
family (adapted from (76)). 
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REDUCTION OF BITTER TASTE 
Strategies for masking or reduction of bitter taste 
For the majority of bitter tasting food products, efforts have been made to either reduce the 
level of bitter tasting compounds or to mask the bitter taste. In vegetables, for example, 
selective breeding has been applied for a long time, leading to e.g. Brussels sprouts 
varieties, which have low bitterness (1). Besides traditionally bitter food products, there are 
also products in which bitterness is a newly introduced problem. These are either functional 
foods, fortified with health promoting, but bitter, ingredients, or they are low-sugar / low-
fat / low-salt products, developed due to health concerns in the context of overweight, 
diabetes, and cardiovascular disease. The reduced amount of sugar, fat, and / or salt can 
lead to the perception of previously masked, undesired taste properties (sour, bitter, 
astringent) (72). Designing healthier products while maintaining consumer acceptability 
has, therefore, become an important challenge. 
 
Table 4. Overview of bitterness reduction methods (partially adapted from (72)). 
Bitterness reducing method Description Examples 
removal / reduction of bitter 
compounds 
selective breeding 
 
reduction of sinigrin in Brassica 
vegetables (111) 
 physical removal (filters, resins, 
solvents, precipitation) 
fining of wine with gelatins (112) 
 conversion (enzymes, 
microorganisms, cooking) 
enzymatic deglycosylation of 
naringin (113) 
addition of tastants / flavors masking effect (salts, sugars, 
acids, strong or co-congruent 
flavors) 
reduced bitter perception of 
pharmaceuticals by sodium, 
glutamate and AMP (114) 
encapsulation of bitter 
compounds 
physical barrier surrounding the 
molecule 
encapsulation of poly-phenols 
with maltodextrins by spray-
drying (115) 
complexation of bitter 
compounds 
molecular complexation debittering of tea extract 
polyphenols by addition of 
casein (116) 
 molecular inclusion elimination of bitter taste of milk 
casein hydrolysates by β-
cyclodextrins (117) 
blocking of bitter receptors full antagonism (4-(2,2,3-trimethylcyclo-
pentyl)butanoic acid blocks 
activation of hTAS2R31 (109) 
 partial agonism 3β-hydroxypeleolide reduces 
activation of hTAS2R46 (103) 
 
An overview of bitterness reduction strategies is given in Table 4. Besides application 
in foods, many strategies are used in the pharmaceutical industry. The choice of methods 
often depends on whether the compounds causing bitterness are naturally present in the 
1
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food product or are added. The taste of health promoting ingredients should be masked, 
because removal would also remove their potential health benefits. Methods such as 
encapsulation of compounds by spray drying are not applicable when the bitter compounds 
are already present in the food raw material. Often, a combination of methods has to be 
used to eliminate bitter taste. 
 
Complexation of bitter compounds 
A molecular complex is formed by loose association involving two or more molecules. The 
bonding between the components of a complex is of a reversible nature and weaker than a 
covalent bond (118).  
One form of complexation applied in pharmaceutical and food industry is molecular 
inclusion by cyclodextrins (117). It is used in order to reduce unpleasant tastes or smells, or 
to enhance the water solubility of hydrophobic compounds. Cyclodextrins represent a 
family of cyclic oligosaccharides, consisting of glucose units bound through α-(1,4) 
linkages. α-, β-, and γ-cyclodextrins are composed of 6, 7, and 8 units, respectively (119). 
They form a cylinder-shaped structure (host), comprising of a hydrophilic outer surface and 
a hydrophobic cavity. This cavity can include a (hydrophobic) guest molecule, mostly by a 
host:guest ratio of 1:1, providing that the guest molecule fits geometrically into the cavity 
(117). In food applications, cyclodextrins are most often used as β-form. They have been 
shown to mask bitter taste of various dietary compounds, e.g. protein hydrolysates, 
vitamins and phenolic compounds (117, 119). 
Another form of complexation makes use of the interactions between proteins and 
phenolic compounds. Complex formation between proteins and phenolic compounds is 
mainly driven by hydrophobic interactions and hydrogen bonding. Hydrophobic 
interactions occur primarily between apolar amino acid residues (mainly proline) and the 
aromatic rings of phenolic compounds. Hydrogen bonds are formed between the amine or 
carbonyl groups of amino acid residues and the hydroxyl groups of phenolic compounds 
(120). The formation and stability of a protein-phenolic complex is largely determined by 
the accessibility of proline residues as well as the structural properties of phenolic 
compounds. Proteins having open structures favor binding to phenolics, in contrast to 
proteins having globular structures. With respect to phenolic compounds, conformation, 
flexibility, galloylation and degree of polymerization have been shown to be important 
drivers of protein-phenolic interactions (121).  
 
Reduction of bitter taste by receptor blockers 
One of the newest approaches to reduce bitter taste is the use of so-called bitter receptor 
blockers. These are antagonists of the bitter taste receptor, which inhibit receptor activation 
by the bitter compound. A simplified mechanism of receptor blocking is shown in Figure 
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9. When the bitter receptor blocker occupies the binding pocket, the bitter receptor is not 
activated and the signaling cascade resulting in intracellular calcium release is not started. 
To our knowledge, it is not known whether the G-protein binds to the receptor in presence 
of a blocker in the binding pocket. In order to establish the dose-response behavior of a 
bitter receptor blocker, the activation of the respective hTAS2R is measured at constant 
agonist and various antagonist concentrations. Based on the fluorescent signals, a dose-
response curve of receptor inhibition is plotted, from which a half maximal inhibitory 
concentration (IC50) can be calculated. 
 
 
Figure 9. Simplified mechanism of bitter taste receptor activation and blocking. 
 
The first hTAS2R antagonist was published in 2010 (109). The small molecule (4-
(2,2,3-trimethylcyclopentyl)butanoic acid (also denoted as GIV 3727) was reported as 
inhibitor of hTAS2R31, and was also able to inhibit three other taste receptors in a dose-
dependent way (hTAS2R4, hTAS2R40, and hTAS2R43). Additionally to blocking of the 
receptor response, this compound effectively reduced the bitter aftertaste of artificial 
sweeteners acesulfame K and saccharin in sensory tests, without changing the sweet taste 
perception. In 2011, inhibitory activity of two sesquiterpene lactones was discovered, 
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namely of 3β-hydroxydihydrocostunolide (3HDC) for hTAS2R30, hTAS2R40, and 
hTAS2R46, and of 3β-hydroxypelenolide (3HP) for hTAS2R30, hTAS2R31, hTAS2R43, 
and hTAS2R46 (103). The latter compound was shown to activate hTAS2R46 weakly, thus 
the reduction of receptor activation was caused by partial agonism. Although a partial 
agonist activates the receptor as well, it competes with the full agonist for receptor binding 
and its action results in a much lower receptor activation compared to the full agonist. 
Furthermore, it was shown (103) that a compound can act as agonist towards one taste 
receptor, but as antagonist towards another taste receptor, as the two compounds 3HDC and 
3HP, besides their inhibitory properties, showed agonistic properties towards other bitter 
receptors. 
At present, few compounds have been published to act as antagonists on bitter taste 
receptors. This is shown in the ligand overview in Figure 8. It should be noted that only 
dose-dependent receptor inhibition has been included in the figure, as dose-independent 
inhibition (e.g. reported by (122)) might have been caused by mechanisms other than 
receptor antagonism. 
 
Mechanisms of receptor antagonism 
There are two basic molecular mechanisms of receptor antagonism. When the antagonist 
blocks the access of the agonist to the receptor through steric hindrance, this is referred to 
as orthosteric antagonism. When the antagonist binds to another binding site on the receptor 
than the agonist, a change of affinity of the receptor to the agonist is induced through a 
change in conformation of the receptor. This is referred to as allosteric antagonism (123). In 
experimental pharmacology, cell lines expressing the receptor of interest are pre-incubated 
with the antagonist and then challenged with increasing agonist concentrations (124). In the 
orthosteric mechanism, agonist and antagonist compete for the same binding site, and the 
relative affinity and concentrations of agonist and antagonist determine which molecule 
occupies the binding site. Figure 10 illustrates that it depends on the kinetics of the system 
whether this results in surmountable antagonism (dextral displacement of the dose-response 
curve without depression of maximal amplitude) (A), in an intermediate state between 
surmountable and insurmoutable antagonism (dextral displacement and moderate 
depression of the maximal response) (B), or in insurmountable antagonism (depression of 
maximal amplitude) (C). The first case is observed when agonist and antagonist are in 
equilibrium with each other, meaning that there is sufficient time for the antagonist to 
dissociate from the receptors, and the agonist to bind to unbound receptors (125). The 
second case is called “hemi-equilibrium”, whereby agonist, antagonist and receptors have 
partially come to equilibrium with each other (123). The last phenomenon is observed when 
the dissociation rate of the antagonist from the receptors is slower than a competing process 
with the agonist (126). It should be noted that more than one molecular mechanism can 
produce the same pattern of dose-response curves, e.g. insurmountable antagonism (C) can 
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be caused by orthosteric inhibition with insufficient equilibration time, by allosteric 
inhibition, or by irreversible inhibition (covalently bound antagonist) (125, 126). Allosteric 
antagonists produce saturable effects, i.e. after a maximum antagonistic effect is obtained, 
increases in antagonist concentration have no further effect. Furthermore, their effect can be 
agonist specific, which is not possible for orthosteric antagonists (125). 
 
 
Figure 10. Mechanisms of orthosteric antagonism (125). Surmountable (competitive) (A), surmountable 
 insurmountable (hemi-equilibria) (B), insurmountable (non-competitive) (C). ● no antagonist added; 
from ○ until ■: increasing antagonist concentrations. 
 
OUTLINE OF THIS THESIS 
Many (iso)flavonoids have been associated with potential beneficial health effects. 
Therefore, consumption of (iso)flavonoid-rich food products, and enrichment of foods with 
(iso)flavonoids is becoming increasingly popular. This trend might be compromised by 
undesirable taste properties of these compounds. Several (iso)flavonoids have been reported 
to be bitter, albeit contradictory findings have been made in sensory tests. Other 
(iso)flavonoids have unknown taste properties, as they have never been incorporated in 
high concentrations in food products. Therefore, objective measures are necessary to 
identify which (iso)flavonoids activate bitter receptors and thus have the potential to 
contribute to bitterness of a food product, and which are the molecular signatures involved. 
Furthermore, little has been reported about reducing bitterness of (iso)flavonoids at the 
molecular level. Nonetheless, enhanced application of (iso)flavonoids might necessitate 
targeted measures against bitter taste.  
This thesis can be divided into two parts. The first part of this thesis addresses the 
identification of bitter taste receptors for bitter dietary compounds. It was hypothesized that 
compounds causing bitter taste in soy products can be assigned to bitter taste receptors and 
that there are signatures that underlie receptor activation. Out of all 25 human bitter taste 
receptors, two receptors, hTAS2R14 and hTAS2R39, were identified to be activated by the 
bitter soy compound genistein (Chapter 2). Structure-activity relationships were 
established for the activation of hTAS2R14 and hTAS2R39 by structurally similar 
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isoflavonoids. Moreover, a substitution pattern of isoflavonoids most favorable for 
activation of these two bitter receptors was determined. Next, it was hypothesized that bitter 
flavonoids hold a molecular signature involved in bitter receptor activation, which enables 
prediction of intrinsic bitterness. Therefore, in Chapter 3, a large group of structurally 
similar flavonoids was measured on the same two receptors. The aim was to investigate 
chemical characteristics for (iso)flavonoids to activate hTAS2R14 and hTAS2R39. This 
investigation was underpinned by 2D-fingerprint and 3D-pharmacophore modeling, and led 
to the identification of the molecular features necessary for (iso)flavonoids to activate 
hTAS2R14 and hTAS2R39, and the differences therein.  
The second part of this thesis addresses debittering strategies. Based on known bitter 
masking effects of flavanones in sensory studies, it was assumed that flavanones have the 
ability to block (iso)flavonoid bitter receptors on the molecular level. Chapter 4 describes 
the identification and characterization of flavanones as antagonists for hTAS2R39. Their 
ability to reduce hTAS2R39 activation by ECG, their pharmacological properties, as well 
as their ability to block hTAS2R14 were investigated. In Chapter 5 it was hypothesized 
that bitter taste reduction for dietary flavonoids by complexation with food proteins can be 
predicted by use of in vitro assays. The potential of β-casein, β-lactoglobulin and different 
gelatins to reduce hTAS2R39 activation by complexation of bitter tea EGCG was evaluated 
in in vitro binding studies, and transferred to the in vivo situation, in which a trained 
sensory panel determined bitterness. Finally, Chapter 6 discusses the findings presented in 
this thesis, addresses prospects and limitations of the bitter receptor cell assay, presents 
additional results on testing (iso)flavonoids for possible antagonistic properties, and 
compares taste evaluation by sensory tests, receptor assays and modeling. Furthermore it 
evaluates strategies for bitter taste reduction, and applies the findings to soy products and 
tea. 
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ABSTRACT 
The aim of this study was to identify the bitter receptor(s) that recognize the bitter taste of 
the soy isoflavone genistein. Screening of all 25 human bitter receptors revealed genistein 
as agonist of hTAS2R14 and hTAS2R39. Genistein displayed threshold values of 4 and 8 
µM on hTAS2R14 and hTAS2R39, and EC50 values of 29 and 49 µM, respectively. In 
addition, the behavior of structurally similar isoflavonoids was investigated. Although the 
two receptors are not closely related, the results for hTAS2R14 and hTAS2R39 were 
similar towards most isoflavonoid aglycones. By trend, threshold values were slightly lower 
on hTAS2R14. Glucosylation of isoflavones seemed to inhibit activation of hTAS2R14, 
whereas four of five glucosylated isoflavones were agonists of hTAS2R39, namely glycitin, 
genistin, acetyl genistin, and malonyl genistin. A total of three hydroxyl substitutions of the 
A- and B-rings of the isoflavonoids seemed to be more favorable for receptor activation 
than fewer hydroxyl groups. The concentration of the trihydroxylated genistein in several 
soy foods exceeds the determined bitter receptor threshold values, whereas those of other 
soy isoflavones are around or below their respective threshold value. Despite its low 
concentration, genistein might be one of the main contributors to the bitterness of soy 
products. Furthermore, the bioactive isoflavonoids equol and coumestrol activated both 
receptors, indicating that their sensory impact should be considered when used as food 
ingredients. 
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INTRODUCTION 
Soybeans (Glycine max L. Merrill) are consumed by Asian populations on a regular basis. 
Growing evidence of positive health effects of soy compounds (1) and the need for 
alternatives to dairy products, due to food-related allergies and intolerances, increase the 
interest for soybean products in North-America and Europe. An important group of health-
beneficial compounds from soybean are isoflavones, of which genistein is the predominant 
representative (2). Soybeans contain mainly 12 isoflavones, the aglycones genistein, 
daidzein, and glycitein, and their respective malonyl glucosides, acetyl glucosides, and 
unsubstituted glucosides (3). The quantities of isoflavones in soybeans depend on cultivar 
and year of cultivation (4). Commonly, the malonyl glucosides and unsubstituted 
glucosides dominate in soybeans, whereas acetyl glucosides and aglycones are present in 
very small amounts (3). Processing can lead to the conversion of malonyl glucosides into 
acetyl glucosides (decarboxylation due to dry heating) and unsubstituted glucosides (mainly 
due to moist heating) (5, 6). Fermentation strongly increases the amount of aglycones due 
to action of β-glucosidases (5). In the whole bean, genistein forms are most abundant, 
followed by daidzein and glycitein forms (6). Unfortunately, soybean isoflavones have 
undesirable sensory properties, e.g. bitterness and astringency. Interestingly, the outcomes 
of sensory studies are not consistent and the undesirable sensory properties are not ascribed 
to the same isoflavones (7-11). The aglycone genistein is frequently reported as being bitter 
(8-11). 
Bitter taste is perceived by bitter taste receptors, referred to as T2Rs or TAS2Rs, which 
belong to the family of G-protein coupled receptors (12). For almost all 25 human bitter 
receptors (hTAS2Rs) agonists have been identified (13). The remaining orphan receptors 
are hTAS2R411, -42, -45, -482, and -60. Despite of the occurrence of many bitter 
compounds in food, research has mainly been focused on toxic compounds, and only a few 
studies have been carried out on dietary compounds (13-19). Bitter taste receptor activation 
by isoflavonoids has not been studied yet. The umbrella term “isoflavonoids” incorporates, 
amongst others, isoflavones, isoflavans, and coumestans.  
The objective of the present study was to identify the bitter receptors activated by the 
soy isoflavone genistein. Our second objective was to map the structural requirements for 
receptor activation, using a variety of structurally similar isoflavonoids. 
 
 
 
                                                  
1
 hTAS2R41 has been deorphanized in 2013, see Chapter 1 
2
 The name of hTAS2R48 has been changed into hTAS2R19, see Chapter 1 
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MATERIALS AND METHODS 
Materials 
Isoflavonoids were purchased from Indofine Chemical Company (Hillsborough, NJ, USA), 
Extrasynthese (Genay, France), Sigma-Aldrich (Steinheim, Germany), Brunschwig 
(Amsterdam, The Netherlands), Bioconnect (Huissen, The Netherlands) and WAKO 
(Neuss, Germany). All compounds were dissolved in DMSO (Sigma-Aldrich, Steinheim, 
Germany) at a 100 mM stock concentration. Trypan blue solution (0.4 %) was purchased 
from Sigma-Aldrich (Steinheim, Germany). 
Tyrode’s buffer (140 mM NaCl, 5 mM KCl, 10 mM glucose, 1 mM MgCl2⋅6H2O, 1 
mM CaCl2, and 20 mM Hepes, pH 7.4) was used for dilution of compound-DMSO stock 
solutions and for calcium imaging assays. If not mentioned otherwise, it contained 0.5 mM 
probenecid (Sigma-Aldrich). 
 
Expression of hTAS2Rs in HEK293 cells 
For functional expression of the human bitter taste receptors, HEK293 T-Rex Flp-In cells 
(Invitrogen, San Diego, CA, USA) stably expressing the chimeric G-protein α-subunit 
Gα16-gust44 (cloned into pcDNA4 (Invitrogen)) (20) and one of the 25 human bitter 
receptor genes (cloned into pcDNA5/FRT (Invitrogen)), were used. In order to improve 
membrane targeting of the receptor protein, each bitter receptor gene contained a DNA 
sequence encoding the first 45 amino acids of rat somatostatin receptor type 3 at its 5’ end 
(the receptor expression was achieved according to (21), with exception of the HSV-tag). 
The nomenclature of bitter receptors is identical to that of Meyerhof et al. (13). Cells were 
maintained in DMEM and 10 % (v/v) tetracycline-free FBS (both Lonza, Verviers, 
Belgium) supplemented with blasticidin (5 µg/mL), geneticin (400 µg/mL) and hygromycin 
(100 µg/mL) (all from Invitrogen). All cells were grown and maintained at 37 °C and 5 % 
(v/v) CO2. 
 
Monitoring hTAS2Rs activation by intracellular calcium release 
Activation of human TAS2 receptors releases intracellular Ca2+, which can be measured by 
a fluorescent calcium dye (22). Variations in intracellular Ca2+ concentrations were 
monitored with a FlexStation II 384 (Molecular Devices Corporation, Sunnyvale, CA, 
USA). hTAS2R-expressing cells were seeded into poly-L-lysine-coated (Sigma-Aldrich) 
96-well plates (black wall, clear bottom, Greiner bio-one, Frickenhausen, Germany) at a 
density of 104 cells in 100 µL/well and cultured for 24 h. Transcription of the receptors was 
induced by adding 0.25 µg/mL doxycycline (Sigma-Aldrich). Cells were induced for 24 h 
and then loaded with the calcium-sensitive fluorescent dye Fluo-4-AM (2.5 µM, Molecular 
Probes, Eugene, OR, USA), which was dissolved in Tyrode’s buffer containing 5 % (v/v) 
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tetracycline-free FBS (Lonza). One hour after loading, cells were washed with Tyrode’s 
buffer and taken up in Tyrode’s buffer. Stock solutions of test compounds were prepared in 
DMSO and diluted to the appropriate concentration in Tyrode’s buffer, not exceeding a 
DMSO concentration of 1 % (v/v). Screening of the 25 bitter receptors was done at 400 µM 
for genistein and genistin. For acetyl genistin and malonyl genistin, this was 100 µM due to 
limited availability of the compounds. Both hTAS2R14 and hTAS2R39 were screened for 
activation by the other isoflavonoids at 500 µM. In case of activation they were measured at 
different concentrations up to 1 mM in order to establish dose-response curves. For 
hTAS2R16, the applied concentrations were 100 µM acetyl genistin and malonyl genistin, 
and 1 mM genistin, daidzin, and glycitin. Calcium responses of induced cells upon test 
compound addition were measured using a Flexstation II 384 for 90 s as described 
elsewhere (23). The first 17 s before compound addition were used for baseline 
determination. After compound addition, the fluorescence signals (excitation 485 nm / 
emission 520 nm) were measured for an additional 70 s at 37 °C. Maximum fluorescence 
was reached within the measuring time of 90 s, but for some compounds the decrease of 
fluorescence back to baseline levels lasted longer than the time frame (for example, see 
Figure S1 in the Supporting information). As negative control, non-induced cells were 
always measured in parallel. As positive controls, two wells/plate were measured with 
epicatechin gallate (18) for hTAS2R39 and with naphthoic acid (21) (or genistein) for 
hTAS2R14. All experiments were conducted in duplicate on two or more different days.  
 
Tests for toxicity and autofluorescence 
In order to investigate the effect of the isoflavonoids on the viability of the cells, dye 
exclusion tests were conducted after 2 min incubation with each isoflavonoid (1 mM). The 
number of viable cells within one well was quantified using trypan blue (0.1 %) and a 
cellometer Auto T4 (Nexcelom Bioscience, Lawrence, MA, USA). Per compound, six cell 
counts were carried out and an average number of cells was calculated. Viability of cells 
was determined by dividing the viable cell count by the total cell count. Furthermore, all 
isoflavonoids were tested for autofluorescence at their highest concentration (1 mM). For 
this, they were measured in a FlexStation II 384 under the conditions applied during the 
bitter receptor assay, with the exception that no cells were seeded in the 96-well plate. As 
positive control, the autofluorescent compound riboflavin was used. 
 
Data processing and statistical analysis 
SoftMax Pro 4.8 software (Molecular Devices Corporation) was used to plot the 
fluorescence signals. The fluorescence values (∆F/F0) were calculated by subtracting the 
baseline fluorescence (F0) prior to loading from the maximum fluorescence (F) after 
addition of the bitter compounds, divided by the signals of the baseline in order to 
2
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normalize to background fluorescence (19). Besides the response of induced cells, also the 
response of non-induced cells was measured as negative control for every compound at 
every concentration on the same plate. In cases that a non-specific signal occurred, the 
respective compound was considered as active when the signal of the induced cells was 
significantly higher than that of the negative control cells (P = 0.05). The signal intensity of 
non-induced cells was taken at the reading point at which the signal of the induced cells 
was maximal. Threshold values of the agonists towards receptor activation were determined 
as first concentration showing significant difference to the baseline and to the response of 
non-induced cells. Differences were considered to be significant at P<0.05, using a t-test 
(two sided, non-paired) (SAS 9.2, Sas Institute Inc., Cary, NC, USA). Between four and 
twelve concentrations were used to fit non-linear regression curves using Graph Pad Prism 
(version 4 for Windows, Graph Pad Software, San Diego, CA, USA). The error bars reflect 
the standard error of the mean (SEM). For all compounds that reached a maximum in the 
concentration-response curve, the EC50 values were calculated (after subtraction of the 
response of non-induced cells, if applicable). For compounds that evoked non-specific 
signals at higher concentrations, only the data for the appropriate concentrations are shown 
in the figures. Some compounds were not completely soluble and, therefore, their real 
potency might be underestimated, leading to lower values than determined.  
 
RESULTS 
Screening for bitter receptor activation by various forms of genistein 
Genistein, one of the compounds strongly associated with bitterness of soybeans and soy 
products, and its glucoside forms genistin, acetyl genistin and malonyl genistin, were tested 
using HEK293 cell lines, each cell line expressing one of the 25 different human bitter 
receptors. This was done in order to determine whether they activated one or more bitter 
receptors. At screening concentrations, two receptors were unambiguously activated by the 
aglycone genistein: hTAS2R14 and hTAS2R39 (Figure 1), whereas no bitter receptor was 
clearly activated by any of the three glucosides genistin, acetyl genistin, and malonyl 
genistin (data not shown). The activation of hTAS2R14 was stronger than that of 
hTAS2R39. 
Screening for agonists was done with hTAS2Rs containing the most frequent single 
nucleotide polymorphisms (SNPs). For hTAS2R38 the taster haplotype PAV (24) was 
used. As there are no agonists for the five orphan bitter receptors identified yet, we cannot 
be sure that they are functional. Therefore, we cannot exclude that receptors other than 
hTAS2R14 and hTAS2R39 might be activated by genistein and its glucoside forms.  
hTAS2R14 is a well-known bitter receptor, which is activated by many, structurally 
diverse, bitter compounds (e.g. (13, 15, 21)). hTAS2R39 was just recently deorphanized 
and it was stated that this receptor belonged to a group of bitter receptors that has a 
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penchant for natural compounds (13). Its agonist spectrum was smaller than that of the 
broadly tuned receptor hTAS2R14.  
 
Figure 1. Bitter receptor activation by genistein. (A) Screening of HEK293 cells, each stably expressing 
one of the 25 hTAS2Rs3, towards activation by genistein (400 µM). The signals of induced cells are 
depicted with white background. Non-induced cells were used as negative controls (grey background). 
(B) Calcium traces of hTAS2R14 and hTAS2R39 and their respective negative controls. 
 
Dose-response behavior of genistein and its glucoside forms on hTAS2R14 and 
hTAS2R39 
To compare the activation of hTAS2R14 and hTAS2R39 by genistein accurately, responses 
were recorded in the concentration range of 0.5-500 µM of genistein. Genistein displayed 
threshold values of 4 and 8 µM on hTAS2R14 and hTAS2R39, respectively (dose–response 
curves shown in Figure 2). The EC50 values after correction for non-specific signals were 
calculated to be 28.9 µM ± 8.2 µM for hTAS2R14 and 49.4 µM ± 8.9 µM for hTAS2R39. 
Additionally, the three glucoside forms of genistein were investigated. None of them 
clearly activated hTAS2R14, whereas acetyl genistin activated hTAS2R39 from 125 µM 
onwards, and genistin and malonyl genistin activated hTAS2R39 at 500 µM. EC50 values of 
the glucoside forms could not be determined because no maximum was reached in the 
concentration-response curves. 
                                                  
3
 The names of hTAS2R44, -47, -48, and -49 have meanwhile been changed into hTAS2R31, -30, -
19, and -20, respectively, see Chapter 1 
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Based on the threshold values for each of the two receptors, the compounds were classified 
into four groups, I ≤32 µM (low), 32 µM < II ≤ 125 µM (medium), and 125 µM < III ≤ 500 
µM (high), and IV no activation up to 500 µM (not active, (n.a.)). hTAS2R14 was activated 
by four compounds at low threshold, by two compounds at medium threshold, and seven 
compounds had a high threshold. Six compounds were considered inactive on hTAS2R14. 
For hTAS2R39, less compounds belonged to the low (2x) and the medium threshold group 
(2x), but more compounds belonged to the high threshold group (11x). Four compounds 
were inactive on hTAS2R39. In a number of cases it was not possible to determine whether 
a compound activated the receptor or not, due to non-specific signals in the negative 
controls, which were not significantly lower than those in the induced cells. Those 
compounds were considered as not active. Dye exclusion tests were conducted in order to 
investigate whether the applied isoflavonoid concentrations influenced the viability of the 
cells. Even at highest concentration (1 mM), no toxic effect on the cells was observed (see 
Supporting information, Figure S2). Furthermore, all compounds were tested for 
autofluorescence. None of the isoflavonoids in this study showed fluorescent behaviour 
under the conditions used in the assay.  
 
Effect of glucosylation 
Aglycones showed similar effects on hTAS2R14 and hTAS2R39, whereas glucosides 
showed different effects. Thirteen out of the fourteen aglycones activated hTAS2R14, while 
there were eleven for hTAS2R39. Most of them activated hTAS2R14 at lower 
concentrations than hTAS2R39. By contrast, glucosylated isoflavones did not show any 
activity on hTAS2R14. Although thresholds were generally high, hTAS2R39 could be 
activated by four out of five isoflavone glucosides, viz. glycitin, genistin, acetylgenistin, 
and malonyl genistin (Figure 2). This finding suggested that glucosylation inhibited 
activation of hTAS2R14.  
As β-glucopyranosides are reported to activate hTAS2R16 (27), the five glucosides 
daidzin, glycitin, genistin, acetyl genistin, and malonyl genistin  were additionally tested on 
hTAS2R16. None of them activated this receptor. A very recent publication reported the 
inhibition of hTAS2R16 by probenecide (28), a compound commonly used in G-protein 
coupled receptor assays to prevent the efflux of calcium-sensitive dyes from the cells (29). 
Therefore, experiments on hTAS2R16 were repeated without probenecide in the buffer. 
Also without probenecide, no activation of hTAS2R16 by soy isoflavone glucosides 
occurred. 
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Table 1. Summary of threshold and EC50 values of various isoflavonoids on hTAS2R14.  
Compound 
name 
Subgroup Positions EC50 Threshold 
(code)  α β γ δ ε ζ [µM] [µM] group 
Genistein 
(Gein)a,b 
Isoflavone H OH H OH H OH 28.9 4 
I 
(+/-)-Equol 
(10)c 
Isoflavan H OH H H H OH 47.2 8 
Prunetin (6) Isoflavone H OCH3 H OH H OH n.d. 16 
7-Hydroxy-
isoflavone (3) 
Isoflavone H OH H H H H n.d. 32 
Biochanin A 
(1)a 
Isoflavone H OH H OH H OCH3 n.d. 63 
II 7,8,4'- 
Trihydroxy-
isoflavone (8) 
Isoflavone OH OH H H H OH 124 63 
Isoflavone (5) Isoflavone H H H H H H n.d. 250 
III 
6,7,4'-
Trihydroxy-
isoflavone (7) 
Isoflavone H OH OH H H OH 378 250 
7,3',4'-
Trihydroxy-
isoflavone (9) 
Isoflavone H OH H H OH OH 264 250 
Coumestrol 
(11)a 
Coumestan H OH H H H OH 358 250 
Formononetin 
(2)a 
Isoflavone H OH H H H OCH3 n.d. 500 
Daidzein 
(Dein)a,b 
Isoflavone H OH H H H OH n.d. 500 
Glycitein 
(Glyein)a 
Isoflavone H OH OCH3 H H OH n.d. 500 
7-Hydroxy-6-
methoxy-
isoflavone (4) 
Isoflavone H OH OCH3 H H H n.d. n.sp. 
IV 
Acetyl genistin 
(AGe)a 
Isoflavone 
glucoside 
H O-Glc-
6”-O-
Acetyl 
H OH H OH n.d. n.a. 
Daidzin (D)a,b Isoflavone 
glucoside 
H O-Glc H H H OH n.d. n.a. 
Genistin (Ge)a,b Isoflavone 
glucoside 
H O-Glc H OH H OH n.d. n.a. 
Glycitin (Gly) a Isoflavone 
glucoside 
H O-Glc OCH3 H H OH n.d. n.a. 
Malonyl 
genistin 
(MGe)a,b 
Isoflavone 
glucoside 
H O-Glc-
6”-O-
Malonyl 
H OH H OH n.d. n.a. 
Not specific (n.sp.) means that activity could not be determined due to non-specific signals in the 
negative control. Four groups of thresholds for activation of hTAS2R14 correspond to I (low) (≤ 32 µM), 
II (medium) (>32 µM - 125 µM), III (high) (>125 µM - 500 µM) and IV not active up to 500 µM (n.a.).  
n.d., not determined, a occurring in soybean (Glycine max L. Merrill) (3, 25), b compound frequently 
reported as bitter (7-11), c S-(-)equol is an intestinal metabolite of daidzein (26). 
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Table 2. Summary of threshold and EC50 values of various isoflavonoids on hTAS2R39.  
Compound 
name 
Subgroup Positions EC50 Threshold 
(code)  α β γ δ ε ζ [µM] [µM] group 
Genistein 
(Gein)a,b 
Isoflavone H OH H OH H OH 49.4 8 
I (+/-)-Equol 
(10)c 
Isoflavan H OH H H H OH 55.8 32 
7,8,4'- 
Trihydroxy-
isoflavone (8) 
Isoflavone O
H 
OH H H H OH 184 63 
II Acetyl genistin 
(AGe)a 
Isoflavone 
glucoside 
H O-Glc-
6”-O-
Acetyl 
H OH H OH n.d. 125 
7-Hydroxy-
isoflavone (3) 
Isoflavone H OH H H H H 315 250 
III 
6,7,4'-
Trihydroxy-
isoflavone (7) 
Isoflavone H OH OH H H OH n.d. 250 
7,3',4'-
Trihydroxy-
isoflavone (9) 
Isoflavone H OH H H O
H 
OH n.d. 250 
Coumestrol 
(11)a 
Coumestan H OH H H H OH n.d. 250 
Biochanin A 
(1)a 
Isoflavone H OH H OH H OCH3 n.d. 500 
Formononetin 
(2)a 
Isoflavone H OH H H H OCH3 n.d. 500 
Daidzein 
(Dein)a,b 
Isoflavone H OH H H H OH n.d. 500 
Genistin (Ge)a,b Isoflavone 
glucoside 
H O-Glc H OH H OH n.d. 500 
Glycitein 
(Glyein)a 
Isoflavone H OH OCH3 H H OH n.d. 500 
Glycitin (Gly)a Isoflavone 
glucoside 
H O-Glc OCH3 H H OH n.d. 500 
Malonyl 
genistin 
(MGe)a,b 
Isoflavone 
glucoside 
H O-Glc-
6”-O-
Malonyl 
H OH H OH n.d. 500 
Prunetin (6) Isoflavone H OCH3 H OH H OH n.d. n.sp. 
IV 
7-Hydroxy-6-
methoxy-
isoflavone (4) 
Isoflavone H OH OCH3 H H H n.d. n.sp. 
Isoflavone (5) Isoflavone H H H H H H n.d. n.a. 
Daidzin (D)a,b Isoflavone 
glucoside 
H O-Glc H H H OH n.d. n.a. 
Not specific (n.sp.) means that activity could not be determined due to non-specific signals in the 
negative control. Four groups of thresholds for activation of hTAS2R39 correspond to I (low) (≤ 32 µM), 
II (medium) (>32 µM - 125 µM), III (high) (>125 µM - 500 µM) and IV not active up to 500 µM (n.a.).  
n.d., not determined, a occurring in soybean (Glycine max L. Merrill) (3, 25), b compound frequently 
reported as bitter (7-11), c S-(-)equol is an intestinal metabolite of daidzein (26). 
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Influence of C-ring configuration 
To investigate the influence of the C-ring of isoflavonoids on bitter receptor activation, the 
isoflavone daidzein (Dein), the isoflavan equol (10) and the coumestan coumestrol (11) 
were compared. They all have two hydroxyl groups (on positions β and ζ) in common, 
whereas the C-ring is different (position labeling illustrated on skeletons in Figure 3). All 
three compounds were able to activate hTAS2R14 and hTAS2R39, which is illustrated in 
Figure 4A for hTAS2R14 (equol >> daidzein, coumestrol). The results suggested that bitter 
receptor activation is not hindered by variation in C-ring structure, although potency and 
efficacy might be affected. Although only three compounds were compared, our data might 
suggest that planarity of the C-ring is less favorable for binding to the bitter receptors.  
 
 
Figure 4. Concentration-response curves of hTAS2R14 for (A) the isoflavone daidzein (Dein), the 
isoflavan equol (10), and the coumestan coumestrol (11), and (B) the three isoflavones 6,7,4'-
trihydroxyisoflavone (7), 7,8,4'-trihydroxyisoflavone (8), and 7,3',4'-trihydroxyisoflavone (9). 
 
Substitutions of A- and B-rings 
In Figure 4B, the activation of hTAS2R14 by three isoflavones is compared. These three 
isoflavones (7,8,9)  are all substituted by three hydroxyl groups. (7) and (8) have two 
hydroxyl groups on the A-ring and one hydroxyl group on the B-ring, whereas (9) has vice 
versa. They all activated the bitter receptor, but with differences in potency and efficacy. 
The exact location of hydroxylation is of importance, as for example two hydroxyl groups 
on positions α and β (compound 8) led to higher efficacy and potency than two hydroxyl 
groups on positions β and γ (compound 7). Also the number of substitutions matters; in 
most cases, three substitutions were more favorable for activation than two, which can be 
seen (Table 1) when comparing (Glyein) to (4), (1) to (2), or (Gein) to (Dein). For the 
activation of hTAS2R39, substitution of the A-ring is important, as the unsubstituted 
compound (5) was inactive. Absence of substitutions had less influence on hTAS2R14 
activation. For both receptors, an O-methyl group instead of a hydroxyl group negatively 
influenced receptor activation (with the exception of prunetin (6) on hTAS2R14). 
Hydroxylation of β and ζ and one additional position seemed to be most favorable for 
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receptor activation, as all compounds containing these features were able to activate 
hTAS2R14 and hTAS2R39. 
 
DISCUSSION 
Common agonists on hTAS2R14 and hTAS2R39 
The identity between amino acid sequences of hTAS2R14 and hTAS2R39 is only 25 % 
(30). Despite this, they are both activated by a largely overlapping group of isoflavonoids. 
We found 11 isoflavonoids that were able to activate both bitter receptors (compounds 
Gein, Dein, Glyein, 1, 2, 3, 7, 8, 9, 10, 11). Until now, only four compounds were 
described that stimulated both hTAS2R14 and hTAS2R39, which are azathioprine, 
chlorpheniramine, diphenidol and quinine (13) (see Supporting information). These four 
compounds and the newly identified isoflavonoid-agonists do not share structural 
characteristics regarding to charge, hydrophobicity, or the ability to act as proton donor or 
acceptor. In Figure 5A, the threshold values of the agonists on hTAS2R14 are displayed 
against the threshold values on hTAS2R39. It was remarkable that the compounds with low 
threshold at one receptor also demonstrated low threshold at the other receptor. The dashed 
line in the figure depicts the correlation. A similar trend was observed for EC50 values on 
hTAS2R14 and hTAS2R39, as illustrated in Figure 5B. Aglycones showed similar effects 
on both receptors, but the agonists were by trend less active on hTAS2R39 than on 
hTAS2R14. 
The question remains, which of the two bitter receptors is more important for 
recognition of isoflavones. In situ hybridization experiments indicated that the expression 
frequencies of hTAS2R14 and hTA2R39 in taste receptor cells of human circumvallate 
papillae were similar (31). They were reported to be 5.4 % for hTAS2R14 and 4.2 % 
hTA2R39. It might be concluded from our results that hTAS2R14 is slightly more 
important for the recognition of isoflavone aglycones, as the determined bitterness 
threshold values were lower for hTAS2R14 than for hTAS2R39. In contrast, hTAS2R39 
was activated by isoflavone glucosides, and, therefore, might be seen as more important 
bitter receptor for the recognition of soy isoflavone glucosides, as glucosides are more 
abundant in most soy products. For fermented soy products, which are richer in aglycones, 
hTAS2R14 gains importance.  
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Figure 5
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Relevance for sensory perception 
Okubo et al. (9) described the threshold values for bitterness and astringency together to be 
in nM to µM range (10-6 M to 10-7 M for genistein, 5x 10-7 M to 5x 10-8 M for daidzein). 
Kudou et al. (10) determined threshold values for undesirable taste and determined 10-5 M 
for genistein and 10-6 M for daidzein, and 10-5 M for the three glucoside forms of genistin. 
Another study (8) investigated daidzein and genistein regarding bitterness alone, but 
applied them in starch solutions. Reported bitter threshold values (4x 10-3 M for genistein, 
2.9x 10-3 M for daidzein) are in the mM range, whereas the bitter receptor threshold values 
determined in our study are in µM range. This observation is in line with the investigations 
of Intelmann et al. (15) comparing results of taste receptor assays with those of human 
psychophysical experiments. From that study, it was concluded that the difference between 
receptor threshold values (low) and sensory threshold values (higher) was caused by 
interaction of bitter compounds with the oral mucosa. It is remarkable that the results from 
sensory studies on soy isoflavones differ so much. This might have been caused by genetic 
variation of sensory panelists. Different SNPs in hTAS2R genes might lead to differences 
in the perception of soy products. In our study, screening for agonists was done with 
hTAS2Rs which contained the most frequently occurring SNPs, and the taster haplotype 
PAV of hTAS2R38. The receptors hTAS2R14 and hTAS2R39, identified for soy 
isoflavones in our study, contained the SNPs which occur with a frequency of 99 % (GPCR 
Natural Variance database http://nava.liacs.nl (33)). Therefore we assume that the various 
outcomes of the sensory studies described above were more likely caused by different 
experimental setups and the fact that subjects can perform differently, than by genetic 
variation. Besides interaction of bitter tastants with oral mucosa, also changes in salivary 
flow and composition (34), adaptational states and hormone levels can cause variable taste 
responses (35). With the bitter receptor activation assay, we have now measured the 
intrinsic bitterness of a number of (dietary) isoflavonoids, in which the actual taste 
characteristic is uncoupled from the other influences mentioned above. Confirmation of the 
bitterness of newly identified bitter receptor agonists in a sensory study remains to be 
established.  
The concentrations of isoflavones in soy foods can be variable. For example, the 
concentration of genistein reported by Prabhakaran (36) varied between 0.4 and 14.3 µg/g 
in soy milk and 2.4 and 60.4 µg/g in tofu. This is approximately 2 to 225 µM, which is 
exceeding the bitterness threshold values determined. Despite its low concentrations in 
relation to other soy isoflavonoids, the presence of genistein can have a significant impact 
on the bitter taste of soy food. During processing, malonyl forms decrease drastically in 
concentration, whereas the amount of the other three forms increases (37-39). Malonyl 
forms might therefore be less important for the perception of the final products. Acetyl 
forms are generated during dry heating, so they occur in a subset of soy products, only. 
Their concentration in common soy products ranges from 0 to 110 µg/g (soy milk (40) and 
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fried tofu (41), respectively), which is approximately 0 to 250 µM. Therewith, depending 
on the soy product, it is below or just above the determined threshold values on hTAS2R39 
and will probably not lead to strong bitter perception. The concentration of genistin in soy 
products is between 23 µg/g (soy milk (40)) and 562 µg/g (tofu, (41)), which is 
approximately 50 µM to 1.3 mM, so it can be above the threshold values determined for 
hTAS2R39. In soy products, the bitter taste of isoflavones might be masked by other 
constituents present in the product. 
Irrespective the amounts of isoflavones in different soy products, most of the 
investigated isoflavonoids belonged to the high threshold group III. From a nutritional 
perspective, this is probably advantageous, as strong bitterness would prevent consumption 
of soy products which can provide multiple health benefits. Today’s attempts to make 
healthier food include the incorporation of more bioactive isoflavonoids as ingredients. For 
example equol, which is originally an intestinal metabolite formed from daidzein, and now 
considered as neutraceutical, is more estrogenic than its precursor (26). Also coumestrol, 
which is formed from daidzein by combined malting by a food-grade fungus, is more 
estrogenic than its precursor (42). The results of our study show that equol and coumestrol 
are intrinsically more bitter than most of the common soybean isoflavones, indicating that 
their sensory impact should be considered when formulating food products enriched in 
these compounds.  
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SUPPORTING INFORMATION 
Table S1. Agonists of hTAS2R14 and hTAS2R39. 
Compounds Agonist Detected by 
 hTAS2R14 hTAS2R39  
1,8-Naphthalaldehydic acid +  Behrens et al. 2004 
1-Naphthoic acid +  Behrens et al. 2004 
1-Nitronaphthalene +  Behrens et al. 2004 
Picrotin +  Behrens et al. 2004 
Picrotoxinin + 
+ 
 
- 
Behrens et al. 2004 
Meyerhof et al. 2010 
Piperonylic acid +  Behrens et al. 2004 
Sodium benzoate + 
+ 
 
- 
Behrens et al. 2004 
Meyerhof et al. 2010 
(-)-α-Thujone + 
+ 
 
- 
Behrens et al. 2004 
Meyerhof et al. 2010 
Aristolochic acid + 
+ 
+ 
 
 
- 
Sainz et al. 2007 
Pronin et al. 2007 
Meyerhof et al. 2010 
Herbolide D +  Brockhoff et al. 2007 
Casein hydrolysate (peptides) +  Maehashi et al. 2008 
trans-Isocohumulone +  Intelmann et al. 2009 
trans-Isohumulone +  Intelmann et al. 2009 
trans-Isoadhumulone +  Intelmann et al. 2009 
cis-Isocohumulone +  Intelmann et al. 2009 
cis-Isohumulone +  Intelmann et al. 2009 
cis-Isoadhumulone +  Intelmann et al. 2009 
Lupulone +  Intelmann et al. 2009 
Adlupulone +  Intelmann et al. 2009 
8-Prenylnaringenin +  Intelmann et al. 2009 
Humulone isomers +
 
- Meyerhof et al. 2010 
Hoodia gordonii glycoside H.g.-12 +
 
- Le Nevé et al. 2010 
Hoodia gordonii aglycone +
 
- Le Nevé et al. 2010 
Absinthin + - Meyerhof et al. 2010 
Arborescin + - Meyerhof et al. 2010 
Arglabin + - Meyerhof et al. 2010 
Artemorin + - Meyerhof et al. 2010 
Campher + - Meyerhof et al. 2010 
Caffeine + - Meyerhof et al. 2010 
Cascarillin + - Meyerhof et al. 2010 
Cumarin + - Meyerhof et al. 2010 
Cucurbitacin B + - Meyerhof et al. 2010 
Falcarindiol + - Meyerhof et al. 2010 
Noscapine + - Meyerhof et al. 2010 
Papaverine + - Meyerhof et al. 2010 
Parthenolide + - Meyerhof et al. 2010 
Quassin + - Meyerhof et al. 2010 
Benzamide + - Meyerhof et al. 2010 
Benzoin + - Meyerhof et al. 2010 
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Compounds Agonist Detected by 
 hTAS2R14 hTAS2R39  
Carisoprodol + - Meyerhof et al. 2010 
Chlorhexidine + - Meyerhof et al. 2010 
Diphenhydramine + - Meyerhof et al. 2010 
Diphenylthiourea + - Meyerhof et al. 2010 
Divinylsulfoxid + - Meyerhof et al. 2010 
Flufenamic acid + - Meyerhof et al. 2010 
Haloperidol + - Meyerhof et al. 2010 
4-Hydroxyanisol + - Meyerhof et al. 2010 
Quinine + + Meyerhof et al. 2010 
Azathioprine + + Meyerhof et al. 2010 
Chlorpheniramine + + Meyerhof et al. 2010 
Diphenidol + + Meyerhof et al. 2010 
Amarogentin - + Meyerhof et al. 2010 
Chloramphenicol - + Meyerhof et al. 2010 
Colchicine - + Meyerhof et al. 2010 
Thiamine - + Meyerhof et al. 2010 
Acetaminophen - + Meyerhof et al. 2010 
Chloroquine - + Meyerhof et al. 2010 
Denatonium benzoate - + Meyerhof et al. 2010 
(-)-Epicatechin  + Narukawa et al. 2011 
(-)-Epicatechin gallate  + Narukawa et al. 2011 
(-)-Epigallocatechin  + Narukawa et al. 2011 
(-)-Epigallocatechin gallate  + Narukawa et al. 2011 
Peptide: Phe-Phe-Pro-Arg  + Ueno et al. 2011 
Peptide: Pro-Arg  + Ueno et al. 2011 
Isoflavone + - this study 
Prunetin + - this study 
Biochanin A + + this study 
Coumestrol + + this study 
Daidzein + + this study 
(+/-)-Equol + + this study 
Formononetin + + this study 
Genistein + + this study 
Glycitein + + this study 
7-Hydroxyisoflavone + + this study 
6,7,4'-Trihydroxyisoflavone + + this study 
7,3',4'-Trihydroxyisoflavone + + this study 
7,8,4'- Trihydroxyisoflavone + + this study 
Acetyl genistin - + this study 
Genistin - + this study 
Glycitin - + this study 
Malonyl genistin - + this study 
 + activation, - no activation 
 
previously described agonists of hTAS2R14 and hTAS2R39 
 
                       new agonists of hTAS2R14 and hTAS2R39 
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Figure S1. Activation of hTAS2R39 by genistein (measuring time: 180 s). The grey line indicates the 
end of normally performed measuring after 90 s. 
 
Figure S2. Cell viability after 2 min incubation with isoflavonoids, Tyrode’s buffer (negative control for 
toxicity), and methanol (positive control for toxicity). 
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ABSTRACT 
Many flavonoids and isoflavonoids have undesirable bitter taste, which hampers their use 
as food bioactives. The aim of this study was to investigate the effect of a large set of 
structurally similar (iso)flavonoids on the activation of bitter receptors hTAS2R14 and 
hTAS2R39, and to predict their structural requirements to activate these receptors. In total, 
68 compounds activated hTAS2R14 and 70 compounds activated hTAS2R39, amongst 
which 58 ligands were overlapping. Their activation threshold values varied over a range of 
three log units between 0.12 and 500 µM. Ligand-based 2D-fingerprint and 3D-
pharmacophore models were created to detect structure activity relationships. The 2D-
models demonstrated excellent predictive power in identifying bitter (iso)flavonoids and 
discrimination from inactive ones. The structural characteristics for an (iso)flavonoid to 
activate hTAS2R14 (or hTAS2R39), were determined by 3D-pharmacophore models to be 
composed of two (or three) hydrogen bond donor sites, one hydrogen bond acceptor site, 
and two aromatic ring structures, of which one had to be hydrophobic. The additional 
hydrogen bond donor feature for hTAS2R39 ligands indicated the possible presence of 
another complementary acceptor site in the binding pocket, compared to hTAS2R14. 
Hydrophobic interaction of the aromatic feature with the binding site might be of higher 
importance in hTAS2R14 than in hTAS2R39. Together, this might explain why OH-rich 
compounds showed different behavior on the two bitter receptors. The combination of in 
vitro data and different in silico methods created a good insight in activation of hTAS2R14 
and hTAS2R39 by (iso)flavonoids and provided a powerful tool in prediction of their 
potential bitterness. By understanding the “bitter motif”, introduction of bitter taste in 
functional foods enriched in (iso)flavonoid bioactives might be avoided. 
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INTRODUCTION 
Phenolic compounds, such as flavonoids and isoflavonoids, are in the focus of health 
research. Isoflavonoids are mainly occurring in legumes, such as soybeans, and have been 
associated with prevention of some cancers, cardiovascular disease, menopausal complaints 
and osteoporosis (1). Flavonoids occur in many different plants and are widely present in 
our diet. Amongst others, they might play a role in the reduced incidence of cancer and 
cardiovascular diseases (2, 3). Unfortunately, many (iso)flavonoids have a negative impact 
on sensory perception as they can taste bitter (4). The bitter taste of soybean isoflavones has 
been described in several sensory studies (5, 6). Recently, we showed that several soybean 
isoflavones activated the human bitter taste receptors hTAS2R14 and hTAS2R39 and 
partially elucidated the isoflavonoid substitution pattern favorable for activation of both 
receptors (7). 
Bitter taste receptor hTAS2R14 is known to be activated by a large number of 
compounds originating from different chemical classes (7-13). For hTAS2R39 on the other 
hand, a rather moderate number of agonists has been reported (7, 9, 14-17) and this receptor 
seemed to be less broadly tuned than hTAS2R14 (9). Recently, hTAS2R39 has been 
reported to be activated by tea catechins (14), which belong to the group of flavonoids. 
There are also numerous flavonoids, which do not traditionally occur in our diet, and 
for which the taste is often not known. It is hypothesized that the bitter taste characteristics 
can be predicted, once the molecular signatures of (iso)flavonoids for activation of 
hTAS2R14 and hTAS2R39 are known. Originating in pharmaceutical science, the concept 
of molecular modeling gains importance in food science (18), and might be employed in 
facilitating such predictions. A 2D-fingerprint model is based on a binary representation of 
a molecule in which each bit indicates the presence or absence of a molecular fragment 
(19). A 3D-pharmacophore model operates with a set of features together with their relative 
spatial orientation, which relates to a set of chemical features in a molecule. These features 
are recognized by amino acid residues in the receptor binding site with complementary 
functions, ultimately explaining that molecule’s biological activity (20, 21). Recently, Ley 
et al. (22) described a pharmacophore model, which on docking in a hTAS2R10 structural 
model allowed identification of a masking agent for the bitter taste of caffeine. 
Furthermore, ligand-based pharmacophore modeling has been applied to understand 
structure-activity relationships of odors (23), and to explain interactions between flavor 
compounds and β-lactoglobulin (24).  
The objective of the present study was to study the behavior of flavonoids towards 
activation of hTAS2R14 and hTAS2R39. Their activation would indicate that the 
compounds tested have a bitter taste. To this end, a large subset of flavonoids, or flavonoid 
analogues, was tested, and the threshold and EC50 values of the active compounds were 
determined. A second objective was to investigate the chemical space of flavonoids, and 
isoflavonoids, in relation to the activation of bitter receptors hTAS2R14 and hTAS2R39. 
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By linking the receptor activation with the compound’s molecular structure, 2D-fingerprint 
models and ligand-based 3D-pharmacophore models for each of the two bitter receptors 
were established. These models map the structural requirements for ligands with an 
isoflavonoid, flavonoid, or similar structure for these two receptors. Altogether, they 
distinguish active from inactive (iso)flavonoids and enable predicting bitterness of similar 
compounds with unknown taste properties.  
 
MATERIALS AND METHODS 
Receptor assays 
Materials 
Compounds tested were purchased from Indofine Chemical Company (Hillsborough, NJ, 
USA), Extrasynthese (Genay, France), Sigma-Aldrich (Steinheim, Germany), Brunschwig 
(Amsterdam, The Netherlands), Bioconnect (Huissen, The Netherlands), or WAKO (Neuss, 
Germany). The majority of compounds were ≥99% (18 compounds), ≥98% (44 
compounds) or ≥97% (15 compounds) pure. Compounds 38 and 71 were ≥96% pure, 22, 
39, 43, 45, 50, 51, 59, 70, 78, and 94 were ≥95% pure, 33, 54, 56, 74, 79, 80, and 88 were 
≥90% pure, and 37 was ≥85% pure. Each compound was dissolved in DMSO (Sigma-
Aldrich, Steinheim, Germany) to a 100 mM stock concentration. Trypan blue solution (0.4 
% w/v) was purchased from Sigma-Aldrich (Steinheim, Germany). 
Tyrode’s buffer (140 mM NaCl, 5 mM KCl, 10 mM glucose, 1 mM MgCl2, 1 mM 
CaCl2, and 20 mM Hepes, pH 7.4) with 0.5 mM probenecid (Sigma-Aldrich) was used for 
dilution of compound-DMSO stock solutions and for calcium imaging assays. All 
compounds were tested for autofluorescence and toxic effects on the cells used at a 
concentration of 1 mM as described before (7), without observing abnormalities.  
 
In vitro assessment of hTAS2R14 and hTAS2R39 activation by intracellular calcium 
release 
Activation of bitter taste receptors expressed in HEK293 cells leads to release of 
intracellular Ca2+ (25). This was measured using the fluorescent calcium dye Fluo-4-AM 
(2.5 µM, Molecular Probes, Eugene, OR, USA) in a FlexStation II 384 or FlexStation III 
(Molecular Devices Corporation, Sunnyvale, CA, USA) for 90 s (excitation 485 nm / 
emission 520 nm). The expression of hTAS2R14 and hTAS2R39 in HEK293 cells, the 
maintenance of the cells, and the measuring procedure were performed as reported earlier 
(7). 
In total, a set of 97 compounds are described in this study, of which 19 isoflavonoids 
were reported in our earlier publication (7), and 78 other compounds were tested 
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additionally. Stock solutions of test compounds were prepared in DMSO and diluted to the 
appropriate concentration in Tyrode’s buffer, not exceeding a DMSO concentration of 1 % 
(v/v). Screening of hTAS2R14 and hTAS2R39 for activation was performed at 500 µM 
concentrations of test compounds. In case of activation, test compounds were measured at 
concentration ranges up to 1 mM in order to establish dose-response curves. Non-induced 
cells, not expressing the bitter receptors, were always measured in parallel to verify 
specificity of receptor activation. As positive controls for receptor activation, in each plate 
duplicate measurements with epicatechin gallate (14) for hTAS2R39 or with naphthoic acid 
(8) (or genistein) for hTAS2R14 were performed. All experiments were conducted in 
duplicate on two or more different days. Some compounds were not completely soluble at 
high concentrations and, therefore, their real potency might be underestimated. 
 
Calcium assay data processing and statistical analysis 
Data processing and statistical analysis were done as reported previously (7). SoftMax Pro 
5.4 software (Molecular Devices Corporation) was used to plot the fluorescence signals. 
The fluorescence value (∆F/F0), representing receptor activity, was calculated by 
subtracting the baseline fluorescence (F0) prior to loading from the maximum fluorescence 
(F) after addition of the bitter compounds, divided by the signal of the baseline in order to 
normalize background fluorescence (26). Besides the response of induced cells, also the 
response of non-induced cells (not expressing the bitter receptor) was measured as negative 
control for every compound at every concentration on the same plate. In cases that a non-
specific signal occurred, the respective compound was considered as active when the signal 
of the induced cells was significantly higher than that of the negative control cells (P = 
0.05). The signal intensity of non-induced cells was taken at the reading point at which the 
signal of the induced cells was maximal. Threshold values of the agonists towards receptor 
activation were determined as first concentration showing significant difference to the 
baseline and to the response of non-induced cells. Differences were considered to be 
significant at P<0.05, using a t-test (two sided, non-paired) (SAS 9.2, Sas Institute Inc., 
Cary, NC, USA). Dose-response curves were established as non-linear regression curves 
using Graph Pad Prism (version 4 for Windows, Graph Pad Software, San Diego, CA, 
USA). The error bars reflect the standard error of the mean (SEM). EC50 values were 
calculated for compounds that reached a maximum in the dose-response curve (after 
subtraction of the response of non-induced cells, if applicable). For compounds that evoked 
high non-specific signals at higher concentrations, only the data for the appropriate 
concentrations were shown in the figures. 
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Modeling 
2D-fingerprint modeling  
2D-modeling was performed using Pipeline Pilot v8.0, (Accelrys, San Diego, CA, USA). 
The chemical structures of the 97 compounds tested were derived from the SMILES 
(simplified molecular-input line-entry system) notations (supplementary material S1). 
Results at the screening concentration of 500 µM were used. Compounds showing 
ambiguous results (22 compounds for hTAS2R14; 21 compounds for hTAS2R39) were 
excluded. This resulted in 75 and 76 compounds suitable for modeling of receptor 
activation of hTAS2R14 and hTAS2R39, respectively. The majority of these compounds 
was used for model building (training set), containing both active and inactive compounds, 
whereas ~10 % of the structurally most diverse compounds were excluded from model 
building for validation purposes (test set).  
The optimal fingerprint model was obtained by building numerous models based on 
different fingerprint types. This optimization was done with the training set, using the 
Bayesian interference method and leave-one-out settings (19, 27). Three-fold cross-
validations were performed to evaluate the models, in which ranking of the best models was 
primarily based on the Receiver Operating Characteristic (ROC) scores (see 
supplementary material S2-S4). The highest ranking models were further validated by the 
test sets, resulting in the final model selection. ECFP-10 and ECFP-8 fingerprint models 
were selected for hTAS2R14 and hTAS2R39, respectively. Their ROC scores were close to 
1, which indicated excellent accuracy. Extended-Connectivity Fingerprints (ECFP) use 
charge and hybridization of the atom (extended (E)) and connectivity (C) and return a list of 
fragments present in the molecule (19), of which in this case the maximum diameter of a 
fragment was 10 and 8 bond lengths, respectively. 
For identification of key molecular features for bitter receptor activation, 20 “good” 
(“G”) and 20 “bad” (“B”) fingerprint fragments were calculated for each model. Each of 
them has a Bayesian score. If this score is positive, the likelihood that the fragment is a 
member of the active subset increases, and vice versa. A selection of four illustrative 
fragments is shown in the results section; the full list is specified in the supplementary 
material (S5-S9). 
 
3D-pharmacophore modeling 
3D-pharmacophore modeling was performed using Discovery Studio v3.1 (Accelrys). In 
contrast to 2D-fingerprint modeling, a training set for 3D-pharmacophore modeling is 
based on only a few highly active compounds. The selection for pharmacophore training 
ligands on bitter receptor activation was based on activation thresholds, as EC50 values 
were not available for all (iso)flavonoids. Compounds were categorized by their threshold 
values into highly active (threshold ≤32 µM), moderately active (threshold > 32 – 500 µM) 
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and inactive compounds (not active up to 500 µM) (Table 2). 24 compounds for 
hTAS2R14 and 20 compounds for hTAS2R39 showed ambiguous results or high non-
specific signals and were excluded from modeling. Besides low threshold, the training 
ligands had to be diverse in backbone structure and substitution pattern. Seven highly active 
compounds were chosen as training ligands for each receptor (Table 1). One of the training 
ligands selected for building the hTAS2R39 pharmacophore was an anthocyanidin and 
required special attention. Due to the pH dependence of the anthocyanidin structure 
(shifting equilibria between flavylium cation structure, quinoid tautomers, hemiketal, and 
chalcone) (28, 29), multiple forms were included for modeling.  
Training compounds were subjected to internal strain energy minimization and 
conformational analysis (maximum number of conformers = 200; generation type: best 
quality; energy range = 10 kcal / mol above the calculated global minimum). Using the 
hiphop and hiphop refine algorithms of Discovery Studio, the chemical features optimized 
for exploring the spatial pharmacophore map of this group of compounds were “hydrogen 
bond acceptor”, “hydrogen bond donor”, “hydrophobic aromatic”, “hydrophobic aliphatic”, 
and “ring aromatic”. The “hydrophobic aromatic” feature describes an aromatic ring which 
is hydrophobic, the spatial orientation of which is irrelevant. The “ring aromatic” feature 
describes an aromatic ring which can be hydrophobic or hydrophilic, depending on its 
substitutions. Furthermore, the plane of this aromatic ring has a fixed orientation towards 
the receptor binding site. The pharmacophore models were trained with qualitative data and 
thus the features are not weighed and the relevance of each feature was considered as equal. 
The quality of mapping is described by fit values. A feature that maps exactly on the 
respective atom has a fit value of 1, and a feature that does not map has a fit value of 0. The 
fit values and relative energies of all compounds are summarized in the supplementary 
material S1. Mapping is done by rotation and translation of the molecule to optimize the 
superimposition of the molecule on the features, meanwhile additionally the torsion angles 
are altered whereby the maximal relative energy should not exceed 10 kcal / mol, compared 
to its optimal energetic state of 0 kcal / mol. 
The pharmacophore protocol created 10 hypotheses for each run. These hypotheses 
were analyzed to find the optimal model. Hypotheses were scored based on the confusion 
matrix table, ROC plots, rank score, direct hit/partial hit and maximal fit value (additional 
information given in supplementary material S10-S14). The optimization involved 
variation of features and/or locations to optimize sensitivity and specificity of the structure 
based activity prediction.  
Pharmacophore building for ligands of hTAS2R14 resulted in a 5-feature 
pharmacophore, whereas for ligands of hTAS2R39, it resulted in a 6-feature 
pharmacophore. In the case of the model built for hTAS2R14, a ligand had to map all five 
features in order to be predicted as active, whereas in the case of the model built for 
hTAS2R39, ligands were allowed to map five out of six features, without disqualifying  
3
  
Chapter 3 
 
66 
 
Table 1. Chemical structures (related to structure depicted in Figure 1) of compounds tested and their 
behavior on hTAS2R14 and hTAS2R39 concerning activity, threshold, and EC50 values. Activity was 
determined at 500 µM screening concentration (+ active, - inactive, +/- results ambiguous).  
 
 
Compound No 
Activity 
hTAS2R 
 Threshold 
hTAS2R 
 EC50 
hTAS2R 
14 39  14 39  14 39 
Flavones          
Acacetin 1 - +/-  n.a. n.sp.  n.d. n.d. 
Apigenin  2 + +  8 1  n.d. n.d. 
Chrysin  3 + +  63 16  n.d. n.d. 
Chrysoeriol  4 + +/-  500 n.a.  n.d. n.d. 
5,2’-Dihydroxyflavone 5 - +  n.a. 500  n.d. n.d. 
5,3’-Dihydroxyflavone 6 +/- +/-  n.a. n.a.  n.d. n.d. 
5,4’-Dihydroxyflavone 7 + +  250 500  n.d. n.d. 
6,4’-Dihydroxyflavone 8 + +  125 500  n.d. n.d. 
7,4'-Dihydroxyflavone 9 + +  16 125  n.d. n.d. 
5,7-Dimethoxyflavoned 10 + +  16 32  n.d. n.d. 
6,7-Dimethoxyflavone 11 + -  125 n.a.  n.d. n.d. 
Flavone 12 + +  8 8  20.5 45.9 
Gardenin A  13 - +/-  n.a. n.a.  n.d. n.d. 
Genkwanin 14 - +  n.a. 500  n.d. n.d. 
5-Hydroxyflavone 15 +/- +  n.a. 500  n.d. n.d. 
4’-Hydroxyflavone 16 +/- +  n.a. 500  n.d. n.d. 
5-Hydroxy-3’-methoxyflavone 17 - -  n.a. n.a.  n.d. n.d. 
4’-Hydroxy-6-methoxyflavone 18 + -  125 n.a.  n.d. n.d. 
4’-Hydroxy-7-methoxyflavone 19 + +  250 250  n.d. n.d. 
Luteolin  20 + +  2 0.5  6.0 7.3 
6-Methoxyflavone 21 +/- -  n.a. n.a.  n.d. n.d. 
6-Methoxyluteolina 22 + +  4 8  11.0 22.9 
Scutellareina,b 23 + +  8 8  35.0 40.3 
Tricetin 24 +/- +  n.a. 250  n.d. n.d. 
5,7,2'-Trihydroxyflavone 25 + +  8 4  21.1 35.3 
5,3’,4’-Trihydroxyflavone 26 +/- +/-  n.a. n.sp.  n.d. n.d. 
7,3',4'-Trihydroxyflavone 27 + +  16 16  67.3 141 
5,7,4’-Trimethoxyflavone 28 + +/-  250 n.a.  n.d. n.d. 
Flavonols          
Datiscetina  29 + +  2 16  10.0 41.6 
Fisetin  30 +/- +  n.sp. 1  n.d. n.d. 
Flavonol  31 +/- +/-  n.a. n.a.  n.d. n.d. 
Gossypetinc 32 - +  n.a. 250  n.d. 388 
Herbacetin 33 + +  125 125  n.d. n.d. 
Isorhamnetin 34 + +  125 0.12  n.d. n.d. 
Kaempferol 35 + +  8 0.5  n.d. n.d. 
6-Methoxyflavonol  36 - +/-  n.a. n.sp.  n.d. n.d. 
Morin 37 + +  8 2  n.d. n.d. 
Myricetinc 38 + +  250 1  n.d. n.d. 
Quercetagetin 39 +/- +  250 2  n.d. n.d. 
Quercetin 40 +/- +/-  n.sp. n.sp.  n.d. n.d. 
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Backbones A: flavone (R3=H) / flavonol (R3=OH), B: flavanone (R3=H) / flavanonol (R3=OH), C: flavan 
(R3=H) / flavanol (R3=OH), D: chalcone, E: dihydrochalcone, F: anthocyanidin (R3=OH) / 
deoxyanthocyanidin (R3=H), G: isoflavone, H: isoflavan, I: coumestan, J: stilbene, K: aurone, L: 
xanthone. Side groups a: 6’’-O-acetyl glucose, b: 6’’-O-malonyl glucose, c: glucose, d: 4-((2S)-3-
(hydroxylmethyl)-1,4-dioxan-2-yl)-2-methoxyphenol, e: gallic acid. (based on Figure 1) 
Back-
bone R1 R3 R5 R6 R7 R8 R2’ R3’ R4’ R5’ 
           
A  H OH H OH H H H OCH3 H 
A  H OH H OH H H H OH H 
A  H OH H OH H H H H H 
A  H OH H OH H H OCH3 OH H 
A  H OH H H H OH H H H 
A  H OH H H H H OH H H 
A  H OH H H H H H OH H 
A  H H OH H H H H OH H 
A  H H H OH H H H OH H 
A  H OCH3 H OCH3 H H H H H 
A  H H OCH3 OCH3 H H H H H 
A  H H H H H H H H H 
A  H OH OCH3 OCH3 OCH3 H OCH3 OCH3 OCH3 
A  H OH H OCH3 H H H OH H 
A  H OH H H H H H H H 
A  H H H H H H H OH H 
A  H OH H H H H OCH3 H H 
A  H H OCH3 H H H H OH H 
A  H H H OCH3 H H H OH H 
A  H OH H OH H H OH OH H 
A  H H OCH3 H H H H H H 
A  H OH OCH3 OH H H OH OH H 
A  H OH OH OH H H H OH H 
A  H OH H OH H H OH OH OH 
A  H OH H OH H OH H H H 
A  H OH H H H H OH OH H 
A  H H H OH H H OH OH H 
A  H OCH3 H OCH3 H H H OCH3 H 
           
A  OH OH H OH H OH H H H 
A  OH H H OH H H OH OH H 
A  OH H H H H H H H H 
A  OH OH H OH OH H OH OH H 
A  OH OH H OH OH H H OH H 
A  OH OH H OH H H OCH3 OH H 
A  OH OH H OH H H H OH H 
A  OH H OCH3 H H H H H H 
A  OH OH H OH H OH H OH H 
A  OH OH H OH H H OH OH OH 
A  OH OH OH OH H H OH OH H 
A  OH OH H OH H H OH OH H 
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Compound No 
Activity 
hTAS2R 
 Threshold 
hTAS2R 
 EC50 
hTAS2R 
14 39  14 39  14 39 
3,6,3',4'-Tetrahydroxyflavone 41 +/- +  8 2  n.d. n.d. 
3,7,4'-Trihydroxyflavone 42 + +  1 0.5  n.d. n.d. 
Flavanones          
Eriodictyola 43 + +  32 16  61.4 62.0 
Flavanone 44 + +/-  32 n.a.  n.d. n.d. 
Hesperitin 45 +/- +/-  16 8  n.d. n.d. 
Homoeriodictyolb 46 + +  32 32  63.9 84.9 
4’-Hydroxyflavanonec 47 - +/-  n.a. n.a.  n.d. n.d. 
Liquiritigenin 48 + +  32 16  59.2 64.5 
6-Methoxyflavanone 49 +/- -  n.a. n.a.  n.d. n.d. 
Naringenin 50 + +  16 8  36.2 32.9 
Pinocembrin 51 + +  8 4  39.1 48.9 
Flavanonols          
Fustin 52 + +  500 250  n.d. n.d. 
Silibininc 53 + +  8 8  56.1 99.2 
(+)-Taxifolin 54 + +  63 125  n.d. n.d. 
Flavanols          
(+)-Catechinc 55 + +  500 250  n.d. n.d. 
(-)-Epicatechin (EC) 56 +/- +  500 250  n.d. n.d. 
(-)-Epicatechin gallate (ECG) 57 + +  125 32  n.d. 151 
(-)-Epigallocatechind (EGC) 58 - +  n.a. 500  n.d. n.d. 
(-)-Epigallocatechin gallateb 
(EGCG) 59 + + 
 250 32  n.d. 161 
Chalconese          
Butein 60 + +  16 125  n.d. n.d. 
Chalcone 61 + +/-  32 n.a.  n.d. n.d. 
3,2’-Dihydroxychalcone 62 +/- +  8 8  24.5 53.6 
4,2’-Dihydroxychalcone 63 +/- +/-  n.a. n.a.  n.d. n.d. 
2’,4’-Dihydroxychalcone 64 +/- +/-  n.sp. n.sp.  n.d. n.d. 
Eriodictyolchalconeb 65 + +  32 16  40.7 55.5 
4’-Hydroxychalcone 66 +/- +/-  16 n.sp.  n.d. n.d. 
Isoliquiritigenin 67 +/- +/-  16 16  n.d. n.d. 
2,2’,4’-Trihydroxychalcone 68 + +  8 2  n.d. n.d. 
4,2’,5’-Trihydroxychalconed 69 + +  125 2  n.d. n.d. 
Dihydrochalconese          
Phloretina 70 + +  16 8  30.2 41.3 
Anthocyanidins          
Cyanidin chlorideb 71 + +  250 32  n.d. 187 
Pelargoninidin chloride 72 + +  63 32  n.d. n.d. 
Deoxyanthocyanidins          
Apigeninidin chlorided 73 - -  n.a. n.a.  n.d. n.d. 
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Back-
bone R1 R3 R5 R6 R7 R8 R2’ R3’ R4’ R5’ 
A  OH H OH H H H OH OH H 
A  OH H H OH H H H OH H 
           
B  H OH H OH   OH OH  
B  H H H H   H H  
B  H OH H OH   OH OCH3  
B  H OH H OH   OCH3 OH  
B  H H H H   H OH  
B  H H H OH   H OH  
B  H H OCH3 H   H H  
B  H OH H OH   H OH  
B  H OH H OH   H H  
           
B  OH H H OH   OH OH  
B, d  OH OH H OH   d d  
B  OH OH H OH   OH OH  
           
C  OH OH  OH   OH OH H 
C  OH OH  OH   OH OH H 
C, e  e OH  OH   OH OH H 
C  OH OH  OH   OH OH OH 
C, e  e OH  OH  
 
 OH OH OH 
D           
D H  OH  OH H H OH OH  
D H  H  H H H H H  
D H  OH  H H H OH H  
D H  OH  H H H H OH  
D H  OH  OH H H H H  
D OH  OH  OH H H OH OH  
D H  H  OH H H H H  
D H  OH  OH H H H OH  
D H  OH  OH H OH H H  
D H  OH  H OH H H OH  
           
E OH  OH  OH H H H OH  
           
F  OH OH  OH   OH OH  
F  OH OH  OH   H OH  
           
F  H OH  OH   H OH  
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Compound No 
Activity 
hTAS2R 
 Threshold 
hTAS2R 
 EC50 
hTAS2R 
14 39  14 39  14 39 
Isoflavones          
Acetyl genistinb,c,d,f 74 - +  n.a. 125  n.d. n.d. 
Biochanin Af 75 + +  63 500  n.d. n.d. 
Daidzeinf 76 + +  500 500  n.d. n.d. 
Daidzinf 77 +/- +/-  n.a. n.a.  n.d. n.d. 
7,4'-Dimethoxy-5-
hydroxyisoflavoned 78 - - 
 
n.a. n.a. 
 
n.d. n.d. 
7,4'-Dimethoxy-isoflavone 79 + -  500 n.a.  n.d. n.d. 
Formomonetinc,f 80 + +  500 500  n.d. n.d. 
Genisteina,b,f 81 + +  4 8  28.9 49.4 
Genistinf 82 - +  n.a. 500  n.d. n.d. 
Glyciteinf 83 + +  500 500  n.d. n.d. 
Glycitinf 84 - +  n.a. 500  n.d. n.d. 
7-Hydroxyisoflavonef 85 + +  32 250  n.d. 315 
7-Hydroxy-6-methoxyisoflavonef 86 +/- +/-  n.sp. n.sp.  n.d. n.d. 
Isoflavoned,f 87 + -  250 n.a.  n.d. n.d. 
Malonyl genistinf 88 - +  n.a. 500  n.d. n.d. 
Prunetinf 89 + +/-  16 n.sp.  n.d. n.d. 
6,7,4’-Trihydroxyisoflavonef 90 + +  250 250  n.d. n.d. 
7,8,4’-Trihydroxyisoflavonef 91 + +  63 63  124 184 
7,3’,4’-Trihydroxyisoflavonef 92 + +  250 250  n.d. n.d. 
Isoflavans          
Equola,f 93 +/- +/-  8 32  47.2 55.8 
Coumestanse          
Coumestrolf 94 + +  250 250  n.d. n.d. 
Stilbenese          
Resveratrol 95 + +  16 63  30.3 109 
Auronese          
Sulfuretinb 96 + +  16 16  21.5 48.0 
Xanthones          
Xanthoned 97 + +  250 500  n.d. n.d. 
a training set used for pharmacophore building of hTAS2R14. 
b training set used for pharmacophore building of hTAS2R39. 
c test set used for fingerprint model of hTAS2R14. 
d test set used for fingerprint model of hTAS2R39. 
e to facilitate comparison of position of substitution with the majority of the flavonoids, the residue 
numbering for chalcones, coumestans, stilbenes, and aurones, the usually applied residue numbering 
was adapted. 
f published previously (7). 
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Back-
bone R1 R3 R5 R6 R7 R8 R2’ R3’ R4’ R5’ 
           
G, a   OH H a H  H OH  
G   OH H OH H  OH OCH3  
G   H H OH H  H OH  
G, c   H H c H  H OH  
G 
 
  OH H OCH3 H  H OCH3  
G   H H OCH3 H  H OCH3  
G   H H OH H  H OCH3  
G   OH H OH H  H OH  
G, c   OH H c H  H OH  
G   H OCH3 OH H  H OH  
G, c   H OCH3 c H  H OH  
G   H H OH H  H H  
G   H OCH3 OH H  H H  
G   H H H H  H H  
G, b   OH H b H  H OH  
G   OH H OCH3 H  H OH  
G   H OH OH H  H OH  
G   H H OH OH  H OH  
G   H H OH H  OH OH  
           
H     OH    OH  
           
I     OH    OH  
           
J   OH  OH    OH  
           
K     OH   OH OH  
           
L           
n.a., not active up to 500 µM. 
n.d., not determined. 
n.sp., not specific, means that activity could not be determined due to non-specific signals in the non-
induced cells.  
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Figure 1. Backbone structures (A-L) and larger substituents (a-e). 
 
them as active. Quality of mapping and correctness of predictions were analyzed with a 
heat map (supplementary material S15-S16). 
OR7
R4'
A B C
D E F
G H I
J K L
A C
B
a b c
d e
OH
OH
OH
HO
O
R3
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RESULTS 
Compound selection and qualitative screening for hTAS2R activation 
Ninety seven compounds were screened for activation of bitter receptors hTAS2R14 and 
hTAS2R39, based on variation in backbone structure and their substitution pattern (Table 1 
and Figure 1). One example is shown in Figure 2A. 6,7-Dimethoxyflavone (11) clearly 
activated hTAS2R14, whereas it did not activate hTAS2R39. All test compounds were 
categorized into “+”, “-”, and “+/-”, depending on their extent of receptor activation. The 
latter designation was given when results were ambiguous even after three repetitions in 
duplicate. In vitro results identified that 60 compounds activated hTAS2R14 and 67 
compounds activated hTAS2R39 at the screening concentration of 500 µM. In contrast, 15 
compounds did not activate hTAS2R14, whereas 9 compounds did not activate hTAS2R39. 
The remaining compounds could not be unambiguously classified at the screening 
concentration (Table 1). 
 
Dose-response behavior of selected (iso)flavonoids on hTAS2R14 and hTAS2R39 
All (iso)flavonoids (or similar) that activated one or both of the two bitter receptors at the 
screening concentration were measured at different concentrations in order to establish 
dose-response curves, the threshold and EC50 values of which are summarized in Table 1. 
Their threshold values varied over a range of three log units between 0.12 and 500 µM. 
Although many compounds activated both bitter receptors, the threshold concentrations for 
each individual receptor sometimes varied. For example, resveratrol (95) (Figure 2B) had a 
threshold value with hTAS2R14 of 16 µM and an EC50 value of 30.3 µM, whereas with 
hTAS2R39 this was 63 µM and 109 µM, respectively. An even larger difference in bitter 
receptor activation was observed for epigallocatechin gallate (59) (Figure 2C), with a 
threshold of 32 µM and an EC50 of 161 µM for hTAS2R39, and a threshold of 250 µM for 
hTAS2R14. The EC50 value for hTAS2R14 could not be calculated. Other compounds 
showed almost identical behavior towards both bitter receptors. For example, scutellarein 
(23; Figure 2D) activated both receptors from 8 µM onwards with EC50 values of 35.0 and 
40.3 µM for hTAS2R14 and hTAS2R39, respectively. 
 
The influence of small structural changes on bitter receptor activation 
Small structural changes had different effects on receptor activation. A few examples for 
hTAS2R39 are shown in Figure 3. Phloretin (70) and naringenin (50) have the same A- 
and B-ring substitutions, but differ in an open and closed C-ring, respectively (Figure 3A). 
Nevertheless, both compounds have the same threshold of 8 µM, and differ only slightly in 
EC50 values (41.3 µM for (70) and 32.9 µM for (50)). In this case, the change of C-ring 
structure had a small effect. In contrast, eriodictyolchalcone (65) and luteolin (20), differing 
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similarly in C-ring configuration, showed different behavior in receptor activation (Figure 
3B). The thresholds were 16 µM for (65) and 0.5 µM for (20), whereas the EC50 values 
were 55.5 µM for (65) and 7.3 µM (20).  
 
 
Figure 2. Effect of 500 µM 6,7-dimethoxyflavone (11) on hTAS2R14 (──) and hTAS2R39 (──), and on 
the corresponding non-induced cells, not-expressing the bitter receptors (- - -) and (- - -) (A); dose-
response curves of resveratrol (95) (B), epigallocatechin gallate (59) (C), and scutellarein (23) (D) on 
both bitter receptors hTAS2R14 (■) and hTAS2R39 (▲). 
 
In some cases, similar effects were observed for variation in B-ring structure. For 
example, the structural difference between eriodictyol (43) and homoeriodictyol (46) did 
not affect receptor activation (Figure 3C). For other compounds, a change in B-ring 
substituents had an effect, e.g. comparing luteolin (20) (two OH-groups on the B-ring, 
highly active) to tricetin (24) (three OH-groups on the B-ring, threshold 250 µM, curve not 
shown). Figure 3D compares three flavones that vary in A-ring substitution: 3’,4’,7-
trihydroxyflavone (27), 6-methoxyluteolin (22), and luteolin (20) with effects on threshold 
(16 µM, 8 µM, and 0.5 µM, respectively), and EC50 values (141 µM, 22.9 µM, and 7.3 µM, 
respectively).  
There was no obvious universal relation between structural denominator and activity. 
Considering the large number of compounds tested, modeling was employed to detect 
structure/activity relationships. 
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Figure 3. Comparison of dose-response curves on hTAS2R39 of phloretin (70) and naringenin (50) (A), 
luteolin (20) and eriodictyolchalcone (65) (B), eriodictyol (43) and homoeriodictyol (46) (C), and 3’,4’,7-
trihydroxyflavone (27), 6-methoxyluteolin (22), and luteolin (20) (D). 
 
2D-fingerprint modeling 
The best separation between active and inactive compounds was achieved by the ECFP-10 
and ECFP-8 fingerprint models for hTAS2R14 and hTAS2R39, respectively. Figure 4 
displays the predictions for the complete set of training and test molecules used for 
modeling. The ECFP-10 model for hTAS2R14 agonists predicted 93% of all compounds 
correctly. Two compounds were falsely predicted as active and three compounds were 
falsely predicted as inactive. The ECFP-8 model for hTAS2R39 agonists predicted 96% of 
all compounds correctly. One compound was falsely predicted as active and two 
compounds were falsely predicted as inactive.  
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Figure 4. Predictions of 2D-fingerprint models with true positives, true negatives, false positives, 
and false negatives (in percentage) for hTAS2R14 (n=75) and hTAS2R39 (n=76) ligands. 
 
In order to identify key molecular features involved in bitter receptor activation, 
“good” and “bad” fingerprint fragments were established (see supplementary material S5-
S9), of which a selection of four illustrative fragments is shown here for the hTAS2R14 
model (Figure 5). Based on the fragments it was observed that the flavanones and 
isoflavones were likely to trigger hTAS2R14. Flavones could activate this receptor as well, 
but there were fragments within some flavones assigned to the “bad” fragments, implying 
that some flavones caused less or no activation. Methoxylation and glycosylation seemed to 
impair activation of this receptor. Receptor hTAS2R39 had a high probability of activation 
by flavanones and flavonols and showed a similar behavior towards flavones as compared 
to hTAS2R14. Methoxylation fragments were not beneficial for activation by 
isoflavonoids. Glycosylation was not an obvious bad feature for this receptor. The 
fingerprint fragments helped in understanding which molecular features were obviously 
favorable and unfavorable for receptor activation were, but it was not possible to develop a 
most common substructure.  
In conclusion, the 2D-models possessed excellent predictive value for identification of 
bitter (iso)flavonoids activating hTAS2R14 or hTAS2R39, but did not give sufficient 
insight into understanding of the general molecular signature involved in bitter receptor 
activation of (iso)flavonoids. Therefore, 3D modeling was used as a next step in 
understanding which chemical characteristics influence bitter receptor interaction.  
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Figure 5. Selected “good” (positive Bayesian score) and “bad” 
(negative Bayesian score) fingerprint fragments for hTAS2R14. 
 
3D-pharmacophore modeling 
The structural requirements for (iso)flavonoids to activate hTAS2R14 were best described 
by a 5-feature pharmacophore (Figure 6A), of which all five features had to be mapped. It 
comprised two hydrogen donor features, one hydrogen acceptor feature, one “hydrophobic 
aromatic” feature, and one “ring aromatic” feature. The ROC-plot area under the curve 
value was of 0.751 (for confusion matrices and ROC plots, see supplementary material 
S11-S14). This model was able to correctly predict the activation or absence of activation 
of two thirds of the ligands and performed better for highly active than for moderately 
active compounds (the division into threshold groups is shown in Table 2). Of the highly 
active compounds, 81% was predicted correctly, but for the moderately active compounds 
this was 52%. Two thirds of the inactive compounds were predicted correctly. The reason 
behind and remedy for incorrect predictions will be discussed in another section.  
The best results for modeling the activation of hTAS2R39 by (iso)flavonoids were 
achieved with a 6-feature pharmacophore (shown in Figure 6B), which allowed the ligands 
to map five out of six features. It comprised three hydrogen donor features, one hydrogen 
acceptor feature, one “hydrophobic aromatic” feature, and one “ring aromatic” feature. The 
ROC-plot area under the curve value was 0.873, while returning 9 false positives and 3 
false negatives. This model was able to map 84% of the compounds correctly. Divided into 
threshold groups, 94% of the highly active compounds, 75% of the moderately active 
compounds, and 79% of the inactive compounds were predicted correctly. 
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Figure 6. Pharmacophores for hTAS2R14 (A) and hTAS2R39 (B). The colors of the spheres represent 
the following features: pink - hydrogen donors, green - hydrogen acceptors, blue - hydrophobic 
aromatic, and yellow - ring aromatic. The green rectangle represents a plain within a ring structure. The 
small spheres indicate the presence of the feature on the ligand and the large spheres indicate the 
possible position of the amino acids on the receptor, interacting with this feature. The direction of 
interaction is shown with an arrow. The numbers represent the distance between the features in 
Ångström. 
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Visualization of mapped molecules 
In Figure 7A, the pharmacophore for hTAS2R14 ligands is shown including the mapped 
molecule luteolin (20). The features of the pharmacophore almost precisely mapped the 
respective atoms of the flavonoid. This was reflected in an excellent fit value of 4.9, very 
close to the maximal attainable fit value of 5. The molecule was mapped with a relative 
energy of 0.14 kcal / mol, meaning that it required little energy to fit the conformation of 
the molecule into the pharmacophore. Compound 78 (7,4’-dimethoxy-5-hydroxyisoflavone) 
was unable to activate hTAS2R14, which is illustrated by suboptimal mapping (Figure 
7B). One hydrogen bond donor feature did not map at all, which is indicated by a darker 
shade of pink in this feature than when the feature mapped. The structure of 7,4’-
dimethoxy-5-hydroxyisoflavone (78) was applied with the relative energy 6.4 kcal / mol. 
So even with rotation, translation, and torsion, and in spite of a reasonable fit value of 2.1, 
the molecule did not map, in accordance with the compound being inactive. Often, high fit 
values indicate good mapping, but low fit values do not necessarily mean mismapping of 
molecules. As long as all features are met somehow, a bad fit value can still lead to 
activation. This is for example the case for 7,8,4’-trihydroxyisoflavone (91), which has a fit 
value of 0.8, but still maps the features and activates the receptor.  
In Figure 7C, kaempferol (35) is mapped on the pharmacophore for hTAS2R39. The 
points in the middle of the sphere and the position of the respective atoms were close to 
each other. The mapping of the ligand was good, which is reflected in a fit value of 5.0 (out 
of 6 maximum attainable). Figure 7D shows an inactive flavonoid on hTAS2R39, namely 
4’-hydroxy-6-methoxyflavone (18). As shown by the darker shade of pink, two of the three 
hydrogen donor features did not map at all. 
To illustrate the influence of the absence of a C-ring, the mapped molecules for a 
chalcone (butein (60)) and a stilbene (resveratrol (95)) are depicted in Figures 7E and 7F, 
respectively. As a result of the flexibility of butein (60), it mapped most of the features of 
the hTAS2R39 very well, except for the shifted hydrogen bond acceptor feature, resulting 
in a good fit value of 4.8. Its relative energy used for modeling was very low (0.08 kcal / 
mol).  
Although the aromatic rings of resveratrol (95) are in closer proximity of each other 
than in flavonoids, it mapped the hTAS2R14 pharmacophore with all five features (fit value 
3.6, relative energy 0.06 kcal / mol), indicating that the pharmacophore model might also 
be applicable to compounds that are structurally similar to flavonoids. Thus, a small 
variation in distance might have minor influence on binding. This is not self-evident, as the 
length of a molecule can be crucial for receptor activation, which can be observed for 
estrogen receptor agonists (30).  
Furthermore, the C-ring seems to be of less influence for bitter receptor activation than the 
A-and the B-rings. This is coherent with the observations in our previous study on  
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Figure 7. Examples of hTAS2R14 ligand pharmacophores including luteolin (20) (A), 7,4’-dimethoxy-5-
hydroxy-isoflavone (78) (B), and resveratrol (95) (E). Examples of hTAS2R39 ligand pharmacophores 
including kaempferol (35) (C), 4’-hydroxy-6-methoxy-flavone (18) (D), and butein (60) (F). 
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isoflavonoids (7), showing that the hydroxylation positions on A-and B-rings were more 
crucial for activation than the exact structure in the center (e.g. C-ring) of the molecule. 
 
DISCUSSION 
(Iso)flavonoid agonists of hTAS2R14 and hTAS2R39 and their effects on bitter taste 
receptors and taste perception 
Amongst aglycones, catechins are the most important group of flavonoids occurring in our 
diet. We identified catechins as agonists of two bitter receptors, hTAS2R14 and 
hTAS2R39. Previously, only activation of hTAS2R39 was reported (14). On hTAS2R39, 
we identified thresholds of ECG, EGCG, EC, and EGC, to be 32, 32, 250, and 500 µM, 
respectively. Previously reported thresholds were between 10 and 30 µM for all four 
catechins (14). Thus, our thresholds for galloylated catechins were in the same range as the 
previously reported thresholds, but we observed by a factor of ten higher thresholds for the 
non-galloylated catechins. The same trend applied to the observed EC50 values on 
hTAS2R39. We obtained EC50 values of 150.6 µM and 161.2 µM for ECG and EGCG, 
respectively, and values for EC and EGC could not be calculated within the suitable 
concentration range (EC50 values reported by Narukawa (14) for ECG, EGCG, EGC, EC: 
88.2, 181.6, 395.5, 417.7 µM, respectively). In another recent publication (16), EC was 
identified as an agonist for three bitter receptors: hTAS2R39 (threshold 1 mM, EC50 3.8 
mM), hTAS2R4 (threshold 2 mM, EC50 30.2 mM), and hTAS2R5 (threshold 1 mM, EC50 
3.2 mM). We additionally identified hTAS2R14 (threshold 500 µM; no EC50 determined). 
Thus, differences are reported between the various bitter receptor assays, which might be 
caused by differences in experimental conditions. It should also be noted that in-vitro 
threshold values reported in the elevated µM or in the mM range are very high, and, e.g. in 
the case of EC in green tea, are unlikely to contribute to the bitter taste of the product.  
Amongst the many new agonists of hTAS2R14 and hTAS2R39 reported in this study, 
some compounds were known as bitter before (e.g. taxifolin, resveratrol), some compounds 
had unknown taste properties (e.g. synthetic flavonoids), while three compounds were 
previously reported as bitter taste maskers (homoeriodictyol, eriodictyol and phloretin (22, 
31)). We identified homoeriodictyol and eriodictyol as agonists of hTAS2R14 (thresholds 
32 µM for both compounds) and hTAS2R39 (thresholds 32 µM and 16 µM, respectively). 
These two compounds were reported to mask bitterness of caffeine in sensory tests without 
exhibiting strong taste characteristics at 100 ppm (31). The molecular mechanism of 
masking by homoeriodictyol and eriodictyol requires further clarification. For phloretin, it 
was reported that its masking activity (50 mg / L (= 182 µM)) for caffeine in sensory tests 
competed with its bitterness observed at elevated concentrations (100 mg / L (= 365 µM)) 
(22). It was suggested that this might be an overlapping effect of antagonistic and agonistic 
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activity, as described for sesquiterpene lactones (32). We identified phloretin as agonists of 
hTAS2R14 and hTAS2R39 (thresholds 16 µM and 8 µM, respectively). Thus, the bitterness 
of phloretin could be caused by activation of hTAS2R14 and hTAS2R39, and possibly 
other receptors. Remarkably, the bitterness threshold of phloretin in-vivo was ~20-40 fold 
higher than in-vitro. It has been observed before (10) that bitter compounds (hop acids) can 
display higher sensory than receptor thresholds. In the case of hop acids, this has been 
ascribed to their interaction with the oral mucosa. A bitter receptor assay might thus 
overestimate bitterness, as interaction with mucosa or other in-vivo conditions is not 
accounted for. Nevertheless, overestimation is not necessarily the case, as similar in-vivo 
and in-vitro thresholds have been reported for β-D-glucopyranosides (33) and tea catechins 
(14). 
 
Evaluation of the 2D and 3D models 
Even though they only operated with planar compound structures, the 2D-fingerprint 
models were very effective in predicting active compounds, and discriminating them from 
inactive compounds, leading to low numbers of false predictions. This might be due to the 
relatively planar nature of many (iso)flavonoids. The 2D-fingerprint models can be used as 
a quick in silico screening tool in compound library screening in order to identify 
(iso)flavonoid (or similar) compounds that might taste bitter. Due to lower complexity, they 
are more suitable than the 3D-pharmacophore models for screening large compound 
databases. On the contrary, 2D-fingerprint models created only a partial understanding of 
the molecular features involved in bitter receptor activation. The 3D-pharmacophore 
models provided a broader insight into (iso)flavonoid bitter receptor interaction. The 
structural characteristics for an (iso)flavonoid to activate hTAS2R14 (or hTAS2R39), were 
determined to be composed of two (or three) hydrogen bond donor sites, one hydrogen 
bond acceptor site, one hydrophobic ring structure and one aromatic ring structure. 
The receptor activation threshold values lie within a range of three orders of magnitude, 
which is generally considered as a relatively small range for quantitative structure activity 
relationship (QSAR) modeling. In the attempt of establishing a QSAR model, a clear 
correlation between features and threshold could not be determined. But even without a 
quantitative prediction, the pharmacophore models are a powerful tool in prediction of 
potential bitterness. 
 
Explanation of false predictions by 3D-pharmacophore models 
Several compounds were falsely predicted as positive or negative by the 3D-
pharmacophore models (see Table 2).  
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Table 2. Classification of ligands into threshold groups highly active (≤32 µM), moderately active (>32 
µM - 500 µM), and inactive (not active up to 500 µM). For 3D-pharmacophore modeling, the number of 
ligands per threshold group are given for hTAS2R14 and hTAS2R39, and subdivided by their model 
prediction into true / false positives / negatives. Several compounds measured were not included into 
modeling. 
Activity hTAS2R14  hTAS2R39 
 Total True  False  Total True  False 
  + -  + -   + -  + - 
High 27 22 -  - 5  35 33 -  - 2 
Moderate 23 12 -  - 11  28 21 -  - 7 
Inactive 23 - 15  8 -  14 - 11  3 - 
 
The highly active false negatives, i.e. the actives from the cell assay which did not map 
to the pharmacophores, had a lack of substituents on the B-ring of the (iso)flavonoid in 
common. In most cases, as shown in Figure 8A for pinocembrin (51), the donor feature 
next to the hydrophobic aromatic feature in the pharmacophore for hTAS2R14 ligands 
could not be mapped by these molecules. Consequently, the model classified these 
molecules as inactive. The pharmacophore model for hTAS2R39 ligands was able to 
recognize more of these unsubstituted ligands, probably due to the mapping setting which 
allowed the ligands to miss one feature. The question arises whether the donor feature next 
to the hydrophobic aromatic group might be irrelevant or of less importance for binding. 
Another explanation could be that a second mode of binding to the receptor for ligands 
without substitution on the B-ring occurs. Thus, the current pharmacophore models are 
limited to (iso)flavonoids that contain two (for hTAS2R14) or at least one (for hTAS2R39) 
substituted aromatic ring(s). Nevertheless, naturally occurring (iso)flavonoids are mostly 
substituted (exceptions are e.g. pinocembrin and chrysin), and therefore applicable to the 
model.  
False positives, i.e. molecules which mapped to the pharmacophore(s), even though 
they did not activate the receptor(s), were obtained as well. Only three compounds were 
falsely predicted as positive for hTAS2R39, and eight compounds for hTAS2R14. Out of 
these eight, five were isoflavones glucosylated on position 7 of the A-ring (example given 
for 74 in Figure 8B), which might cause steric hindrance for optimal receptor binding. In 
order to prevent these false positive predictions, excluded volumes might be added to the 
pharmacophore model for receptor hTAS2R14, as shown in Figure 8C. However, this 
option should only be used for isoflavones, as structures with other backbones have not 
been tested. Furthermore, since only the glucoside substitutions on position 7 typical for 
isoflavones were tested, no statement can be made about other glycosylation positions 
frequently occurring in flavonoids, such as position 3. Thus, the resulting model for 
hTAS2R14 ligands is limited to aglycones, while the model for hTAS2R39 ligands can be 
used for certain glycosides as well. An additional reason for false positive prediction might 
be a solubility issue. Some compounds (for example 1 and 14) had limited solubility at high 
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concentrations, thus their real potential to act as bitter compound might have been 
underestimated.  
In conclusion, the prediction of the generated pharmacophore models for activation of 
receptors hTAS2R14 and hTAS2R39 by (iso)flavonoids was successful, and most false 
positive and false negative predictions could be explained, leading to an understanding of 
88% of hTAS2R14 ligands, and 94% of hTAS2R39 ligands within this study. The 
combination of in vitro and in silico data created a good insight in activation of hTAS2R14 
and hTAS2R39 by (iso)flavonoids.  
 
Comparison of ligand-based pharmacophore models for hTAS2R14 and hTAS2R39 
The difference between the two pharmacophore models indicated that despite the largely 
overlapping ligands of both receptors, there was a difference in the molecular structure and 
substitution pattern of ligands recognized by receptor hTAS2R14 and hTAS2R39. The 
additional donor feature of the pharmacophore model for hTAS2R39 ligands indicated the 
possible presence of another complementary acceptor site in the binding pocket of 
hTAS2R39 compared to hTAS2R14. This might explain why the OH-rich compounds 
showed different behavior on the two bitter receptors, as can be observed for compounds 
24, 32, and 58, which activate only hTAS2R39, but not hTAS2R14, and for compounds 38, 
39, 57, and 59, which have a much higher activity on hTAS2R39 than on hTAS2R14. 
Another explanation might be that the hydrophobic aromatic feature, and therewith 
hydrophobic interaction with the binding site, is of higher importance in hTAS2R14 than in 
hTAS2R39, as compounds with three OH groups on the B-ring (24, 38, 58, and 59) have a 
decreased hydrophobicity on this aromatic ring and no or decreased activity on hTAS2R14.  
Both pharmacophore models have two donor features which seem to be equally 
relevant for discrimination between the active and inactive ligands. The aromatic features 
and the acceptor feature did not seem to have a strong discriminator function, but they 
might play a role in ligand alignment.  
 
Tuning breadth of bitter taste receptors 
To date, hTAS2R14 has been regarded as a more broadly tuned receptor, compared to 
hTAS2R39 (9). This idea was based on the activation of hTAS2R14 by structurally very 
diverse compounds, and the fact that fewer agonists for hTAS2R39 were known. During 
recent years, numerous new agonists have been reported for hTAS2R39 (7, 14, 15, 17), 
including the large number of flavonoids from the present study, which exceeds the number 
of hTAS2R39 agonists known before. Hence, hTAS2R39 reveals to be activated by many 
more agonists than initially thought. Also the number of hTAS2R14 agonists keeps 
increasing ((7, 13) and this study).  
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Figure 8. The falsely negative predicted compound pinocembrin (51) on the hTAS2R14 
ligand pharmacophore (A); the falsely positive predicted compound acetyl genistin (74) 
on the hTAS2R14 ligand pharmacophore (B); excluded volumes on the hTAS2R14 
ligand pharmacophore (C). 
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With time, the number of hTAS2R agonists will grow further, and it is questionable 
whether tuning breadth should simply be related to the number of bitter receptor agonists. 
Our present results show that the substitution pattern of (iso)flavonoids was of higher 
importance for receptor activation than their backbone structure (e.g. whether the agonist is 
a flavone or a flavanone). Our pharmacophore modeling revealed, which signatures 
underlay binding to hTAS2R14 and -39. Therefore, it might be better to describe tuning 
breadth of bitter receptors in terms of the number of molecular signatures recognized by the 
receptor. In this way, a collection of molecules with similar signature will only count as one 
with respect to tuning breadth, and tuning breadth is less likely to be overestimated.  
 
In conclusion, this study identified many flavonoids as intrinsically bitter, and 
elucidated the structural requirements for bitterness of (iso)flavonoids. Understanding their 
“bitter motif” might prevent the introduction of bitter taste in the design of functional foods 
enriched in (iso)flavonoid bioactives. 
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SUPPORTING INFORMATION 
Table S1. Fit values and relative energies of tested compounds with number codes and SMILES 
mapped to the pharmacophore models for hTAS2R14 and hTAS2R39. 
No. Fit Value  Relative Energy SMILES 
 
14 39  14 39 
 
1 3,98 3,93  0,92 9,86 O=C2C1=C(O)C=C(O)C=C1OC(C3=CC=C(OC)C=C3)=C2 
2 3,14 3,93  0,04 0,07 O=C2C1=C(O)C=C(O)C=C1OC(C3=CC=C(O)C=C3)=C2 
3 3,98 3,35  0,00 0,98 O=C2C1=C(O)C=C(O)C=C1OC(C3=CC=CC=C3)=C2 
4 3,93 4,38  6,34 2,64 O=C2C1=C(O)C=C(O)C=C1OC(C3=CC=C(O)C(OC)=C3)=C2 
5 2,83 3,19  3,49 0,00 O=C2C1=C(O)C=CC=C1OC(C3=CC=CC=C3O)=C2 
6 3,97 2,57  0,05 2,04 O=C2C1=C(O)C=CC=C1OC(C3=CC=CC(O)=C3)=C2 
7 2,13 3,25  0,09 2,18 O=C2C1=C(O)C=CC=C1OC(C3=CC=C(O)C=C3)=C2 
8 1,77 3,02  0,00 0,00 O=C2C1=CC(O)=CC=C1OC(C3=CC=C(O)C=C3)=C2 
9 2,93 3,72  0,03 0,08 OC2=CC1=C(C=C2)C(C=C(C3=CC=C(O)C=C3)O1)=O 
10 2,90 2,64  0,00 0,86 O=C1C=C(C3=CC=CC=C3)OC2=C1C(OC)=CC(OC)=C2 
11 2,90 2,51  0,00 1,42 O=C1C=C(C3=CC=CC=C3)OC2=C1C=C(OC)C(OC)=C2 
12 2,09 2,44  0,00 0,00 O=C2C1=CC=CC=C1OC(C3=CC=CC=C3)=C2 
13 1,69 2,74  8,16 0,00 COC1=CC(=CC(=C1OC)OC)C2=CC(=O)C3=C(O2)C(=C(C(=C3O)OC)OC)OC 
14 2,54 3,29  9,05 1,61 O=C2C1=C(O)C=C(OC)C=C1OC(C3=CC=C(O)C=C3)=C2 
15 3,00 2,47  0,00 0,00 O=C2C1=C(O)C=CC=C1OC(C3=CC=CC=C3)=C2 
16 2,27 3,20  0,03 0,04 O=C2C1=CC=CC=C1OC(C3=CC=C(O)C=C3)=C2 
17 2,61 2,94  6,30 6,27 O=C2C1=C(O)C=CC=C1OC(C3=CC=CC(OC)=C3)=C2 
18 2,25 3,48  0,00 8,81 O=C1C=C(C3=CC=C(O)C=C3)OC2=C1C=C(OC)C=C2 
19 3,57 3,47  8,52 7,34 O=C1C=C(C3=CC=C(O)C=C3)OC2=C1C=CC(OC)=C2 
20 4,95 4,19  0,14 1,13 O=C2C1=C(O)C=C(O)C=C1OC(C3=CC=C(O)C(O)=C3)=C2 
21 2,12 2,64  0,00 0,87 O=C1C=C(C3=CC=CC=C3)OC2=C1C=C(OC)C=C2 
22 5,00 4,65  2,58 9,12 O=C1C=C(C3=CC=C(O)C(O)=C3)OC2=C1C(O)=C(OC)C(O)=C2 
23 3,09 3,96  0,00 0,73 OC1=C(O)C(O)=C(C(C=C(C3=CC=C(O)C=C3)O2)=O)C2=C1 
24 3,98 3,34  0,00 1,12 O=C2C1=C(O)C=C(O)C=C1OC(C3=CC(O)=C(O)C(O)=C3)=C2 
25 3,82 0,30  3,49 3,25 O=C2C1=C(O)C=C(O)C=C1OC(C3=CC=CC=C3O)=C2 
26 1,72 0,16  0,04 2,13 O=C2C1=C(O)C=CC=C1OC(C3=CC=C(O)C(O)=C3)=C2 
27 3,73 2,95  0,03 0,03 O=C1C=C(C3=CC=C(O)C(O)=C3)OC2=C1C=CC(O)=C2 
28 2,94 2,69  8,02 7,06 O=C1C=C(C3=CC=C(OC)C=C3)OC2=C1C(OC)=CC(OC)=C2 
29 2,90 0,37  2,41 2,41 C1=CC=C(C(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O 
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30 3,52 3,56  0,01 0,01 C1=CC(=C(C=C1C2=C(C(=O)C3=C(O2)C=C(C=C3)O)O)O)O 
31 2,19 2,69  2,44 2,45 O=C2C1=CC=CC=C1OC(C3=CC=CC=C3)=C2O 
32 4,63 4,93  0,00 3,41 OC1=CC(O)=C(O)C2=C1C(C(O)=C(C3=CC=C(O)C(O)=C3)O2)=O 
33 2,92 4,85  0,01 0,07 C1=CC(=CC=C1C2=C(C(=O)C3=C(O2)C(=C(C=C3O)O)O)O)O 
34 3,82 5,42  9,31 7,00 COC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O 
35 2,96 4,97  0,00 3,23 O=C2C1=C(O)C=C(O)C=C1OC(C3=CC=C(O)C=C3)=C2O 
36 2,20 2,65  0,86 0,03 O=C1C(O)=C(C3=CC=CC=C3)OC2=C1C=C(OC)C=C2 
37 2,90 4,95  0,89 0,89 C1=CC(=C(C=C1O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O 
38 3,99 4,07  1,03 3,32 C1=C(C=C(C(=C1O)O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O 
39 4,97 4,92  3,25 3,33 C1=CC(=C(C=C1C2=C(C(=O)C3=C(C(=C(C=C3O2)O)O)O)O)O)O 
40 4,97 4,93  9,66 3,32 C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O 
41 2,56 3,08  0,00 0,01 O=C1C(O)=C(C3=CC=C(O)C(O)=C3)OC2=C1C=C(O)C=C2 
42 2,89 4,34  0,00 3,24 OC2=CC1=C(C=C2)C(C(O)=C(C3=CC=C(O)C=C3)O1)=O 
43 4,90 4,30  2,00 0,09 O=C1CC(C3=CC=C(O)C(O)=C3)OC2=C1C(O)=CC(O)=C2 
44 2,19 2,69  1,52 1,52 O=C2C1=CC=CC=C1OC(C3=CC=CC=C3)C2 
45 4,89 4,59  9,83 8,18 COC1=C(C=C(C=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)O 
46 3,70 4,39  6,03 5,88 COC1=C(C=CC(=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)O 
47 2,02 3,09  1,47 0,99 O=C1CC(C3=CC=C(O)C=C3)OC2=C1C=CC=C2 
48 2,95 3,68  1,87 1,59 OC2=CC1=C(C=C2)C(CC(C3=CC=C(O)C=C3)O1)=O 
49 2,12 2,64  1,48 1,48 O=C1CC(C3=CC=CC=C3)OC2=C1C=C(OC)C=C2 
50 3,09 4,22  1,89 0,00 O=C3C1=C(O)C=C(O)C=C1OC(C3)C2=CC=C(O)C=C2 
51 3,99 3,79  1,46 2,71 C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC=CC=C3 
52 2,23 2,55  1,71 3,04 C1=CC(=C(C=C1C2C(C(=O)C3=C(O2)C=C(C=C3)O)O)O)O 
53 4,24 3,70  5,66 8,78 COC1=C(C=CC(=C1)[C@@H]2[C@H](OC3=C(O2)C=C(C=C3)[C@@H]4[C@H](C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O 
54 2,48 5,51  0,02 0,11 O=C1[C@H](O)C(C3=CC=C(O)C(O)=C3)OC2=C1C(O)=CC(O)
=C2 
55 4,77 5,57  2,57 2,64 OC1=CC(O)=CC2=C1C[C@H](O)C(C3=CC=C(O)C(O)=C3)O2 
56 4,77 5,57  2,57 2,64 OC1=CC(O)=CC2=C1CC(O)C(C3=CC=C(O)C(O)=C3)O2 
57 4,25 4,61  4,76 8,61 C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O 
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58 3,96 4,71  1,85 0,00 OC1=CC(O)=CC2=C1CC(O)C(C3=CC(O)=C(O)C(O)=C3)O2 
59 3,97 3,50  7,43 4,93 O=C(O[C@@H]2Cc3c(O[C@@H]2c1cc(O)c(O)c(O)c1)cc(O)cc3O)c4cc(O)c(O)c(O)c4 
60 3,74 4,83  1,07 0,08 C1=CC(=C(C=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O)O 
61 1,98 2,60  0,00 0,00 O=C(/C=C/C2=CC=CC=C2)C1=CC=CC=C1 
62 1,65 3,12  4,21 2,96 O=C(C2=CC=CC=C2O)/C=C/C1=CC=CC(O)=C1 
63 0,55 3,85  4,20 0,00 O=C(C2=CC=CC=C2O)/C=C/C1=CC=C(O)C=C1 
64 3,54 3,91  0,00 0,00 O=C(C2=CC=C(O)C=C2O)/C=C/C1=CC=CC=C1 
65 3,43 4,72  1,74 0,00 C1=CC(=C(C=C1C=CC(=O)C2=C(C=C(C=C2O)O)O)O)O 
66 2,47 3,25  0,00 0,00 O=C(C2=CC=C(O)C=C2)/C=C/C1=CC=CC=C1 
67 2,35 4,81  0,00 0,00 O=C(C2=C(O)C=C(O)C=C2)/C=C/C1=CC=C(O)C=C1 
68 3,39 1,88  4,21 9,41 O=C(C2=CC=C(O)C=C2O)/C=C/C1=C(O)C=CC=C1 
69 3,29 3,86  1,14 0,09 O=C(C2=CC(O)=CC=C2O)/C=C/C1=CC=C(O)C=C1 
70 2,16 4,70  1,72 0,00 O=C(CCC1=CC=C(C=C1)O)C2=C(C=C(C=C2O)O)O 
71 4,98 4,68  0,22 8,74 C1=CC(=C(C=C1C2=C(C=C3C(=CC(=CC3=[O+]2)O)O)O)O)O 
72 4,30 4,75  7,64 9,64 OC1=C(C=C(O)C(C3=CC=C(O)C=C3)=[O]2)C2=CC(O)=C1 
73 3,92 3,69  0,00 2,04 OC1=C(C=CC(C3=CC=C(O)C=C3)=[O]2)C2=CC(O)=C1 
74 3,17 2,66  5,28 5,41 O=C1C2=C(O)C=C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(C)=O)O3)C=C2OC=C1C4=CC=C(O)C=C4 
75 2,63 3,20  7,87 6,05 O=C2C1=C(O)C=C(O)C=C1OC=C2C3=CC=C(OC)C=C3 
76 2,44 3,18  0,00 0,00 C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O 
77 0,25 1,84  2,88 9,05 C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O 
78 2,12 2,25  6,38 2,46 COC1=CC=C(C=C1)C2=COC3=CC(=CC(=C3C2=O)O)OC 
79 2,26 2,39  9,80 2,07 COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)OC 
80 1,88 3,14  9,45 1,94 O=C1C(C3=CC=C(OC)C=C3)=COC2=C1C=CC(O)=C2 
81 2,90 2,22  0,00 0,00 O=C2C1=C(O)C=C(O)C=C1OC=C2C3=CC=C(O)C=C3 
82 2,93 3,39  6,02 8,69 C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O 
83 2,32 3,47  9,37 9,36 COC1=C(C=C2C(=C1)C(=O)C(=CO2)C3=CC=C(C=C3)O)O 
84 2,50 2,07  3,15 8,46 COC1=C(C=C2C(=C1)C(=O)C(=CO2)C3=CC=C(C=C3)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O 
85 2,99 3,05  0,01 0,00 O=C1C(C3=CC=CC=C3)=COC2=C1C=CC(O)=C2 
86 1,96 3,18  7,00 7,01 O=C1C(C3=CC=CC=C3)=COC2=C1C=C(OC)C(O)=C2 
87 0,52 2,24  0,00 0,00 O=C2C1=CC=CC=C1OC=C2C3=CC=CC=C3 
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88 3,04 2,48 
 
5,18 6,22 
O=C1C2=C(O)C=C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[
C@@H](COC(CC(O)=O)=O)O3)C=C2OC=C1C4=CC=C(O)C=
C4 
89 0,95 2,82  8,06 9,65 O=C2C1=C(O)C=C(OC)C=C1OC=C2C3=CC=C(O)C=C3 
90 2,09 3,31  0,00 0,00 OC1=C(O)C=C(C(C(C3=CC=C(O)C=C3)=CO2)=O)C2=C1 
91 0,80 2,68  0,00 0,29 OC1=CC=C(C(C(C3=CC=C(O)C=C3)=CO2)=O)C2=C1O 
92 1,73 3,81  0,01 0,01 O=C1C(C3=CC(O)=C(O)C=C3)=COC2=C1C=CC(O)=C2 
93 0,04 3,20  2,98 7,92 C1C(COC2=C1C=CC(=C2)O)C3=CC=C(C=C3)O 
94 1,74 3,72  0,00 0,00 C1=CC2=C(C=C1O)OC3=C2C(=O)OC4=C3C=CC(=C4)O 
95 3,58 4,38  0,06 0,31 OC(C=C2)=CC=C2/C=C/C1=CC(O)=CC(O)=C1 
96 3,41 3,75  0,01 1,56 C1=CC(=C(C=C1C=C2C(=O)C3=C(O2)C=C(C=C3)O)O)O 
97 2,00 2,48  0,00 0,00 C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3O2 
 
Additional explanation S2. 2D fingerprint modeling 
A ROC plot is a graph of sensitivity (the ability of a model to avoid false negatives i.e. true 
positive rate) versus specificity (the ability of a model to predict true negatives i.e. false 
positive rate) for different cut-off values. A ROC score of 0.5 is random, and means that the 
model has no predictive value. A score near 1 means a sensitive and accurate model. The 
ROC scores of the fingerprint models created for this study were close to 1 which indicated 
excellent accuracy. The EstXVAUC, which is the ROC score from the leave-one-out cross-
validation process, and the XV_2 and XV_3, which are the ROC scores from the 2-fold and 
3-fold cross-validation process, presented fair values of above 0.7. These models were 
selected to perform "Random Y" cross-validation after 50 iterations. The value obtained 
from this process “P random”, is the probability that the predicted likelihood of activity is 
random. A value of 0.1 indicates a 10% chance that the model is random. From this test it is 
clear that the dumb descriptor model is 100% random, which is good as it is the negative 
control.  
The abbreviations of the molecular descriptors FCFP, ECFP, LCFP, and SCFP can be 
explained as follows. The first letter represents the atom abstraction method. E (atom type) 
uses atom type, charge, and hybridization; F (functional class) uses H-bond donor, H-bond 
acceptor, positive ionizable, negative ionizable, halogen, and aromatic; L (AlogP code) uses 
AlogP category of atoms; S (Sybyl) uses sybyl atom types used in the Tripos Mol2 file 
format. The second letter represents the type of fingerprint to generate, in all here described 
cases extended-connectivity. The last two letters stand for fingerprint. The number behind 
  
the fingerprint name describes the maximum diameter (in bond l
structure represented by the fingerprint.
 
Table S3
Table S4
Additional explanation S5
The key molecular features found from the 2D
S9. Each of the molecule fragments presents information regarding the type of feature: "G" 
for "good" followed by the ranking number (1 to 20 in this case), the fingerpr
unique for each fingerprint, the number of molecules that were active in which the feature 
occurred, the total number of molecules in which the feature was present, and the Bayesian 
score.
 
Table S6
13 good out of 13
Bayesian Score: 0.366
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SCFP_10
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6 good out of 6
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Bayesian Score: 0.333
G10: 
Bayesian Score: 0.322
G14: 
Bayesian Score: 0.322
G18: 
Bayesian 
 
Table S7
Bayesian 
5 good out of 5
5 good out of 5
4 good out of 4
B1: 1811812564
0 good out of 4
B5: 1426096942
0 good out of 4
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Score: 0.307
 
. ECFP 10 Scitegic Bayesian Inference: bad features from ECFP 10
Score: 
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G11: 
Bayesian Score: 0.322
G15: 1644070299
26 good out of 28
Bayesian Score: 0.312
G19: 
Bayesian Score: 0.307
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5 good out of 5
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 Bayesian Score: 
Bayesian Score: 0.322
G12: 
5 good out of 5
Bayesian Score: 0.322
G16: 2081690891
15 good out of 16
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5 good out of 5
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B10: 1277224341
Bayesian Score: 
Bayesian Score: 
Bayesian Score: 
 
Table S8
15 good out of 15
Bayesian Score: 0.183
10 good out of 10
Bayesian Score: 0.177
0 good out of 4
B14: 642771342
0 good out of 3
B18: 966631805
0 good out of 3
G1: 477042227
G7: 658676414
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13 good out of 13
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 Bayesian Score: 0.180
 Bayesian Score: 0.169
 hTAS2R activation
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0 good out of 3
B17: 
0 good out of 3
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12 good out of 12
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7 good out of 7
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G11: 
Bayesian Score: 0.169
Bayesian Score: 0.166
G19: 1849099567
Bayesian Score: 0.166
 
Table S9
Bayesian Score: 
Bayesian Score: 
7 good out of 7
G15: 
6 good out of 6
6 good out of 6
B1: 453543491
0 good out of 2
B5: 425403071
3 good out of 8
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Additional explanation S10
The pharmacophore protocol created 10 hypotheses for each run. 
analysed statistically, based on the confusion matrix and the ROC plot, or visually, by 
looking at ligand mapping and alignment. The confusion matrix gave
total number of positive and negative compounds included in the validation set, compared 
to the number of true positives, true negatives, false positive and false negatives as 
identified by the hypotheses. These numbers resulted in a va
retrieve actives, true positive rate) and a value for the specificity (the ability to discard 
inactives, true negatives rate). The favoured hypothesis was selected for a high sensitivity 
and a high specificity. Additiona
was provided for each hypothesis, which resembles true positives rate against the false 
positives rate. The area under the curve represented the accuracy of the model: a value of 
‘1’ indicated a perfe
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 hTAS2R activation
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 information on the 
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represented a useless test, which found just as many true positives as false positives. The 
ROC curve was also used for the selection of the most optimal model. With the statistical 
scoring two or three ‘good’ models were selected, which were further analyzed graphically. 
The hypotheses were viewed side by side, to find redundancy and to cluster hypotheses. 
Alignment of the ligands to the model was checked for chemical meaningfulness and to 
check whether important features were identified within the hypothesis. The most active 
ligands had to fit the pharmacophore in a reasonable manner. Tools used to analyse the 
visual scoring of the models were the ligand/pharmacophore mapping, the ligand profiling 
and the heat map. If the hypothesis were not satisfactory, the ligands or the settings were 
changed to improve the hypothesis. 
 
Table S11. Confusion matrix of pharmacophore models for hTAS2R14.
 
 
Table S12. Confusion matrix of pharmacophore models for hTAS2R39. 
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Figure S13. ROC plot for selected   Figure S14. ROC plot for selected  
pharmacophore model for hTAS2R14.  pharmacophore model for hTAS2R39. 
 
 
Additional explanation S15. Heat map for the pharmacophore model for hTAS2R14 
The heat map shows the mapping of the ligands to each of the pharmacophore features. If a 
feature maps to a feature in a ligand, the value is 1, if the feature is missed by a ligand, the 
value is 0. The row index indicates the row numbers of the ligands, which are separated in 
highly active and inactive ligands by the first column. A colour code is given to highlight 
the false negatives (yellow) and the false positives (red). All false negatives miss the feature 
HBD_4, which is the donor feature on the B-ring side. However, some of the ligands also 
miss the feature of the hydrophobic aromatic or the HBD_3, therefore the HBD_4 feature is 
not the only determinant for the presence of these false negatives. Another hypothesis 
following from the heat map is that the two donor features are equally relevant for 
discrimination between the active and inactive ligands. The aromatic features and the 
acceptor feature do not have a strong discriminator function, but they play a role in ligand 
alignment.  
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Figure S16. Heat map for the pharmacophore model of hTAS2R14, showing the activity of the 
ligands and the mapping of ligands to the 5 different features. HBA_5 is the hydrogen bond 
acceptor, HBD_3 is the first hydrogen bond donor, HBD_4 is the second hydrogen bond donor 
(at the B-ring side), Hydrophobic Aromatic_2 is the Hydrophobic Aromatic feature (at the B-
ring side) and Ring Aromatic_1 is the Ring Aromatic feature. 
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6-Methoxyflavanones as bitter taste receptor 
blockers for hTAS2R39 
 
 
 
 
 
 
 
 
 
 
 
Based on: Wibke S.U. Roland, Robin J. Gouka, Harry Gruppen, Marianne Driesse, Leo 
van Buren, Gerrit Smit, Jean-Paul Vincken. 6-Methoxyflavanones as bitter taste receptor 
blockers for hTAS2R39. Accepted 
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ABSTRACT 
Many (dietary) bitter compounds, e.g. flavonoids, activate bitter receptor hTAS2R39 in 
cell-based assays. Several flavonoids, amongst which some flavanones, are known not to 
activate this receptor. As certain flavanones are known to mask bitter taste sensorially, 
flavanones might act as bitter receptor antagonists. Fourteen flavanones were investigated 
for their potential to reduce activation of hTAS2R39 by epicatechin gallate (ECG), one of 
the main bitter compounds occurring in green tea. Three flavanones showed inhibitory 
behavior towards the activation of hTAS2R39 by ECG: 4’-fluoro-6-methoxyflavanone, 
6,3’-dimethoxyflavanone, and 6-methoxyflavanone (in order of decreasing potency). The 6-
methoxyflavanones also inhibited activation of hTAS2R14 (another bitter receptor 
activated by ECG), though to a lesser extent. Dose-response curves of ECG at various 
concentrations of the full antagonist 4’-fluoro-6-methoxyflavanone and wash-out 
experiments indicated reversible insurmountable antagonism. The same effect was 
observed for the structurally different agonist denatonium benzoate, suggesting a non-
competitive orthosteric mechanism.  
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INTRODUCTION 
Even though bitter taste can be appreciated in some food products, such as beer, coffee, 
dark chocolate and red wine (1), in most cases bitterness in food is unwanted and efforts are 
taken to reduce bitter taste (2). One approach for masking bitter taste is the use of so-called 
bitter receptor blockers, which inhibit the taste receptor activation caused by the bitter 
compound. On the human tongue, bitterness is perceived by human bitter taste receptors 
(hTAS2Rs, TAS2Rs or T2Rs). The in vitro activation of these hTAS2Rs by bitter 
compounds has been studied intensively during the last decade. For 21 of the 25 the bitter 
receptors, an agonist, or in some cases dozens of agonists, have been identified (3, 4). On 
the contrary, bitter receptor antagonists are still quite rare.  
The small molecule (4-(2,2,3-trimethylcyclopentyl)butanoic acid (or GIV 3727) has 
been reported as inhibitor of six bitter taste receptors (5). It was able to decrease the sensory 
perception of bitter aftertaste of the sweeteners acesulfame K and saccharin, as well as the 
activation of hTAS2R31 and hTAS2R43, the bitter receptors activated by these two 
compounds. Another compound, the decreased bitter receptor activation of which could be 
linked to sensory perception, was p-(dipropylsulfamyl)benzoic acid (better known as 
probenecid). It has been reported to inhibit activation of hTAS2R16, hTAS2R38, and 
hTAS2R43, and to suppress the bitter taste perception of salicin in sensory tests (6). It has 
been reported that a compound can act as an agonist towards one subset of bitter receptors, 
whereas it can act as an antagonist towards another subset of bitter receptors. This has been 
described for the two sesquiterpene lactones 3β-hydroxydihydrocostunolide (3HDC) and 
3β-hydroxypelenolide (3HP) (7).  
Recently, a pharmacophore model for maskers of the bitter taste of caffeine has been 
developed (8). This pharmacophore was docked into a homology model of hTAS2R10 (one 
of the bitter receptors activated by caffeine). Docking of the two substances enterolactone 
and enterodiol predicted their bitterness modulating activities, which could be confirmed by 
sensory tests. Docking was also applied for the compound GIV 3727 in a model of 
hTAS2R31, and the presence of a single binding pocket was reasoned (5), in which both 
agonist and antagonist can bind.  
Apart from in vitro studies on bitter receptor blocking, several molecules are reported 
to mask bitter taste in vivo (2), amongst which the flavanones homoeriodictyol, its Na-salt, 
and eriodictyol. They reduced the bitter taste of different chemical classes of bitter 
molecules up to 40 % with unknown mechanism (9). Their sensorial bitter masking effect 
has not been proven to be caused by inhibition of bitter taste receptor activation. Two other 
flavanones (sakuranetin and 6-methoxysakuranetin) have been described as antagonists for 
hTAS2R31 (10). Hence, flavanones seem to be of importance in reduction of bitter taste 
and bitter taste receptor activation. 
The human bitter taste receptor hTAS2R39 seems to be a bitter receptor for dietary 
compounds, as many agonists are dietary compounds, such as thiamine (vitamin B1), 
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quinine (3) used in tonic water, catechins from green tea (11), wine tannin precursors (12), 
small peptides from casein hydrolysates (13) and cheese (14), isoflavones from soy bean 
(15), and many other flavonoids from several plant sources (16). Hence, it is of interest to 
identify a bitter blocker for this receptor. It is likely that an antagonist might have similar 
structural elements to an agonist in order to fit into the same binding pocket. In our 
previous study on (iso)flavonoid agonists of hTAS2R39, several of the compounds tested, 
amongst which flavanones, did not activate the bitter receptor despite structural similarity 
to active compounds (16). The aim of the present study was to investigate whether these 
and other flavanones could act as antagonists towards hTAS2R39. 
 
MATERIALS AND METHODS 
Materials 
Compounds tested were obtained from Extrasynthese (Genay, France), Indofine Chemical 
Company (Hillsborough, NJ, USA), Interbioscreen (Moscow, Russia), and Sigma-Aldrich 
(Steinheim, Germany). Each compound was dissolved in DMSO (Sigma-Aldrich) to a 100 
mM stock concentration. Trypan blue solution (0.4 % w/v) and isoproterenol were 
purchased from Sigma-Aldrich. 
Tyrode’s buffer (140 mM NaCl, 5 mM KCl, 10 mM glucose, 1 mM MgCl2, 1 mM 
CaCl2, and 20 mM Hepes, pH 7.4) with 0.5 mM probenecid (Sigma-Aldrich) was used for 
dilution of compound-DMSO stock solutions and for calcium imaging assays. The presence 
of probenecid in the buffer did not lead to inhibition of hTAS2R14 or hTAS2R39. All 
compounds were tested for autofluorescence and toxic effects on the cells used at a 
concentration of 1 mM as described before (15).  
 
Expression of hTAS2R39 and hTAS2R14 in HEK293 cells 
For functional expression of the human bitter taste receptor hTAS2R39, HEK293 T-Rex 
Flp-In cells (Invitrogen, San Diego, CA, USA) were used, stably expressing the chimeric 
G-protein α-subunit Gα16-gust44 (cloned into pcDNA4 (Invitrogen)) (17) and the human 
bitter receptor genes for hTAS2R39 (cloned into pcDNA5/FRT (Invitrogen)). The bitter 
receptor gene contained a DNA sequence encoding the first 45 amino acids of rat 
somatostatin receptor type 3 at its 5’ end (the receptor expression was achieved according 
to (18) with exception of the HSV-tag), in order to improve membrane targeting of the 
receptor protein. The same procedure was applied for stable expression of hTAS2R14. 
Cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) and 10 % (v/v) 
tetracycline-free FBS (both Lonza, Verviers, Belgium) supplemented with blasticidin (5 
µg/mL), geneticin (400 µg/mL) and hygromycin (100 µg/mL) (all from Invitrogen). Cells 
were grown and maintained at 37 °C and 5 % (v/v) CO2. 
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Monitoring bitter receptor activation by intracellular calcium release 
Cells were seeded into poly-L-lysine-coated (Sigma-Aldrich) 96-well plates (black wall, 
clear bottom, Greiner bio-one, Frickenhausen, Germany) at a density of 7*103 cells in 100 
µL/well and cultured for 24 h. Transcription of the receptors was induced by adding 0.25 
µg/mL doxycycline (Sigma-Aldrich). Cells were induced for 24 h and then loaded with the 
calcium-sensitive fluorescent dye Fluo-4-AM (2.5 µM, Invitrogen), which was dissolved in 
Tyrode’s buffer containing 5 % (v/v) tetracycline-free FBS (Lonza). One hour after 
loading, cells were washed with Tyrode’s buffer and taken up in Tyrode’s buffer. Stock 
solutions of test compounds were prepared in DMSO and diluted to the appropriate 
concentration in Tyrode’s buffer, not exceeding a DMSO concentration of 1 % (v/v).  
Receptor activation or inhibition was measured via intracellular Ca2+ release (19) in a 
FlexStation II 384 or FlexStation III (Molecular Devices Corporation, Sunnyvale, CA, 
USA) by measuring fluorescence (excitation 485 nm / emission 520 nm) for either 90 s or 
240 s at 37 °C. Two methods of compound administration were applied: simultaneous and 
stepwise addition of potential antagonist and agonist. The first 17 s before compound 
addition were used for baseline determination. For the simultaneous method, agonist and 
potential antagonist were pre-mixed, administered after 17 s, and fluorescence was 
measured for in total 90 s. For the stepwise method, after 17 s, the potential antagonist was 
added, fluorescence was measured until 120 s, and after 120 s the agonist was added and 
measured for another 120 s, in total 240 s. Non-induced cells, which did not express the 
taste receptor, were measured in parallel to verify specificity of receptor activation. All 
experiments were conducted in duplicate on two or more different days.  
 
Calcium assay data processing 
Data processing was done as reported previously (15). In brief, SoftMax Pro 5.4 software 
(Molecular Devices Corporation) was used to plot the fluorescence signals. The 
fluorescence value (∆F/F0), representing receptor activity, was calculated by subtracting the 
baseline fluorescence (F0) prior to loading from the maximum fluorescence (F) after 
compound addition, divided by the signal of the baseline in order to normalize background 
fluorescence (20). Dose-response curves were established as non-linear regression curves 
using Graph Pad Prism (version 4 for Windows, Graph Pad Software, San Diego, CA, 
USA). Half-maximal effective concentrations (EC50) and half-maximal inhibitory 
concentrations (IC50) were calculated. Error bars reflect the standard error of the mean 
(SEM). Statistical analysis was performed in Graph Pad Prism (one-way ANOVA at 5% 
risk level, followed by Bonferroni’s post hoc test). 
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Investigation of inhibitory behavior of flavanones 
Measuring dose-response curves of ECG on hTAS2R39 under the conditions used in this 
study revealed an EC80 concentration of 200 µM. Screening for hTAS2R39 inhibition by 
flavanones was performed with simultaneous application of agonist (200 µM ECG) and 
putative antagonist (250 µM flavanone). Inhibition was indicated when 
∆/	(	

	
)
∆/	(	
)
< 1. In case of indicated inhibition, flavanones were applied at 
different concentrations, in order to test for dose-dependent inhibition, at the EC80 
concentration of the agonist. Another agonist of hTAS2R39, denatonium benzoate, was 
used in inhibition experiments at 1.7 mM (EC80). hTAS2R14 inhibition was tested with 640 
µM ECG or 70 µM genistein as agonists, representing their respective EC80 concentrations. 
To determine whether inhibition was specific for the bitter taste receptor, the effect of 
the antagonists was tested on the β2-adrenergic receptor agonist isoproterenol (50 µM). To 
this end, the antagonists were applied at ~IC50 concentrations (100 µM 4’-fluoro-6-
methoxyflavanone, 500 µM 6,3’-dimethoxyflavanone, and 500 µM 6-methoxyflavanone). 
To distinguish between reversible and irreversible inhibition, washout experiments were 
performed. Cells were stimulated with 200 µM ECG in the absence and in the presence of 
each antagonist (~IC50 concentrations), washed with Tyrode’s buffer (80 µL/well), and 
again stimulated with 200 µM ECG. 
 
RESULTS 
Identification and characterization of hTAS2R39 inhibitors 
Epicatechin gallate (ECG) (Figure 1A), one of the main bitter compounds in green tea (11), 
was chosen as agonist of hTAS2R39. In a previous study we identified nine flavanones as 
agonists of hTAS2R39, whereas three other flavanones did not activate this receptor (16). 
As some flavanones have been reported as bitter blockers (9, 10), it was investigated 
whether the three inactive flavanones, as well as other flavanones, might have antagonistic 
properties towards hTAS2R39. Fourteen flavanones (Table 1) were screened for their 
ability to reduce the activation of hTAS2R39 by ECG.  
 
Figure 1. Chemical structures of hTAS2R39 agonists 
epicatechin gallate (ECG) (A) and denatonium benzoate (B). 
A B
OHO
OH
OH
OH
O
O
OH
OH
OH
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Table 1. Flavanones tested for reduction of activation of hTAS2R39 by ECG. 
 
R5 R6 R7 R8 R3’ R4’ 
6-Chloro-4-methylflavanone (1) H Cl H H H CH3 
8-Chloro-4-methylflavanone (2) H H H Cl H CH3 
6,3’-Dimethoxyflavanone (3) H OCH3 H H OCH3 H 
Eriodictyola (4) OH H OH H OH OH 
Flavanoneb (5) H H H H H H 
4’-Fluoro-6-methoxyflavanone (6) H OCH3 H H H F 
Homoeriodictyola (7) OH H OH H OCH3 OH 
6-Hydroxyflavanone (8) H OH H H H H 
7-Hydroxyflavanone (9) H H OH H H H 
4’-Hydroxyflavanoneb (10) H H H H H OH 
6-Methoxyflavanoneb (11) H OCH3 H H H H 
7-Methoxyflavanone (12) H H OCH3 H H H 
4’-Methoxyflavanone (13) H H H H H OCH3 
Sakuranetinc (14) OH H OCH3 H H OH 
a
 activation of hTAS2R39 in a previous study (16), but it was selected for testing as antagonist due to 
ability to reduce bitter taste perception in sensory tests (9).  
b
 no activation of hTAS2R39 in a previous study (16).  
c
 reported as antagonist of hTAS2R31 (10) 
 
Inhibition was indicated when the ratio between ECG response in the presence of a 
flavanone and the ECG response in the absence of a flavanone was <1 (Figure 2). Three 
compounds showed reduction of ECG responses on hTAS2R39: 6,3’-dimethoxyflavanone 
(3), 4’-fluoro-6-methoxyflavanone (6), and 6-methoxyflavanone (11). They were further 
investigated by two different ways of compound addition: simultaneous and stepwise 
addition. Simultaneous addition of agonist and antagonist to the receptor reflects the 
situation of ideal blocker application in food products. Stepwise addition of agonist and 
antagonist is commonly applied in pharmaceutical research when examining 
pharmacodynamics of receptor-antagonist interaction (21). 
 
OR7
O
R6
R5
R4'
R3'
R8
A C
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Figure 2. Screening of flavanones for reduction of ECG response on hTAS2R39. Values <1 indicate 
possible inhibitory effect.  
 
The compound 4’-fluoro-6-methoxyflavanone (6) showed inhibitory activity towards 
ECG on hTAS2R39 both after simultaneous (Figure 3A) and after stepwise addition 
(Figure 3B). Application of (6) prior to addition of ECG led to 100 % receptor blocking 
(Figure 3B). For this full receptor blocker, the half-maximal inhibitory concentration (IC50) 
was 102 µM. An overview of inhibition thresholds and IC50 values is given in Table 2. 
When (6) was added simultaneously with ECG, it had a lower inhibition threshold than 
when added in the stepwise way. Upon simultaneous addition, a maximal signal reduction 
of 65 % was reached at 63 µM, and further signal reduction could not be observed due to 
non-specific signals of the compound itself. The same holds for the simultaneous addition 
of 6,3-dimethoxyflavanone (3) (Figure 3C), where a maximal signal reduction of 55 % was 
reached at 500 µM. Due to increasing non-specific signals of (3), the full efficacy upon 
simultaneous addition could not be established. As shown in Figure 3D, a maximal 
reduction of ~85 % at 1000 µM was reached by (3) after stepwise addition. In contrast to 
(6) and (3), the compound 6-methoxyflavanone (11) showed negligible inhibitory activity 
against ECG on hTAS2R39 when applied simultaneously (Figure 3E), whereas it showed 
inhibitory activity when applied stepwise (ca. 50 % reduction of activation at 500 µM) 
(Figure 3F). When investigating the inhibitory behavior of the compounds identified, it 
thus became clear that the way of antagonist addition influenced the efficacy of the 
antagonist.  
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Figure 3. Inhibition of response of 200 µM ECG (---) on hTAS2R39 (induced (●), non-induced (○)) by 4’-
fluoro-6-methoxyflavanone (6) after simultaneous addition (A) and stepwise addition (B), by 6,3’-
dimethoxyflavanone (3) after simultaneous addition (C) and stepwise addition (D), and by 6-
methoxyflavanone (11) after simultaneous addition (E) and stepwise addition (F). 
 
Next, it was investigated whether the activation of hTAS2R39 by another agonist could 
also be reduced by the inhibitors identified. Denatonium benzoate (Figure 1B) was selected 
as well known agonist of hTAS2R39, which is different from ECG, in terms of structure 
and activation concentrations. Dose-response curves of denatonium benzoate were 
measured, and an EC50 of 711 µM, and an EC80 of 1.7 mM were established (data not 
shown). Figure 4 shows the inhibitory behavior of 4’-fluoro-6-methoxyflavanone (6) 
towards 1.7 mM denatonium benzoate on hTAS2R39. The same trends as for ECG 
combined with antagonists were observed. The receptor activation of denatonium benzoate 
was reduced upon simultaneous addition of (6) up to a concentration of 63 µM (not further 
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reduced due to increasing non-specific signals), leading to maximal signal reduction of 58 
%. Stepwise application of (6) led to 100 % receptor blocking, as already seen with ECG. 
The IC50 was calculated to be 55 µM. The results of all antagonists applied with 
denatonium benzoate are summarized in Table 2. Due to the fact that structurally different 
agonists were inhibited in a similar manner, we conclude that the reduced receptor response 
was not achieved by interaction between agonist and inhibitor, but by actual receptor 
antagonism. 
 
 
Figure 4. Inhibition of response of 1.7 mM denatonium benzoate (---) on hTAS2R39 (induced (●), non-
induced (○)) by 4’-fluoro-6-methoxyflavanone (6) after simultaneous addition (A) and stepwise addition 
(B). 
 
Table 2. Thresholds and IC50 values of 6-methoxyflavanones for inhibition of hTAS2R39 responses 
towards 200 µM ECG and 1.7 mM denatonium benzoate.  
  Simultaneous  Stepwise 
 hTAS2R39 Threshold 
(µM) 
 IC50 
(µM) 
 Threshold 
(µM) 
 IC50 
(µM) 
EC
G
 
(20
0 
µM
) 6-Methoxyflavanone n.b.  n.b.  250  479 
6,3-Dimethoxyflavanone 63  282  125  407 
4’-Fluoro-6-
methoxyflavanone 8  32  63  102 
D
e
n
a
to
-
n
iu
m
 
b.
 
(1.
7 
m
M
) 6-Methoxyflavanone n.b.  n.b.  500  n.d. 
6,3-Dimethoxyflavanone 8  89  63  240 
4’-Fluoro-6-
methoxyflavanone 8  22  32  55 
n.b., no blocking; n.d., not determined 
 
Specificity of hTAS2R39 inhibitors 
It was investigated whether the antagonists identified specifically inhibit hTAS2R39, or 
also hTAS2R14, as many flavonoids behave similarly towards these two receptors (16). As 
agonist for hTAS2R14, ECG was used. Figure 5 shows that no blocking of hTAS2R14 
occurred upon simultaneous application of 4’-fluoro-6-methoxyflavanone (6) and ECG 
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(here at 640 µM, EC80 on hTAS2R14). The increase of signal at increasing concentrations 
of (6) is of non-specific nature, which can also be seen in the increase of response of non-
induced cells, in which the bitter receptor is not expressed. Upon stepwise application, an 
inhibitory effect was observed. The three methoxyflavanones were also tested with 
genistein, another agonist of hTAS2R14, at 70 µM (EC80). The results were similar to the 
results obtained with ECG. An overview of inhibition thresholds and IC50 values on 
hTAS2R14 is given in Table 3. It is remarkable that none of the three methoxyflavanones 
blocked hTAS2R14, when applied simultaneously with one of the agonists. 
 
 
Figure 5. Inhibition of response of 640 µM ECG (---) on hTAS2R14 (induced (●), non-induced (○)) by 4’-
fluoro-6-methoxyflavanone (6) after simultaneous addition (A) and stepwise addition (B). 
 
Table 3. Thresholds and IC50 values of 6-methoxyflavanones for inhibition of hTAS2R14 responses 
towards 640 µM ECG and 70 µM genistein.  
  Simultaneous  Stepwise 
 hTAS2R14 Threshold 
(µM) 
 IC50 
(µM) 
 Threshold 
(µM) 
 IC50 
(µM)      
EC
G
 
(64
0 
µM
) 6-Methoxyflavanone n.b.  n.b.  250  447 
6,3-Dimethoxyflavanone n.b.  n.b.  125  ~250 
4’-Fluoro-6-
methoxyflavanone n.b.  n.b.  < 8  79 
G
e
n
is
te
in
 
(70
 
µM
) 6-Methoxyflavanone n.b.  n.b.  500  741 
6,3-Dimethoxyflavanone n.b.  n.b.  n.d.  n.d. 
4’-Fluoro-6-
methoxyflavanone n.b.  n.b.  32  ~500 
n.b., no blocking; n.d., not determined 
 
In order to further investigate the specificity of the antagonists identified towards taste 
receptors, isoproterenol responses were measured. Inhibition of isoproterenol response 
would indicate non-specific inhibition of β2-adrenergic receptors, endogenous to HEK293 
cells. The results (Figure 6) show that the isoproterenol responses were not reduced and 
therewith the inhibition is concluded to be specific for taste receptors.  
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Figure 6. Isoproterenol responses upon application with buffer, ECG, 
4’-fluoro-6-methoxyflavanone (6), 6,3’-dimethoxyflavanone (3), and 6-
methoxyflavanone (11). n.s., not significant. 
 
Pharmacological characterization of 4’-fluoro-6-methoxyflavanone  
Due to full elimination of agonistic responses by 4’-fluoro-6-methoxyflavanone (6) on 
hTAS2R39, this molecule seemed to be the most effective antagonist identified in this 
study. The mechanism of antagonism was further clarified by measuring dose-response 
curves of ECG (Figure 7A) and denatonium benzoate (Figure 7B) in the presence of 
various concentrations of (6). Two effects were observed upon increasing antagonist 
concentrations: the dose-response curves shifted to the right, and the signal amplitudes 
decreased. The dose-response curves for the inhibition of ECG and denatonium benzoate 
showed the same pattern. EC50 values at all antagonist concentrations were calculated and 
are given in Table 4. 
To distinguish between reversible and irreversible inhibition, washout experiments 
were performed. In Figure 7C it can clearly be seen that the inhibition was reversible. 
 
Table 4. EC50 values of ECG and denatonium benzoate in the presence of various 
concentrations of 4’-fluoro-6-methoxyflavanone (6) on hTAS2R39. 
 
Concentration of 4’-fluoro-6-methoxyflavanone 
0 µM 50 µM 100 µM 200 µM 
ECG 128 µM 156 µM 501 µM 781 µM 
Denatonium benzoate 659 µM 1.09 mM 3.36 mM 6.94 mM 
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Figure 7. Dose-response curves for epicatechin gallate (ECG) (●) (A) and denatonium 
benzoate (●) (B) on hTAS2R39, and their modification by increasing 4’-fluoro-6-
methoxyflavanone (6) concentrations (○ 50 µM, ∆ 100 µM, □ 200 µM). Wash-out experiments 
(C). Cells were stimulated with 200 µM ECG in the absence (open bars) and in the presence 
(filled bars) of 100 µM 4’-fluoro-6-methoxyflavanone (6), or 500 µM 6,3’-dimethoxyflavanone (3), 
or 500 µM 6-methoxyflavanone (11), washed with Tyrode’s buffer, and again stimulated with 
200 µM ECG (hatched bars; control: grey bar). Significance of signal reduction is indicated by 
*** (p≤0.001), ** (p≤0.01), and n.s. (not significant, p>0.05). 
 
DISCUSSION 
In this paper we describe, to our knowledge for the first time, the identification of 
antagonists for hTAS2R39. For hTAS2R39, 4’-fluoro-6-methoxyflavanone (6), 6,3’-
dimethoxyflavanone (3), and 6-methoxyflavanone (11) were identified as antagonists (in 
decreasing order of potency), amongst which (6) fully eliminated the agonistic response. 
This was observed both for the bitter tea flavonoid ECG and for the synthetic bitter 
compound denatonium benzoate. The activation of hTAS2R14, another bitter receptor 
recognizing ECG (16), was also inhibited by the three flavanones, though to a lesser extent.  
In view of the fact that the application of (11) and (3) did not lead to full inhibition of 
the ECG signal on hTAS2R39, the question arises whether these two compounds are 
antagonists or partial agonists. They were tested for hTAS2R39 agonism as well, but none 
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of them activated the receptor (data not shown). Hence, they probably act as real 
antagonists. 
 
Structural requirements for hTAS2R39 antagonists 
Several flavanones similar to the antagonists identified did not show inhibitory activity 
towards bitter receptor hTAS2R39. It turned out that only flavanones with a methoxy group 
on the 6-position of the A-ring, and various B-ring configurations were able to act as 
antagonists of hTAS2R39, as flavanone (5) (substitution of flavanone crucial for 
inhibition), 6-hydroxyflavanone (8) (methoxy-substitution crucial for inhibition), 4’-
methoxyflavanone (13) (A-ring methoxylation crucial for inhibition), and 7-
methoxyflavanone (12) (6-position crucial for inhibition) did not show inhibitory activity. 
Additionally, the compound 6-methoxyflavone was unable to inhibit hTAS2R39 activation 
(data not shown), which indicated that absence of a double bond in the C-ring is essential 
for inhibition. 
Amongst the antagonists identified for hTAS2R39, the difference in substitution of the 
B-ring determined the blocking potency. Compound (11), which is unsubstituted on the B-
ring, showed poor blocking behavior compared to (6) and (3). It might be speculated that 
size, electronegativity and/or electron withdrawing effect of the B-ring substituent 
influences the potency of antagonists.  
 
Pharmacological characterization of 4’-fluoro-6-methoxyflavanone  
Due to full elimination of agonistic responses by 4’-fluoro-6-methoxyflavanone (6) on 
hTAS2R39, this molecule was investigated further with respect to a possible antagonistic 
mechanism. Two effects were observed when increasing 4’-fluoro-6-methoxyflavanone 
concentrations: the dose-response curves shifted to the right, and the signal amplitudes 
decreased. These phenomena suggest that it can be classified as insurmountable antagonist 
(22). This curve pattern can be an indication for three different mechanisms: (i) irreversible 
antagonism, (ii) reversible non-competitive orthosteric antagonism, in which an equilibrium 
is not reached, and (iii) reversible insurmountable allosteric antagonism (22). Washout 
experiments (Figure 7C) clearly showed that the ECG responses after washing-out the 
antagonist were similar to the ECG responses prior to application of the antagonist. It can 
thus be concluded that the interaction was reversible. Next, in order to distinguish between 
(ii) and (iii), the antagonistic behavior towards another, structurally different, agonist was 
investigated. If the antagonist would be unable to inhibit a structurally different agonist, it 
would strongly suggest allosteric antagonism (22). As can be seen in Figure 7B, the 
synthetic hTAS2R39 agonist denatonium benzoate was also inhibited by 4’-fluoro-6-
methoxyflavanone and exhibited a curve pattern almost alike that by ECG upon different 
blocker concentrations. Analogous results for two structurally different agonists might on 
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the one hand indicate orthosteric antagonism, but on the other hand they do not completely 
exclude allosteric antagonism (22).  
For hTAS2R46, hTAS2R31, hTAS2R43 (23), hTAS2R16 (24), and hTAS2R38 (25), 
docking simulations into homology models, validated by site-directed mutagenesis, have 
predicted the presence of a single binding pocket in the respective bitter receptors. 
Furthermore, the mechanism of antagonism of GIV3727 on hTAS2R31 was described as 
orthosteric, insurmountable antagonism (5), supported by docking the antagonist into the 
same binding pocket as the agonist. In contrast, one study suggests allosteric antagonism as 
mechanism for inhibition of hTAS2R16 and hTAS2R38 by probenecid (6). No information 
has been reported yet on the binding pocket of hTAS2R39. As the majority of studies 
suggests the presence of a single binding pocket in different bitter receptors, an orthosteric 
mechanism seems most likely for explaining our observations. 
 
Application of bitter receptor blockers 
For application of blockers in food products, several requirements should be met. (i) The 
blocker should be functional at a low dose. Therefore, an antagonist that has to be applied 
in equimolar or higher quantity to the agonist, is not efficient. (ii) In order to block the 
bitter taste of dietary compounds, for practical reasons, it is necessary that a bitter receptor 
blocker is also functional when applied simultaneously with the bitter compound. 
Therefore, compounds like (3) and (6) seem to be more suitable than (11). (iii) In order to 
achieve a sensorial effect, blocking of all bitter receptors activated by one compound is 
desirable. A blocker, that can only inhibit hTAS2R39, but not hTAS2R14, might be too 
specific to effectively reduce bitterness of ECG. On the other hand, it is not known yet 
whether these two receptors have an equally important role in the mouth. (iv) The blocker 
should preferably be of natural origin, and should be available in sufficient quantity. We 
could not find any natural source of the three inhibitors described in this study, and assume 
that they are only available synthetically. (v) Only compounds that are known as safe for 
consumption are of interest for food applications. Due to unknown safety of 4’-fluoro-6-
methoxyflavanone, we abstained from sensory tests, which might confirm the function as 
bitter taste blocker in vivo. As not all criteria are met by the blockers discovered in the 
present study, they might not be applicable to food products. Nevertheless, a 6-methoxy 
substituent on the A-ring of a flavanone has been identified as important for inhibition of 
hTAS2R39, which might form the basis for other, more suitable, blockers. 
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ABSTRACT 
Epigallocatechin gallate (EGCG) has been ascribed to several health benefits, but its bitter 
taste influences the liking of products with high concentrations of this compound. β-Casein, 
in particular, and several gelatins are known as strong binders of EGCG, contrary to β-
lactoglobulin. The current study aimed at relating the EGCG-binding characteristics of 
those proteins, and their food-grade equivalents, to their effects on reducing bitter receptor 
activation by EGCG in vitro and their bitter-masking potential in vivo. Also in the bitter 
receptor assay, β-casein showed the strongest effect, with a maximum reduction of 
hTAS2R39 activation of about 93%. A similar potency was observed for Na-caseinate. β-
Lactoglobulin had little effect on bitter receptor activation, as expected based on its low 
binding affinity for EGCG. The bitter-masking potential of Na-caseinate was confirmed in 
vivo using a trained sensory panel. β-Lactoglobulin also slightly reduced EGCG bitter 
perception, which could not be directly related to its binding capacity. The bitter receptor 
assay appeared to be a valid tool to evaluate in vitro the efficacy of food proteins as 
complexing agents for bitter-masking. 
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INTRODUCTION 
Epigallocatechin gallate (EGCG) is known to be the most abundant catechin in green tea 
(ca. 60 % of the total catechins) and has been ascribed to several beneficial health effects 
(e.g. anticarcinogenic and cardioprotective effects) (1). With respect to taste, tea catechins 
are known to be astringent and bitter (2). The mechanism of astringency perception is not 
yet fully defined, but can be partially attributed to the interaction of EGCG with salivary 
proteins. Astringency seems sensorially coupled with bitterness, although, compared to the 
latter, it has been usually reported as a secondary attribute in time-intensity experiments (3, 
4).On the human tongue, bitter compounds are perceived by bitter taste receptors, referred 
to as hTAS2Rs, which are part of the family of G-protein coupled receptors (5). To date, 21 
hTAS2Rs out of the 25 known have identified agonists (6, 7). Amongst these, hTAS2R39 
has been associated with taste perception of green tea catechins (8). As evaluated in vitro 
with hTAS2R39, EGCG has a two times lower EC50 value (181.6 µM) compared to its non-
galloylated equivalent epigallocatechin (EGC; EC50 = 395.5 µM). This difference was 
confirmed in vivo by a higher perceived bitterness for EGCG (2, 8). 
Effective health benefits against cardiovascular and metabolic diseases have been 
associated with a daily intake of green tea containing 200-300 mg of EGCG (9). Food 
products with high concentrations of EGCG may have off-tastes and consequently low 
consumer acceptance (10). Various approaches to modulate bitterness of bioactive 
compounds in functional foods have been described, such as the use of sweeteners, blockers 
for bitter taste receptors and complexation with other compounds. In the latter approach, 
cyclodextrins are the most commonly used carriers while other carriers (e.g. proteins) are 
seldomly reported (10-13). A typical example of off-taste reduction in food is the addition 
of milk to tea, which has been linked to the interaction of tea catechins with milk proteins 
(3) without impairing their bioavailability (14). Milk proteins have also been suggested as 
carriers for bioactive compounds and, in particular, thermally-induced β-lactoglobulin-
EGCG complexes (12, 15).  
In our previous work (16), we investigated the potential of food proteins as carriers for 
flavonoids. Based on affinities and binding capacities measured, β-casein and gelatins, in 
particular fish gelatin, were found to be the most promising carriers for EGCG. One 
necessary condition for the applicability of those complexes in food is their effective 
reduction in bitter taste perception of EGCG. Bitter receptor activation by flavonoids can be 
evaluated in vitro by a cell-based receptor assay (8, 17). To our knowledge, the present 
study is the first report using such a setup to evaluate the reduction in activation of bitter 
receptors by EGCG after forming complexes with proteins. This primary approach can help 
to predict the outcome of sensory panels. The aim of the present study was to correlate 
EGCG-binding of pure β-casein, food-grade caseinates and several gelatins to the potential 
of these proteins for reducing bitterness perception of EGCG. This was first tested in vitro 
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using a cell-based bitter receptor assay and then in vivo with a trained sensory panel, in 
order to evaluate the applicability of those complexes in foods. 
 
MATERIALS AND METHODS 
Materials 
Bovine β-casein (≥98% of total protein), bovine β-lactoglobulin (≥90% of protein), solid 
fish gelatin (Gelatin F1) from cold water fish skin, and gelatin type B (Gelatin B1) from 
bovine skin (75 bloom) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The 
protein contents of the two gelatins were estimated to be ≥90% as detailed in a previous 
study (16). Food-grade EGCG (≥94%), Sunphenon 90LB (>80% catechins including ~50% 
EGCG), and food-grade calcium and sodium caseinates (protein content ≥90%, N×6.38) 
were kindly provided by DSM Nutritional Products (Delft, The Netherlands), Taiyo GmbH 
(Filderstadt, Germany) and DMV International (Veghel, The Netherlands), respectively. 
Bovine Vinoferm® gelatin powder (≥85% of protein; N×5.55), Vinoferm® gelatin liquid 
(20% (w/v) gelatin (supplier information)) and Vinoferm® Isinglass (fish gelatin, 2% (w/v) 
protein (supplier information)) were food-grade and purchased from Brouwland (Beverlo, 
Belgium). Throughout this study, these gelatins are referred to as gelatin B2, gelatin B3, 
and gelatin F2, respectively. Food-grade BioPURE - β-lactoglobulinTM (≥90% of total 
protein) was kindly provided by Davisco Food International (Eden Prairie, MN, USA). 
Water for in vitro tests was obtained from a Milli-Q system (Millipore, Billerica, MA, 
USA). Water (Spa Reine, Spadel Group, Brussels, Belgium) for in vivo tests was obtained 
from a local supermarket. All other chemicals were of analytical grade and purchased from 
Merck (Darmstadt, Germany). 
 
Assessment of binding of proteins to EGCG by ultrafiltration (UF assay) 
Determination of binding parameters of food-grade proteins for EGCG (UF assay – 
method 1). All samples were prepared in a 50 mM sodium phosphate buffer, pH 7.0. 
Protein stock solutions (0.2 mM) were prepared freshly before each experiment. For both 
caseinates, an average molecular mass of 23.3 kDa was calculated from the protein 
composition in bovine milk (18). Gelatins were prepared at a concentration equivalent to 
0.2 mM β-casein (i.e. 4.72 mg/mL). Similarly, a stock solution of EGCG (6 mM) was used 
to obtain a range of dilutions between 0 and 6 mM. EGCG-protein mixtures were prepared 
and the binding affinities of each protein towards EGCG measured using an ultrafiltration 
microtiter plate setup (Ultracel 10, Millipore, Cork, Ireland) as described previously (16). 
The protein-bound and free fractions of EGCG at each concentration tested were 
calculated and plots of the bound fraction versus the concentration of free EGCG were used 
to determine the binding parameters. For each binding curve obtained, a linear regression 
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was used on the initial linear increase (R2>0.8) in order to estimate the binding affinity (K) 
of the compounds. A maximal binding capacity (Rmax) was derived from the plateau value 
or the highest bound fraction observed at high phenolic compound/protein molar ratios. 
Binding parameters were reported as mean ±standard deviation (SD) of two replicates. 
Determination of [EGCG]free with increasing concentrations of various proteins (UF 
assay – method 2)An EGCG stock solution (0.5 mM) and solutions of proteins with 
concentrations ranging from 0.013 to 0.2 mM (EGCG-to-protein molar ratios from 2.5 to 
40) were prepared in a similar way as described above. The concentration of free EGCG 
remaining in the mixtures after incubation was determined using an ultrafiltration microtiter 
plate setup as described previously (16). 
 
In vitro assessment of hTAS2R39 activation by intracellular calcium release 
Activation of bitter receptors was investigated by the release of intracellular Ca2+, using a 
fluorescent calcium dye (19). The expression of hTAS2R39 in HEK293 cells and the 
detailed procedure for monitoring its activation were performed as reported elsewhere (17). 
All samples were prepared in Tyrode’s buffer (140 mM NaCl, 5 mM KCl, 10 mM 
glucose, 1 mM MgCl2, 1 mM CaCl2, and 20 mM Hepes, pH7.4). EGCG stock solution (1 
mM) was prepared freshly before each experiment. Similarly, stock solutions of proteins 
(0.8 mM) were used to obtain a concentration range from 0.006 to 0.8 mM. Protein-EGCG 
complexes were made in a microtiter plate by mixing protein solutions 1:1 with EGCG 
solutions. Controls were made by mixing EGCG with buffer without proteins. The 
microtiter plate was incubated at room temperature under constant shaking (300 rpm, 10 
min). 
Next, the complexes were loaded (ratio 1:1 (v/v)) in a microtiter plate containing the 
cells (final concentrations of EGCG of 0.25 mM and of protein between 0 and 0.2 mM) and 
evaluated for their potential to activate bitter receptor hTAS2R39 at 37 °C with a 
FlexStation II 384 (Molecular Devices Corp., Sunnyvale, CA, USA) for 90 s as described 
elsewhere (17). Prior to the addition of the complexes to the cells, the baseline signal was 
determined in the first 17 s. Then, fluorescence signals (excitation 485 nm/emission 520 
nm) were measured until 90 s. As negative control, non-induced cells, which do not express 
the hTAS2R receptor, were always measured in parallel. Additionally, a dose-response 
curve of EGCG was determined in the same way by measuring concentrations of EGCG up 
to 1 mM without proteins. Measurements were performed at least in duplicates on two or 
more different days. 
 
Sensory analysis 
Panelists. The panel consisted of 13 persons (10 males and 3 females), which were part of a 
larger sensory panel familiar to bitterness rating and selected within Unilever R&D 
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(Vlaardingen, The Netherlands) for their ability to taste and rank bitterness. Panelists could 
join each session on a voluntary basis and participated in at least one of the sessions 
described below. Panelists were trained to taste bitterness and rate it on a scale from 1 to 10 
using a known reference (Sunphenon 90 LB). Sunphenon 90 LB was sensorially close to 
EGCG as it was mostly bitter with a low astringency (supplier information) (2). The ratings 
reported were relative to this EGCG-rich reference and not to pure EGCG. No specific 
training was conducted to discriminate between astringency and bitterness.  
Sample preparation. Proteins (10 g/L) and EGCG (1 g/L) stock solutions were 
prepared freshly before each experiment. The compounds were dissolved in water (Spa 
Reine), known for its neutral pH and low content in minerals. EGCG was mixed 1:1 with 
each protein solution and incubated at room temperature for at least 10 min. 15 mL of each 
sample was poured into a yellow cup. The colored cups were used to limit the visual 
perception of the differences between samples (e.g. slight haze or color) with or without 
proteins and thus to limit its possible impact on the choice and rating by the panelists. 
Additionally, three solutions of Sunphenon 90 LB were prepared: Two references known to 
the panelists (0.3 g/L and 0.8 g/L) and one unknown to the panelists (0.4 or 0.5 g/L). The 
former were used as a calibration for the panelists prior to and throughout each session. The 
latter was used by the panelists to check the accuracy of their rating at the beginning of 
each session. 
Selection of suitable food-grade proteins for quantitative sensory analysis. A 
preliminary session was organized to select food-grade proteins with the highest potential 
for bitterness reduction. Volunteers from the panel (n=8) were allowed to taste a known 
sample with only EGCG (0.5 g/L) and rate it against the references. Then, each protein-
EGCG sample was tasted, described individually and subsequently discussed with the other 
panelists. The group rating and the most recurrent descriptors were used to select the most 
suitable proteins for further experiments. 
2-Alternative Forced Choice (2-AFC) test. EGCG complexed with Na-caseinate and β-
lactoglobulin were evaluated in duplicate against a control EGCG sample without proteins. 
The experiment was conducted on two different days with 12 panelists and 6 of them were 
present on both days (n=36 per sample). Pairs of samples were all provided at once to each 
panelist. In between samples, panelists were instructed to rinse their mouth with water or 
milk, and to eat a piece of cucumber or plain cracker. For each pair, panelists had to 
indicate which sample was the most bitter and to rate the two samples on a scale from 0 to 
10 as described above. 
Ranking test. EGCG (1 g/L) was mixed 1:1 with 4 different concentrations of Na-
caseinate (2, 5, 10, and 15 g/L) and prepared as described above. Panelists were provided 
with a series of 5 samples in duplicate (13 panelists, n=26 per sample) and were instructed 
to rank them in order of increasing bitterness and rate them on a scale from 0 to 10 as 
described above. Series included one control containing only EGCG (0.5 g/L) and no 
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proteins. The instructions given to the panelists for rinsing their mouth between samples 
were the same as for the 2-AFC test. 
 
Data processing and statistical analysis 
For hTAS2R39 activation data, SoftMax Pro 5.4 software (Molecular Devices Corp.) was 
used to plot fluorescence signals. Data processing for the activation curve of hTAS2R39 by 
EGCG was performed as described previously (17). Similarly, for EGCG-protein 
complexes, the fluorescence values (∆F/F0) were calculated by subtracting the baseline 
fluorescence (F0) prior to loading from the maximum fluorescence (F) after addition of the 
compounds, divided by the signals of the baseline to normalize to background fluorescence 
(17). Besides the response of induced cells, also the response of non-induced cells was 
measured as negative control for every compound at every concentration on the same plate. 
In cases that a non-specific signal occurred with ∆F/F0 > 0.25, the corresponding 
concentration of the protein was not considered for further calculations. Response of non-
induced cells was subtracted from its corresponding response of induced cells at all valid 
concentrations. The activation and decrease of receptor activation were expressed as 
percentages relative to the maximum response measured (i.e. EGCG control) and plotted 
versus the protein concentration. Data were reported as the mean value of the replicates and 
error bars represented the standard error of the mean (SEM). 
The dose-response curve of hTAS2R39 by EGCG was fitted with nonlinear regression 
curves in Graph Pad Prism (version 4 for Windows, Graph Pad Software, San Diego, CA, 
USA). The sigmoidal dose-response curve model with variable slope corresponded to the 
following equation: 
∆
 =  + (	)() (equation 1) 
with B, the bottom plateau value; T, the top plateau value; LogEC50, the Log([EGCG]) 
value at which the response is halfway between B and T; and H, the Hill slope or steepness 
of the curve. Best-fit parameters for the activation curve of hTAS2R39 by EGCG were as 
follows: B = 0.107, T = 1.531, LogEC50 = -3.793, and H = 1.976. 
The aforementioned best-fit parameters and the dose-response curve equation were 
used to predict the receptor activation (∆F/F0) which should be observed based on the 
concentration of free EGCG measured in the UF assay – method 2. The theoretical receptor 
activation was plotted as percentage of reduction of activation versus the protein 
concentration using the following equation: 
%	 !"#	$ !%$ !"#	 = 	&1 − )∆ + ,-)∆ + ,./ × 100 (equation 2) 
With )∆2 2+ ,3, the theoretical receptor activation at [EGCG]free = i (in µM), and 
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)∆2 2+ ,45, the theoretical receptor activation at [EGCG]free = 250 µM. The data were 
reported as the mean value of the replicates and error bars represented the SEM. 
Averages and confidence intervals (95%) from the 2-AFC and ranking tests were 
calculated. Significance (p<0.05) for the 2-AFC test was determined based on a minimum 
number of correct judgments for paired difference using a statistical table reported 
elsewhere (20). Significance (p<0.05) for the ranking test was determined by Kramer’s rank 
sum test (21). 
 
 
Figure 1. Dose-response curve of hTAS2R39 stimulated with EGCG (A) and example of receptor 
activation by EGCG (250 µM) complexed with increasing concentrations of β-casein (●) or Na-caseinate 
(○) (B). 
 
RESULTS 
Reduction of activation of bitter receptor hTAS2R39 by complexing EGCG to 
proteins 
Based on a previous study on common food proteins binding EGCG (16), β-casein, β-
lactoglobulin, gelatin B1 and gelatin F1 were selected and tested for their potential to 
reduce the activation of the bitter receptor hTAS2R39 by EGCG in a cell-based assay. The 
test was conducted at a concentration of EGCG of 250 µM, which was about the EC70 value 
(EC50 = 161 µM, Figure 1A) and provided sufficient signal to clearly observe the effect of 
the proteins, as illustrated in Figure 1B. The decrease of hTAS2R39 activation by EGCG 
with the various proteins tested is reported in Figure 2. Maximum reductions of receptor 
activation (as percentages of reduction of activation from control EGCG without protein) 
for protein-EGCG complexes are summarized in Table 1.  
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Table 1. Comparison of the bitterness reduction potential of proteins evaluated in vitro and in vivo 
(based on preliminary experiment) at an EGCG-to-protein molar ratio of 5. 
Protein Grade 
% Reduction of 
activation  
(cell assay) 
% Reduction of 
activation  
(UF assay)c 
Reduction of 
rating 
(in vivo)d 
β-Casein analytical 93.3 (±5.3) 72.8 (±2.9) n.a. 
Na-Caseinate food 34.3 (±4.1)a 51.9 (±0.9) 3 
Ca-Caseinate food n.d. 49.2 (±0.5) 3.5 
β-Lactoglobulin analytical -b 5.8 (±2.9) n.a. 
β-Lactoglobulin food -b 9.0 (±0.5) 1 
Gelatin B1 analytical 23.0 (±8.0)a 18.3 (±0.8) n.a. 
Gelatin B2 food n.d. n.d. 2.5 
Gelatin B3 food n.d. n.d. 1.5 
Gelatin F1 analytical 46.0 (±2.6)a 30.6 (±6.5) n.a. 
Gelatin F2 food n.d. n.d. n.a.e 
apercentage of the highest measurable protein concentration in the bitter receptor assay 
bno clear trend in reduction of receptor activation detected 
cpercentages calculated based on concentrations of unbound EGCG in UF assay – method 2 
dreduction of ratings and percentages calculated using a bitterness score of 7 for the EGCG reference 
estrong sour taste overruled bitter taste 
n.a., not applicable; n.d., not determined 
 
Amongst the four tested proteins, β-casein showed the strongest concentration-
dependent reduction of the receptor activation by EGCG, with a decrease of 93.3 (±5.3)% 
at the highest measurable protein concentration applied (i.e. 50 µM). β-Lactoglobulin did 
not show a clear effect on decreasing the receptor activation, and relatively high variations 
between replicates were observed. Gelatin F1 was found to have the second strongest 
reduction of the receptor activation by EGCG (maximum receptor activation decrease 
measured of 46.0 (±2.6)%), whereas its maximum decrease was reached at a lower protein 
concentration than with β-casein. Gelatin B1 did not reduce the activation of hTAS2R39 by 
EGCG by more than 23.0 (±8.0)% in the measurable protein concentration range, indicating 
that it had low potential for masking bitterness. The slight trend of decreasing receptor 
activation with increasing protein concentrations observed for gelatins B1 and F1, contrary 
to the clear trend observed for β-casein, might be caused by the turbidity of these samples, 
affecting the accuracy of the measurements. In fact, the presence of insoluble aggregates 
might have affected the loading volumes on the cells and interfered with fluorescence 
readings. The observations made for gelatins suggest that a larger proportion of EGCG 
remained able to interact with the bitter receptor when applying gelatins compared to β-
casein. 
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reduction of receptor activation in the bitter receptor assay is thought to be linked to its low 
affinity for EGCG. Even though gelatin B1 had an intermediate affinity for EGCG, it had a 
limited effect on the receptor activation by EGCG, suggesting that a minimum affinity is 
required for a significant reduction of receptor activation. Binding affinity seemed to be a 
more important factor than Rmax as gelatin B1 had a higher Rmax than β-casein, but only 
showed a limited effect on decreasing receptor activation.  
A second ultrafiltration method (UF assay – method 2) was used to mimic the 
conditions of the bitter receptor assay (i.e. constant [EGCG] and variable [protein]). The 
concentrations of free EGCG measured in the UF assay – method 2 were used to predict the 
percentage of reduction of receptor activation using equations 1 and 2, and compared to the 
experimental data obtained. β-Casein was used to evaluate the accuracy of this approach 
(Figure 2A). The data derived from the UF assay – method 2 and the bitter receptor assay 
were in good agreement, with an underestimation of only 10-20% for the theoretical values 
compared to the experimental values. 
In contrast to β-casein, the theoretical and experimental values showed clear 
discrepancies for gelatin F1 (Figure 2C). As mentioned earlier, interferences due to 
aggregates could explain this observation. In the case of gelatin B1 (Figure 2D), a limited 
amount of experimental data points could be matched, but similar trends between the 
theoretical and experimental values were observed. The theoretical percentages of reduction 
of receptor activation calculated for gelatin F1 are two times lower than those for β-casein 
although their previously reported affinities for EGCG are similar (Table 2) (16). This 
shows that affinity is not the only parameter for an efficient reduction of receptor 
activation, although it might be a good first indicator. For example, the flexibility of β-
casein and its ability to form micelles which could entrap EGCG might be advantageous 
characteristics compared to the more rigid structure of gelatins (16, 22, 23). Summarizing, 
the bitter receptor assay was in good agreement with the ultrafiltration assay when applying 
a protein with a good binding capacity, such as β-casein. Discrepancies, however, could be 
observed when using proteins forming insoluble aggregates, such as gelatins, or having a 
low binding capacity, such as β-lactoglobulin. 
In the present study, β-casein was confirmed as promising carrier for EGCG in food as 
its previously reported high binding affinity and capacity for EGCG could be linked to an 
effective reduction of bitter receptor activation by EGCG. 
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Efficiency of food-grade protein ingredients to complex EGCG 
Highly purified proteins are not commonly used in the food industry and are, in most cases, 
not commercially available as food ingredients. Hence, the analytical-grade proteins were 
replaced by common food ingredients containing these proteins (e.g. β-casein replaced by 
caseinates). These food-grade proteins were evaluated for their binding potential for EGCG 
by the UF assay and their binding parameters were compared to the ones of their equivalent 
analytical-grade proteins as summarized in Table 2. A higher concentration of proteins as 
used in the current assay (i.e. 100 µM) did not seem to influence the binding affinity as 
found for β-casein ((45.0 ±7.2) ×103 M-1 at 25 µM versus (43.3 ±2.2) ×103 M-1 at 100 
µM). Ca-Caseinate and Na-caseinate were considered as an acceptable replacement for β-
casein with good potential for further application. The lower values obtained for the 
binding parameters of caseinates compared to β-casein might be related to their more 
heterogeneous protein composition, with a ratio αS1:αS2:β:κ of about 11:3:10:4, on a molar 
basis (18). In fact, it has been shown that α-casein had a two times lower binding affinity 
for EGCG compared to β-casein (24). 
Na-Caseinate was tested for its capacity to reduce hTAS2R39 activation by EGCG 
(Figure 1B). Although only a narrower range of protein concentration could be measured 
due to non-specific signals, Na-caseinate showed a similar trend in receptor activation 
decrease compared to β-casein at protein concentrations between 1.5 and 6 µM. Theoretical 
percentages of reduction of receptor activation were calculated for Na-caseinate using the 
UF assay – method 2 and were similar to those obtained for β-casein (Figure 2B), with a 
maximum reduction of 70.1 (±1.2)% at a protein concentration of 100 µM (85.3 (±0.6)% 
for β-casein). Theoretical and experimental values at Na-caseinate concentrations of 6 and 
12.5 µM were in good agreement. Ca-Caseinate showed the same theoretical potential of 
reduction of receptor activation compared to Na-caseinate using the UF assay – method 2, 
with a maximum reduction of 72.0 (±0.9)% (data not shown). Hence, Na-caseinate and Ca-
caseinate were confirmed as acceptable food-grade alternatives to analytical-grade β-casein 
for reducing hTAS2R39 activation by EGCG. 
Gelatin B2 showed similar binding potential compared to the model protein gelatin B1, 
whereas gelatins B3 and F2 displayed lower binding affinities compared to their analytical 
equivalents. This difference compared to the model proteins could be due to variations in 
the characteristics of the gelatin samples (e.g. amino acid composition, average molecular 
mass). Food-grade and analytical-grade β-lactoglobulins had similar low binding affinities 
(Table 2). As shown in Figure 2 and Table 1, the weak binding properties of both β-
lactoglobulins to EGCG also did not result in a significant effect in reduction of hTAS2R39 
activation. This was also shown by the UF assay – method 2 with a maximum value in 
reduction of receptor activation below 15% calculated for both proteins (Figure 2E and 
2F). 
 
5
  
Chapter 5 
 
132 
 
Sensory analysis of EGCG complexed with proteins 
As summarized in Table 3, various food-grade proteins were compared in a preliminary 
sensory experiment for their potential to reduce bitterness of EGCG at a protein-to-EGCG 
mass ratio of 10, which was equivalent to an EGCG-to-protein molar ratio of about 5 using 
the molecular mass of β-casein. Ca-Caseinate and Na-caseinate had similar effects on the 
taste of EGCG with a reduction of EGCG bitterness rating by 3.5 and 3 units, respectively. 
The relatively transparent appearance of Na-caseinate was preferred over the white color of 
Ca-caseinate in water for further investigation as it offers fewer limitations for applications 
(e.g. in clear beverages). β-Lactoglobulin had the least effect on the bitterness reduction of 
EGCG (1 unit). Therefore, it was selected as a negative control for further experiments. The 
three gelatin samples generally had unpleasant off-tastes, especially gelatin F2. In addition, 
gelatins B2 and F2 formed visible aggregates with EGCG at the molar ratio used. Taken 
together, gelatins were considered as unsuitable for further sensory tests and applications as 
bitter masking compounds.  
 
Table 3. Sensorial comparison of EGCG (0.5 g/L) complexed with various food-grade proteins (5 g/L). 
Protein pH in 
watera Rating Aspect Taste attributes (other than bitter) 
EGCG control 6.3 7 clear - 
Ca-Caseinate 6.9 3.5 turbid (milk-like) milky, astringent 
Na-Caseinate 6.9 4 slightly turbid milky, slightly metallic 
Gelatin B2 6.0 5.5 visible aggregates astringent, burned, strong off-taste 
Gelatin B3 4.9 4.5 slightly turbid off-taste 
Gelatin F2 2.6 n.a.b visible aggregates very sour 
β-Lactoglobulin 6.3 6 clear slight off-taste 
apH of EGCG-protein complexes after incubation; bn.a., not applicable, strong sour taste overruled the 
bitter taste 
 
In a 2-AFC test, β-lactoglobulin and Na-caseinate significantly reduced the bitter taste 
of EGCG by 1.4 ±0.4 and 2.3 ±0.5 units, respectively (Figure 3). The effect of Na-
caseinate on EGCG bitterness perception was in accordance with the expectations based on 
the reduction of hTAS2R39 activation by Na-caseinate (Figure 2B). A significant, although 
lower, effect of β-lactoglobulin on bitterness of EGCG was not expected as only a limited 
effect was observed in a preliminary sensory session (Table 3) and also in the in vitro 
assays (Figure 2D). 
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Figure 3. Comparison of perceived bitterness of EGCG, free (grey 
bars) or complexed with Na-caseinate or β-lactoglobulin 
(transparent bars), in a 2-AFC sensory test. (*) significant 
difference (p<0.05). 
 
In a ranking test with increasing concentrations of Na-caseinate, it appeared that the 
lowest bitterness score (~4) was already reached at a concentration of 0.25 % (w/v) of Na-
caseinate (Figure 4A). This observation concurs with a sensory study on olive oil phenolics 
binding Na-caseinate, for which a minimum bitterness score was reached with 1% (w/v) 
protein and did not decrease further with increasing protein concentration (25). In the 
current study, 0.25% (w/v) Na-caseinate resulted in a bitterness reduction of 3 units 
compared to the EGCG reference, and the reduction of  bitterness ratings reported at lower 
EGCG-to-protein molar ratios remained between 3 and 3.5 units (Figure 4B). As shown in 
Figure 4B, the reduction of bitterness ratings measured in vivo at EGCG-to-protein molar 
ratios of 10 and 25 followed the trend of the theoretical percentages for the reduction of 
receptor activation calculated from the UF assay – method 2. At molar ratios lower than 10, 
however, a plateau was observed in vivo while in vitro theoretical values predicted a 
continuously increasing percentage of reduction of hTAS2R39 activation. 
 
DISCUSSION 
In vitro prediction of bitterness reduction compared to in vivo sensory analysis 
According to the in vitro assays conducted in this study (Figure 2), the efficacy in reducing 
bitterness of EGCG of the food-grade proteins tested should be ranked as follows: Ca-
caseinate/Na-caseinate ≥ gelatins > β-lactoglobulin. This order was in line with our first 
sensory experiment (Table 3), confirming the applicability of our in vitro approach for 
screening the potential of food proteins for bitter masking. 
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A 2-AFC test demonstrated a decrease of perceived bitterness of EGCG when 
complexed to Na-caseinate by 2.3 units. The effect of Na-caseinate on the intrinsic 
bitterness of EGCG in vitro at the same EGCG-to-protein molar ratio (i.e. 5) was calculated 
to be a decrease of 50% based on the concentration of free EGCG after binding measured 
by ultrafiltration and related to the activation curve of hTAS2R39 by EGCG. Although our 
in vivo and in vitro results match well, it should be noted that the in vitro assay does not 
take account of actors other than hTAS2R39 in the mouth environment, such as other 
hTAS2Rs being activated by EGCG (although their response will also be modulated by 
complexation of EGCG to protein) and salivary proteins which might interact with EGCG 
and disturb the binding equilibrium. The intrinsic bitterness is calculated under the 
assumptions that hTAS2R39 is the main bitter receptor sensing EGCG, that complexes 
remain stable in the mouth, and that the slight off-taste of Na-caseinate does not influence 
bitterness ratings. In addition, a stronger effect of β-lactoglobulin on EGCG bitterness was 
observed in vivo compared to the in vitro experiments. This effect is unlikely to have 
resulted from its binding to EGCG, nor from a direct interaction of β-lactoglobulin with the 
hTAS2R39 receptor, as suggested for another protein (26). An indirect effect due to the 
interaction of β-lactoglobulin with the buccal environment could have interfered with the 
bitter perception (e.g. interaction with saliva and buccal cells) (27, 28). 
In this study, a maximum reduction in bitterness of EGCG was achieved at 0.25% 
(w/v) of Na-caseinate, although our in vitro assay predicted a continuous decrease in 
receptor activation with increasing protein concentrations (Figure 4B). This concurs with a 
model proposed by Pripp et al., which predicted a minimum bitterness reached at 0.5% 
(w/v) Na-caseinate for olive oil phenolics, assuming a binding affinity of 105 M-1.25 The 
bitter receptor assay complemented with ultrafiltration appears as an appropriate tool to 
evaluate the efficacy of a given macromolecule as a bitter-masking ingredient, although it 
tends to overestimate its potential (Figure 4B). Discrepancies between in vitro and in vivo 
evaluation of bitterness have already been reported. For example, higher threshold 
concentrations and EC50 values for bitter hop compounds were found in a sensory test 
compared to the taste receptor assay, whereas the ranking in order of potency for the 
compounds was the same (29). 
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such as β-casein. Proteins were ranked for their efficacy for reducing receptor activation as 
follows, β-casein > gelatin F1 ≈ Na-caseinate > gelatin B1 > β-lactoglobulin. This ranking 
was in good agreement with findings from a complementary ultrafiltration assay relating 
the concentration of free EGCG with increasing protein concentration to hTAS2R39 
activation. 
Provided that the hTAS2R activated by the bitter compound of interest is known, the 
bitter receptor assay seems to be promising for the discovery of bitter-masking agents. It 
has been applied in several instances for high-throughput screening for so-called bitter 
blockers, i.e. compounds that act antagonistically on the bitter receptor of interest (30, 31). 
These blockers are thought to be rather specific in reducing bitterness, although their 
suggested promiscuity (i.e. the bitter blocker inhibits several hTAS2Rs) (31), or their 
potential agonistic behavior on other bitter receptors, might compromise this idea (32). 
Besides, some bitter compounds have been described to activate more than one bitter 
receptor, which might call for more than one blocker for a particular bitter tastant (6, 17, 
29). Therefore, it might be advantageous to use a more generic approach for masking 
bitterness, e.g. by applying complexing agents, such as food proteins, which do not act 
directly at the receptor. We have now shown that the cell-based bitter receptor assay can be 
used as a tool to study such complexing agents, given that the protein is able to bind a 
significant amount of the bitter tastant. 
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As described in the General Introduction of this thesis, (iso)flavonoids are present in many 
food raw materials and food products. Also, they are additionally incorporated in functional 
food products as bioactive compounds in order to enhance their nutritional value. Due to 
contradictory statements on the bitter taste of some (iso)flavonoids in literature, and the 
unknown taste properties of other (iso)flavonoids, a systematic investigation of intrinsic 
bitterness and structure-activity relationships of these compounds was performed using 
receptor assays. To this end, the research described in this thesis started with (i) 
identification of the bitter receptor(s) activated by soy isoflavones, and (ii) investigation of 
structural requirements for (iso)flavonoids to activate the bitter receptors identified. A 
subsequent aim was the investigation of debittering strategies on receptor level by (iii) 
identification of bitter receptor antagonists, and (iv) complexation of flavonoids with food 
proteins.  
This chapter discusses the findings presented in this thesis, addresses prospects and 
limitations of the bitter receptor cell assay, and compares taste evaluation by sensory tests, 
receptor assays and modeling. Furthermore, it evaluates strategies for bitter taste reduction, 
and applies the findings to soy products and tea. 
 
(ISO)FLAVONOIDS AS DIETARY hTAS2R AGONISTS  
Determination of hTAS2Rs activated by soy isoflavones 
The first hypothesis of this Ph.D. research implied that compounds causing bitterness in soy 
products can be assigned to bitter taste receptors. As no consensus existed in literature 
about the impact of several isoflavones on bitterness, an objective tool to determine 
intrinsic bitterness of isoflavones was needed in order to identify the target molecules for 
modifying bitter taste of soy products. Chapter 2 elaborates on the investigation of bitter 
receptor activation by soy isoflavones, as they are most frequently reported as responsible 
for bitterness in soy products. All 25 hTAS2Rs were screened for activation by genistein, 
genistin, acetyl genistin and malonyl genistin. At screening concentrations, genistein was 
the only compound activating bitter taste receptors, namely hTAS2R14 and hTAS2R39. 
Besides the predominant genistein form, also daidzein, daidzin, glycitein and glycitin were 
screened for activation of all 25 bitter receptors (not reported in Chapter 2), but at 
screening concentrations (400 µM), no receptor was clearly activated (data not shown). 
Investigation of dose-response behavior of all soy isoflavones mentioned towards activation 
of hTAS2R14 and hTAS2R39 revealed that also soy isoflavones other than genistein 
activated these two receptors, though at concentrations above the screening concentrations. 
It can, therefore, not be excluded that bitter receptors other than hTAS2R14 and hTAS2R39 
might be activated by soy isoflavones as well. To conclude, the first hypothesis could be 
accepted, and hTAS2R14 and hTAS2R39 were identified as bitter receptors activated by 
soy isoflavones, with different impact of aglycones and glucosides. 
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Based on sensory tests, there was no consensus in literature about the impact on 
bitterness of genistein, daidzein, genistin, daidzin, and malonyl isoflavones They were all 
reported as bitter (1-4), but while converting isoflavone glucosides enzymatically into their 
aglycones was suggested as method to reduce bitterness and astringency by one author (5), 
another author reported increasing objectionable taste after β-glucosidase treatment, caused 
by aglycones (6). The results presented in Chapter 2 enable us to clarify the potential 
bitterness of soy isoflavones from the more objective receptor point of view. On 
hTAS2R39, the order of intrinsic bitterness was determined genistein > acetyl genistein > 
genistin / malonyl genistin / glycitin / glycitein / daidzein. hTAS2R14 was only activated 
by aglycones (genistein >> glycitein / daidzein). It is not known yet, which of the two 
receptors hTAS2R14 and hTAS2R39 is more important in the mouth, and whether the joint 
activation of two bitter taste receptors can lead to an additive effect in the mouth. Even 
without knowledge about this, it is expected that the aglycone genistein has a much larger 
contribution to bitter taste than daidzein and genistein glucosides, and therefore, probably 
represents the key bitter compound amongst soy isoflavones. This conclusion is discussed 
in Chapter 2 in the context of intrinsic bitterness thresholds and isoflavone concentrations 
in different soy products.  
 
Molecular signature of dietary (iso)flavonoids activating hTAS2R14 and hTAS2R39 
The second hypothesis of this thesis research implied that bitter isoflavonoids and 
flavonoids hold molecular signatures involved in bitter receptor activation. This was 
investigated by comparing several isoflavonoids in their behavior towards hTAS2R14 and 
hTAS2R39 (Chapter 2), and was extended to a large set of flavonoids (Chapter 3). This 
allowed a systematic investigation of the influences of (iso)flavonoid backbones and 
substitutions. Owing to the large number of possible structural variations, molecular 
signatures responsible for bitter receptor activation were not easily recognizable. Therefore, 
different molecular modeling approaches were applied. In the end, molecular features of 
(iso)flavonoids with distinct relative spatial orientation were identified as signatures 
responsible for activation of hTAS2R14 and hTAS2R39. This allowed discrimination 
between active and inactive (iso)flavonoids. The substitution pattern of (iso)flavonoid 
aglycones was shown to be of higher importance for bitter receptor activation than the 
backbone structure. Therewith, the second hypothesis could be accepted, and we were able 
to precise the molecular signature involved. 
Approximately 70 (iso)flavonoids revealed to be agonists of one or both bitter 
receptors hTAS2R14 and hTAS2R39 (Chapter 3). The identification of such a large 
number of agonists can be ascribed to the systematic investigation of substitution patterns 
and backbone variation of the (iso)flavonoids. So far, an approach like this has scarcely 
been reported in literature (7) and has never been applied with such a large set of 
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structurally similar compounds. Mostly, structurally different bitter compounds have been 
tested. 
As discussed in Chapter 3, pharmacophore modeling revealed, which common 
signatures underlay binding of (iso)flavonoids to hTAS2R14 and -39. Therefore, it might 
be better to describe tuning breadth of bitter receptors in terms of the number of molecular 
signatures recognized by the receptor, instead of in terms of the number of receptor 
agonists. In this way, a collection of molecules with similar signature will only count as one 
with respect to tuning breadth, and tuning breadth is less likely to be overestimated. 
 
Taste properties of dietary (iso)flavonoid sources 
Besides looking at structural variation, it is of great interest to look at the occurrence in 
food products of the compounds exhibiting the highest intrinsic bitterness. The dietary 
isoflavonoids identified as bitter receptor agonists occur mainly in soybeans and soy 
products, amongst which fermented products, such as tempeh (8) (an Indonesian soybean 
cake), are especially rich in the aglycones identified. The isoflavonoid activating 
hTAS2R14 and hTAS2R39 with the lowest threshold (4 µM and 8 µM, respectively) was 
genistein, the aglycone of the predominant soy isoflavone form. The dietary flavonoids 
identified as bitter receptor agonists occur in various kinds of honeys, fruits, vegetables, 
herbs and roots (licorice). Some compounds identified with very low bitterness thresholds 
are present in many food sources (9-11) (e.g. kaempferol and luteolin), whereas others are 
quite rare (9-11) (e.g. morin and pinocembrin), or have disappeared from our diet in 
modern days (12) (e.g. silibinin).  
Several dietary sources of (iso)flavonoids have been reported as bitter before, whereas 
other dietary sources, containing (iso)flavonoids identified as intrinsically bitter in Chapter 
3, are not known to be bitter (e.g. strawberries (source of morin and pelargonidin) (9-11), 
licorice root (source of isoliquitirigenin) (13), and oregano (source of apigenin, lutelin, 
pinocembrin, and naringenin). This is probably caused by the low concentrations of 
aglycones, or by naturally occurring masking compounds, such as sweet compounds (e.g. 
high sugar content in fruits and occurrence of intensely sweet triterpenoids in licorice root 
(14), and the intense aroma of herbs. Products containing exceptionally high amounts of 
aglycones are typically tea and fermented soy products, which are discussed further on in 
this chapter.  
(Iso)flavonoid glycosides have scarcely been investigated, although they are often the 
predominant (iso)flavonoid form in foods. So far, the only hTAS2R activation reported for 
flavonoid glycosides is the activation of hTAS2R39 by four isoflavone glucosides (reported 
in Chapter 2, published as (15)) and the activation of hTAS2R7 by malvidin-3-glucoside 
(16). Therefore, a next step of interest would be the investigation of more flavonoid 
glycosides for hTAS2R activation, although this is currently limited by the poor 
commercial availability of these compounds.  
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Possible impact of hTAS2R39 on food perception 
With the identification of (iso)flavonoids as bitter receptor agonists in this thesis, the 
number of dietary bitter taste receptor agonists for hTAS2R14 and hTAS2R39 is elevated 
enormously. The number of agonists for hTAS2R14 was doubled, which is largely 
contributing to the spectrum of dietary agonists for hTAS2R14. More than two thirds of all 
hTAS2R39 agonists have been newly reported in this thesis, of which the majority is of 
dietary origin. Dietary agonists have been reported for 16 of the 25 bitter taste receptors. 
Amongst them, a few receptors are activated by numerous representatives of the same 
chemical class, e.g. sesquiterpene lactones (mainly hTAS2R46, hTAS2R10 and 
hTAS2R14) (17), peptides (mainly hTAS2R1, hTAS2R4, and hTAS2R39) (18-21), hop 
acids (hTAS2R1, hTAS2R14, and hTAS2R40) (22), steviosides (hTAS2R4 and 
hTAS2R14) (23), and flavonoids (mainly hTAS2R14 and hTAS2R39) (this thesis, 
Chapters 2 and 3 and (16)). In contrast to niche compounds, peptides and flavonoids are 
ubiquitously present in many food products consumed in our daily diet. This makes 
hTAS2R39 a potentially important receptor for sensing bitter compounds in foods, although 
its contribution in the mouth (e.g. density in comparison to other hTAS2Rs) is still not 
known. Furthermore, no functional polymorphisms for this receptor are known to result in 
different sensitivities towards certain bitter compounds, as reported for e.g. hTAS2R16, 
hTAS2R38, and hTAS2R43 (24-26). This could mean that everyone should be able to 
perceive the bitter taste of (iso)flavonoids.  
 
PROSPECTS AND LIMITATIONS OF THE BITTER RECEPTOR CELL ASSAY 
In this thesis, it has been demonstrated that the bitter receptor assay is an appropriate tool 
not only for identification of bitter receptor agonists (Chapter 2 and 3) and antagonists 
(Chapter 4), as reported before, but also for identification of reduced receptor activation by 
complexing agents (Chapter 5). So far, bitter receptor assays have been used with 
relatively small molecules only. We have shown now that this cell assay can also be applied 
in combination with macromolecules. The applicable concentrations were, however, limited 
to ~1 g/L for most proteins investigated. 
Some compounds reported in Chapter 2 and 3 could not be characterized due to non-
specific signals. The receptor assay in its widely used form appeared to be inappropriate to 
some bitter compounds. This will be discussed below based on results for soy saponins, 
another class of bitter compounds, not earlier reported in this thesis. 
 
Screening bitter receptors for activation by soy saponins 
In soybeans, not only isoflavones have been reported as bitter, but also saponins. Soybean 
saponins are triterpenoid glycosides, consisting of an aglycone backbone (called sapogenin 
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or sapogenol) and one or two glycosidic chains consisting of two or three units (27). 
Directed measures against the bitter taste of soy products might be rationally taken when 
also the target receptor for saponins is known. Therefore, we tried to identify the bitter taste 
receptor(s) responsible for these molecules. To this end, a bitter receptor screening was 
performed with a soy saponin concentrate1 and with the purified major soy saponin Bb 
(Figure 1, isolated according to (27)), following the same experimental procedures as 
outlined in Chapter 2. Results of screening for bitter receptor activation by saponin Bb are 
shown in Figure 2. The results show non-specific signals without clear distinction between 
signals from induced and non-induced cells. Similar curves were obtained for the soy 
saponin concentrate (data not shown), and at other concentrations. Cell permeabilization 
(determined by ATP test) and influence of micelle formation ability (determined by surface 
tension measurements) of saponins could be excluded as reasons for the phenomena 
observed, as cells were vital at all concentrations used and results were independent of 
critical micelle concentration (data not shown). 
 
 
Figure 1. Structure of the major soy saponin, saponin Bb. Glc-
UA, glucuronic acid; Gal, galactose; Rha, rhamnose. 
 
 
Figure 2. Calcium release signals of HEK293 cells stably expressing hTAS2Rs (except hTAS2R 46 and 
30 (formerly hTAS2R47)) and Gα16-gust44, stimulated with 130 µM soy saponin Bb. Non-induced cells 
(receptor not expressed) are measured as control (depicted with grey background). 
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In order to investigate whether the G-proteins incorporated in the cell lines employed 
might have influence on the non-specific signals, wild type HEK293 cells were stimulated 
with soy saponins as well. Stimulation of wild type HEK293 cells by soy saponins did not 
lead to a calcium release signal, whereas the non-induced HEK293 cells stably expressing 
Gα16-gust44 (not expressing bitter receptors) did (Figure 3). 
 
 
Figure 3. Calcium release signals of wild type HEK293 cells (grey line) versus non-induced HEK293 
cells stably expressing Gα16-gust44 (dashed black line), stimulated with 125 µM soy saponins.  
 
Gα16 is not present in wild type HEK293 cells. It was introduced into HEK293 cells, 
due to its capacity to activate an easy-measurable Ca2+ signaling pathway, as explained in 
the General Introduction of this thesis. The results shown in Figure 3 indicated that the 
promiscuous Gα16 might bind to endogenous GPCRs in HEK293 cells. Saponins might thus 
activate endogenous GPCRs, leading to non-taste receptor specific signals. Alternatively, 
direct activation of G-proteins by saponins might explain our observations. Direct 
activation of G-proteins by amphiphilic bitter compounds has been reported before (28). 
Consequently, the bitter receptor assay in this setting might not be suitable for detection of 
bitter receptor activation by saponins. We speculate that the fact that not all 25 hTAS2Rs 
have been deorphanized yet, and that the target receptor for several bitter compounds has 
not been identified yet, might find its origin, amongst others, in the possibility that certain 
bitter compounds are not compatible with the cell assay employed, similar to our 
observations with saponins. 
In order to develop an assay suitable for soy saponins, and possibly other compounds 
leading to non-specific signals, we suggest one of the following methods. Of most of these 
methods it still remains to be established whether they can indeed function as an alternative. 
(i) Expression of specific G-proteins in HEK293 cells. Due to its presence in native taste 
receptor cells, Gαgustducin might be used. As coupling of Gαgustducin (a Gαi protein) to bitter 
receptors might not result in intracellular Ca2+ release in a cell assay system, Ca2+ release 
has to be triggered by the βγ-subunit via the PLCβ2-IP3/DAG pathway. We suggest the use 
of the native taste receptor cell G-proteins Gβ3 and Gγ13, as it is unknown whether the β- 
and γ-G-proteins naturally occurring in HEK293 cells are able to interact with Gαgustducin. 
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(ii) Use of cells naturally containing Gαgustducin, such as HuTu-80 cells (29), or native taste 
receptor cells, as recent advances have been reported in culturing these cells for a long 
period of time (30). (iii) Use of another signalling method, different from Ca2+ 
measurement by fluorescence, e.g. measuring GTPγS-binding to Gαgustducin in insect 
membranes, as applied previously to bitter receptor assays by (31, 32), or measuring 
bioluminescence resonance energy transfer (BRET) as reported for umami receptors (33).  
Despite the fact that no hTAS2R for soy saponins was identified under the conditions 
used in the receptor assay, it might be speculated which bitter receptor they activate. 
Saponins (which are triterpenoids), have structural characteristics in common with the 
steroid glycoside H.g.-12 (agonist of hTAS2R14 and hTAS2R7) (34), steviol glycosides 
(agonists of hTAS2R14 and hTAS2R4) (23), and with sesquiterpene lactones (agonists of 
mainly hTAS2R46, hTAS2R10 and hTAS2R14) (17, 35). Therefore, one of these 
hTAS2Rs might be a candidate for activation by saponins. In additional experiments, not 
described before in the previous chapters of this thesis, we tested other triterpenoids, not 
occurring in soybean, but structurally very similar to the backbone of soy saponin Bb. 
These were the sapogenin aglycones betulinic acid, betulin, oleanolic acid, and ursolic acid2 
(structures shown in Figure 4), for their ability to activate hTAS2R7, hTAS2R10 and 
hTAS2R14. We found activation of hTAS2R14 by betulin, betulinic acid, and oleanolic 
acid, activation of hTAS2R7 by betulin, oleanolic acid, and ursolic acid, and no activation 
of hTAS2R10 (data not shown). These findings indicate that our assumption was 
reasonable, and likely the glycosidic chain of soy saponins hampered detection in bitter 
receptor assays. However, glycosylation does not hamper recognition by bitter receptors per 
se, as the glycosidic chain(s) of H.g.-12 and steviol glycosides do not seem to impair bitter 
receptor activation (23, 34). 
 
 
Figure 4. Structures of betulin (A), betulinic acid (B), oleanolic acid (C), and ursolic acid (D). 
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ASSESSMENT OF ANTAGONISTIC PROPERTIES OF (ISO)FLAVONOIDS  
In the third hypothesis of this Ph.D. research, it was assumed that flavanones have the 
ability to block (iso)flavonoid bitter receptors at the molecular level. This hypothesis could 
be partially accepted, but also has to be partially rejected. The flavanones homoeriodictyol 
and eriodictyol, reported in literature as masking agents against bitter taste perception of 
caffeine (36), were not identified as antagonists, but as agonists of hTAS2R14 and 
hTAS2R39. Nevertheless, they might act as antagonists on another bitter receptor activated 
by caffeine (hTAS2R7, -10, -14, -43, and -46 (17, 35)). Amongst a set of 14 flavanones, we 
identified three flavanones as receptor blockers (Chapter 4). These three flavanones had a 
methoxy substituent on position 6 of the A-ring in common. 
In Chapter 3, several of the compounds tested did not or poorly activate hTAS2R14 
and/or hTAS2R39. It is likely that an antagonist might have similar structural elements to 
an agonist in order to fit into the same binding pocket. Therefore, additionally to the results 
presented for flavanones in Chapter 4, more (iso)flavonoids were tested for their ability to 
act as antagonists towards hTAS2R14 and/or hTAS2R39. All compounds reported in 
Chapter 3 with a threshold of 250 µM or 500 µM, or with no activation detected on 
hTAS2R14 or hTAS2R39, were selected. They were applied together with genistein on 
hTAS2R14 or ECG on hTAS2R39, following the experimental procedures outlined for 
flavanones in Chapter 4. This resulted in the identification of apigeninidin chloride 
(Figure 5A), able to reduce activation of hTAS2R14 by genistein by 29 %, and of tricetin 
(Figure 5B) able to reduce activation of hTAS2R39 by ECG by 30 %. Based on the 
structural characteristics of these two compounds, similar compounds were selected and 
screened, resulting in the additional identification of luteolinidin chloride (Figure 5C) and 
7,3’,4’,5’-tetrahydroxyflavone (Figure 5D). Luteolinidin chloride decreased the activation 
of hTAS2R14 by genistein by 36%, and 7,3’,4’,5’-tetrahydroxyflavone decreased the 
activation of hTAS2R39 by ECG by 22%. 
Although all four compounds were able to reduce bitter receptor activation during 
simultaneous application with the respective agonist, further investigations of these 
compounds indicated that they were not suitable as bitter receptor blockers. The two 
deoxyanthocyanidins, apigeninidin chloride and luteolinidin chloride, showed signal 
reduction of non-induced cells (bitter receptors not expressed), by the same trend as signal 
reduction of induced cells (bitter receptors expressed). This indicated that these 
deoxyanthocyanidins did not act as hTAS2R antagonists, but reduced fluorescence by 
another mechanism. The two flavanones tricetin and 7,3’,4’,5’-tetrahydroxyflavone were 
able to activate hTAS2R39 at high concentrations, therewith acting as partial agonists on 
hTAS2R39. Their ability to reduce activation of hTASR39 at sub-threshold concentrations 
was not sufficient enough to comply with the requirements for a good receptor blocker. In 
conclusion, it was shown that not only some flavanones, but also other flavonoids can 
reduce bitter receptor activation, though no high potential compounds were part of the set 
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tested. Additionally, it was found that not every reduction of bitter receptor activation 
necessarily implies antagonism. 
 
 
Figure 5. Structures of apigeninidin chloride (A), tricetin (B), 
luteolinidin chloride (C), and 7,3’,4’,5’-tetrahydroxyflavone (D). 
 
When comparing structure-activity relationships of (iso)flavonoids regarding their 
behavior as inactive compounds, as bitter receptor agonists, and as bitter receptor 
antagonists, two additional conclusions can be drawn based on the results presented in 
Chapter 3, Chapter 4 and here (Chapter 6). (i) The substitution pattern of (iso)flavonoids 
is of higher importance for bitter receptor activation than the backbone structure. To 
illustrate this conclusion with one example, seven out of eight (iso)flavonoids with a 
5,7,3’,4’-tetrahydroxy substitution pattern activated hTAS2R14 and hTAS2R39. The 
behavior of the eighth compound could not be determined due to non-specific signals. 
Except for differences in potency, this behavior was independent of their backbone 
structure. Moreover, most (iso)flavonoid subclasses comprised of active as well as inactive 
constituents, meaning that the backbone structure is not crucial for receptor activation, as 
long as the correct substitution pattern is present. (ii) In case of bitter receptor antagonists, 
the substitution pattern as well as backbone structure revealed to be crucial for 
functionality. This was seen for 6-methoxyflavanones, as flavonoids comprising an -OCH3 
group on position 6 were only antagonists, when they included a flavanone backbone, and 
flavanones were only antagonists of hTAS2R39 when they were methoxylated on position 
6.  
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SENSORY TESTS, RECEPTOR ASSAYS AND MODELING COMPARED FOR 
EVALUATION OF BITTER TASTE 
Testing for bitter compounds and bitter taste maskers 
The use of the bitter receptor assay enabled us to identify (iso)flavonoid bitter receptors, 
and to compare and characterize almost 100 (iso)flavonoids regarding their intrinsic 
bitterness, receptor activation thresholds and EC50 values (Chapter 3). With the knowledge 
of the target bitter receptors and the identified bitter receptor agonists, we were able to 
identify three antagonists of hTAS2R39 (Chapter 4). Although we were not able to test 
their functionality as bitter blockers in the mouth, due to unknown safety for human 
consumption, their identification created insight into structural requirements to inhibit 
hTAS2R39. This might lead to other blockers, suitable for food applications. The bitter 
receptor assay is a high throughput method, sometimes limited by poor solubility and non-
specific signals of the test compounds, but without safety concerns. The findings just 
described would not have been possible to achieve by the use of sensory tests. Sensory tests 
have a low throughput, they are laborious, and it is difficult to find panel members for 
tasting unpleasant compounds. Their outcomes can be highly variable, depending on the 
sensory protocol, genetic profile of the panellists, and environmental and physiological 
conditions. Most importantly, only food-grade compounds, safe for human consumption 
(GRAS), can be used. A complicating factor for bitterness detection by sensory tests is that 
bitterness and astringency are difficult to distinguish. On the other hand, only sensory tests 
can establish the real taste perception, as receptor assays cannot account for interactions of 
bitter compounds with saliva, or cross-modal interactions. The bitter receptor assay can 
thus be seen as a filter to reduce the number of candidate compounds to the most potent 
ones. In this way, the services of sensory panels can be minimized to evaluate the impact of 
compounds of high interest.  
In Chapter 5 we demonstrated a successful combination of the advantages of 
bitter receptor assays and sensory tests. We studied the ability of the bitter compound 
EGCG to bind to various proteins (in ultrafiltration assays), investigated whether this 
phenomenon could be translated to reduced availability of EGCG for activation of 
hTAS2R39 (in bitter receptor assays), and selected the protein with the highest ability to 
reduce bitter receptor activation. The best protein, Na-caseinate, was tested in sensory tests 
together with EGCG, and we could show that the in vitro findings were in agreement with 
actual perception in vivo. Therewith, the last hypothesis of this thesis, namely that bitter 
taste reduction for dietary flavonoids by complexation with food proteins can be predicted 
by the use of in vitro assays, was accepted. However, not all in vitro and in vivo 
observations were in full agreement with each other, as slight bitter taste reduction by use 
of β-lactoglobulin was not predicted by in vitro assays. This bitterness reduction was most 
likely not caused by complexation, but by interactions between β-lactoglobulin and the 
buccal environment, which cannot be accounted for in the bitter receptor assays. 
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Consensus and discrepancy between receptor assays and sensory tests 
Findings of in vitro bitter receptor activation do not necessarily imply that exactly the same 
effect will be observed sensorially. This will be discussed here by means of two examples. 
In the bitter receptor assays, catechin and epicatechin activated hTAS2R39 and 
hTAS2R14. No difference was observed between the potency of these two stereoisomers 
(activation thresholds on hTAS2R39: 250 µM, activation thresholds on hTAS2R14: 500 
µM) (Chapter 3). However, in sensory studies, various outcomes have been reported. In 
two sensory studies, bitterness of epicatechin (bitterness threshold 800 µM (37) or 930 µM 
(38)) was perceived as slightly stronger than that of catechin (bitterness threshold 1000 
µM) (37, 38). In another sensory study, the bitterness of epicatechin was perceived as equal 
to that of catechin at low concentrations, but as significantly stronger than that of catechin 
with increasing concentrations (39). It should be mentioned that other bitter receptors than 
hTAS2R14 and hTAS2R39 have been identified for epicatechin at high concentrations, 
namely hTAS2R4 (threshold 2 mM) and hTAS2R5 (threshold 1 mM) (16). Thus, 
epicatechin was probably perceived as more bitter than catechin in sensory tests, because 
more bitter receptors are activated by it. This would explain the findings of (39) at 
increased concentrations. Caution should be taken in the interpretation of these data, as 
catechin has not been tested on hTAS2R4 and hTAS2R5, and might be an agonist as well. 
Furthermore, catechin and epicatechin might differ in binding with salivary proteins or 
mucus layers in the mouth, which can lead to lower bitter perception in the mouth than 
expected based on the outcomes of bitter receptor assays. An effect like this has been 
demonstrated before as reason for discrepancy between intrinsic bitterness and bitterness 
perception of hop acids (22). Altogether, the attribute of catechin and epicatechin both 
being bitter, was consistent in vitro and in vivo. Furthermore, it can be concluded that the 
intensity of bitterness perception becomes difficult to predict by receptor assays when there 
are several bitter receptors involved, as it is not known yet whether some bitter receptors 
play a more important role for bitter perception than others.  
Two compounds showing noticeably different effects in bitter receptor assays and 
sensory tests are eriodictyol and homoeriodictyol. In Chapter 3, they are identified as 
agonists of hTAS2R14 and hTAS2R39. In contrast, they are reported to act as bitter taste 
maskers in sensory tests (36). However, their mechanism of bitterness masking has not 
been established yet. One explanation for this discrepancy between receptor assay and 
sensory perception could be that they are agonists on hTAS2R14 and hTAS2R39, but 
antagonists (not yet identified) on other bitter receptors, and their antagonistic properties 
overrule their agonistic properties. The ability of compounds to act as agonist on one subset 
of hTAS2Rs and as antagonists on another subset of hTAS2Rs has been demonstrated 
before (40).  
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The use of modeling for identification of bitter compounds and bitter taste maskers 
Chapter 3 describes the behavior of many structurally similar (iso)flavonoids towards 
hTAS2R14 and hTAS2R39. Subsequently, it describes the development of fingerprint and 
pharmacophore models predicting whether they activate the respective bitter receptor, or 
not. The question arises whether modeling could replace the measurements with cell assays 
or sensory tests. The models developed in Chapter 3 were suitable for a defined type of 
molecules only, and not applicable to bitter molecules in general. Within their structural 
limitations, they are suitable to make predictions on whether an (iso)flavonoid is likely to 
activate hTAS2R14 or hTAS2R39. Development of quantitative structure activity 
relationship (QSAR) models was not successful, as the bitter receptor thresholds of 
(iso)flavonoid never differed by more than three orders of magnitude. Therefore, no 
prediction could be made on the intensity of intrinsic bitterness, but only on the activation 
or absence of activation. The trend in food industry to fortify products with potentially 
health promoting ingredients, such as (iso)flavonoids, might lead to introduction of bitter 
taste. By means of model-aided predictions, the potential of various (iso)flavonoids to 
introduce bitterness when used for food fortification can thus be accessed before product 
development starts. This can save time and money, and limit laborious sensory tests to a 
minimum. 
Pharmacophore modeling is also of interest as a strategy to identify new bitter blockers. 
It has been shown before that pharmacophore modeling is a valid approach to identify new 
bitter blockers, especially when it is combined with docking into the active site of the target 
receptor (41). For the bitter receptor blockers described in Chapter 4, pharmacophore 
modeling and docking into the active site of hTAS2R39, might enable discovery of new 
receptor blockers as well. Nevertheless, it might be necessary to extend our current data set 
of three antagonists with more molecules for this approach. 
Despite the fact that there can be some discrepancies between bitter receptor assays and 
sensory tests, it can be concluded that bitter receptor assays are a useful tool for high 
throughput identification of bitter receptors and consequently identification of compounds 
able to reduce their activation. This can be aided by modeling, especially in order to 
understand structural requirements involved in receptor agonism or antagonism. In the end, 
the most promising findings should be validated by sensory tests. 
 
EVALUATION OF STRATEGIES FOR BITTER TASTE REDUCTION 
In this thesis, two strategies of bitter taste reduction were investigated: blocking of bitter 
taste receptors (Chapter 4) and complexation of bitter flavonoids with food proteins 
(Chapter 5). In the first case, bitter taste receptor blockers were identified, which reduced 
the activation of hTAS2R39 to a large extent. Unfortunately, we were not able to perform 
sensory tests with the bitter receptor blockers identified, due to unknown safety of the 
6
  
Chapter 6 
 
152 
 
compounds identified. In the second case, we were able to show that reduced activation of 
bitter receptors by addition of food proteins led to a real reduction of bitter perception, as 
both in the bitter receptor assay and in sensory experiments the reduction was observed. In 
the following, the two bitterness reduction strategies will be discussed, followed by an 
overview of their specifications in Table 1.  
Additional to the results presented in Chapter 5, two other bitter compounds, ECG and 
EC, were tested together with food proteins in bitter receptor assays. The effect of complex 
formation between bitter compounds and food proteins on reduction of bitter receptor 
activation was investigated. An example (Figure 6) is shown for β-casein, as it was the 
most effective food protein to reduce EGCG signals. It can be seen that addition of β-casein 
to ECG resulted in similar effects as for EGCG. On the other hand, activation of 
hTAS2R39 by the structurally related non-galloylated EC was not reduced by β-casein. 
This result can be explained by the low binding affinity of EC for β-casein (42), leading to 
weak complexes. It has been reported that complex formation between caseins and 
flavonoids is favored by the presence of rotatable bonds and four or more aromatic rings in 
the flavonoid (43). Therefore, whereas it works for galloylated flavonols, a debittering 
strategy using complexation with food proteins is probably not suitable for monomeric 
(iso)flavonoids and glycosylated (iso)flavonoids containing less than four aromatic rings.  
An alternative for molecules unable to engage in complexation with food proteins, is 
the use of other agents suitable for food applications, such as β-cyclodextrin (E 459). This 
complexing agent can form molecular inclusion complexes with hydrophobic molecules 
and is quite broadly applicable when size and hydrophobicity requirements of the included 
molecule are met. Complexation of catechin with β-cyclodextrin has been reported as 
effective in reduction of bitterness in sensory tests (44). 
The main advantage of complexation with food proteins is the use of a compound 
naturally present in food products. This might provide high consumer acceptability and no 
difficulties with labelling. Quantities needed for complexation of EGCG with e.g. β-casein 
have been shown to be realistic for application in food (42). The EGCG-β-casein or 
caseinate complex is functional during consumption, has a short residence time in the 
mouth, and it can be expected that the complexes will fall apart in the stomach, therewith 
not altering the absorption of EGCG. Furthermore, via complexation of EGCG and food 
proteins not only bitter taste is masked, but also astringency is probably affected. Reduced 
astringency of catechins has been reported for other complexing agents, like sodium 
carboxymethyl cellulose and β-cyclodextrin (44, 45). 
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Figure 6. Change of hTAS2R39 activation by EGCG, ECG, 
and EC, after complexation with β-casein, following the same 
methodology as described in Chapter 5. 
 
In Chapter 3, we reported ECG as agonist of at least two bitter receptors, hTAS2R39 
and hTAS2R14. In order to fully eliminate bitter taste of ECG by an antagonist, all 
receptors activated by ECG have to be inhibited. In Chapter 4 we reported the 
identification of hTAS2R39 antagonists, which were able to decrease bitter receptor 
activation when applied simultaneously with the bitter compound. The same compounds 
also acted as hTAS2R14 antagonists, though only after stepwise administration. For food 
applications, a receptor blocker is only suitable, when it is functional in simultaneous 
administration with the bitter compound. Therefore, blockers that are only functional when 
applied prior to the bitter compound, are not suitable. Although bitter taste by ECG might 
not be eliminated by receptor blockers with these properties, inhibition of one of the two 
bitter receptors might already lead to a decrease of bitter taste. Moreover, a bitter 
compound activating several bitter receptors can be debittered by the use of one 
complexing agent, whereas several receptor blockers might be necessary to achieve this if 
the blocker specificity is narrower than the agonist specificity. On the other hand, the 
advantage of bitter receptor blockers is that they are applicable independently from the 
molecular structure of the bitter receptor agonist, in contrast to debittering by complexation, 
which is dependent on the molecular structure of the bitter compound. Prior to application, 
sensory panels should evaluate complexing agent or receptor blocker for both their 
bitterness reduction ability, and, furthermore, for their own taste profile, in order to avoid 
possible aftertastes. 
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Table 1. Comparison of properties of complexing agents and receptor blockers.  
Characteristics Complexation with food 
proteins 
Bitter receptor blockers 
suitable independent of bitter agonist no yesa 
suitable independent of bitter receptor yes no 
receptor specific no yes 
naturally present in food yes possibleb 
persisting effect on the tongue noc possibleb,d 
affecting also astringency yesc no 
a
 if orthosteric antagonist, b not reported yet, c assumption, d if irreversible antagonist 
 
Altogether, the use of bitter receptor blockers seems to be suitable for molecules of 
which the target receptor is known. Complexation with food proteins seems to be suitable 
for larger molecules, and might for these be broader applicable than receptor blockers, as 
the effect of complexation is independent from the number of receptors activated by one 
bitter compound. Food systems containing both non-complexable smaller bitter compounds 
and complexable larger bitter compounds, might, therefore, be most effectively debittered 
by a combination of the two methods.  
 
APPLICATION OF DEBITTERING STRATEGIES TO SOY PRODUCTS AND TEA 
Debittering strategies for soy 
Application of the debittering strategies targeted for single compounds in complex food 
matrices, such as soy products, is difficult to predict, due to possible interactions of the 
bitter blockers or food proteins with other compounds present. In this paragraph it is 
assumed that such interactions do not hamper accessibility of bitter compounds by 
debittering agents.  
Application of the two debittering strategies described in this thesis to soy products can 
only be predicted for isoflavones. The use of food proteins for complex formation with 
isoflavones is not promising, due to low predicted affinity between food proteins and 
phenolic compounds comprising of less than four aromatic rings (43). The use of receptor 
blockers that block hTAS2R39, and to some extent hTAS2R14, as reported in Chapter 4, 
seems a better option, as isoflavone glucosides activate hTAS2R39, and the less abundant 
aglycones activate hTAS2R14 and hTAS2R39.  
Due to the high variation of isoflavone compositions reported for soybean varieties and 
soy products (46-48), two alternative strategies to control bitterness of soy isoflavones 
should be considered as well: cultivar selection and processing. Applying the information 
about intrinsic bitterness gained with the bitter taste receptor assays (Chapter 2) to the 
isoflavone composition of soy products upon processing and amongst cultivars (46-48), 
results in two main conclusions: (i) Intrinsic bitterness of soybean isoflavones cannot be 
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reduced by transformation into other isoflavone forms due to processing, it can only be 
enhanced. Heating of soybean isoflavones under wet conditions leads mainly to the 
transformation of natively most abundant malonyl glucosides (4) into unsubstituted 
glucosides (by deesterification) (4, 48), not changing intrinsic bitterness, due to the same 
threshold of hTAS2R39 activation by genistin compared to malonyl genistin. Heating of 
soybean isoflavones under dry conditions leads mainly to the transformation of malonyl 
glucosides into acetyl glucosides (by decarboxylation) (48, 49), and can thus implement 
increasing intrinsic bitterness, due to four times lower threshold of hTAS2R39 activation by 
acetyl genistin compared to malonyl genistin. Soaking of soybeans in water leads to modest 
formation of aglycones (6, 48), while fermentation of isoflavones leads to major formation 
of aglycones (48, 50). It will thereby drastically enhance intrinsic bitterness, at least for the 
dominating genistein form. (ii) As genistein forms show the highest intrinsic bitterness, a 
relatively lower bitterness is expected from soybean varieties low in genistein forms, and 
richer in daidzein and glycitein forms. Although not common, existence of cultivars with 
these characteristics has been shown (51, 52). Decreasing bitterness of soy isoflavones by 
heating or enzymatic conversion of glucosides into aglycones is highly unlikely. If 
debittering of soy products can be achieved by processing, it might be caused by certain 
losses of isoflavones into the processing water during boiling (53), or by other soy 
constituents, such as saponins, but not by transformation of isoflavones. The effect of 
saponins on bitterness of soy products, in addition to isoflavones, remains to be established. 
In conclusion, the proposed debittering strategy for soy products is the use of bitter 
receptor blockers against intrinsically bitter isoflavones, and control of genistein occurrence 
by selection of cultivars low in genistein forms, and/or by limitation of processing resulting 
in formation of acetyl glucosides and aglycones. 
 
Effect of debittering strategies on tea 
In Chapter 3, we identified hTAS2R39 (as (54)) and hTAS2R14 (not reported before) as 
tea catechin bitter receptors. Next, we presented solutions on how to reduce bitterness of 
catechins at receptor level by bitter receptor blockers (although not food-grade) (Chapter 
4), or on receptor and sensorial level by complexation with food proteins (Chapter 5). The 
question arises whether these measures are sufficient to reduce bitterness in tea.  
In green tea, the bitter compound present in by far the highest concentrations, and 
additionally exhibiting the highest bitterness, is EGCG. The remaining less bitter 
compounds caffeine, theobromine, and other catechins, are present in much lower 
concentration than EGCG. Due to the key impact of EGCG, complexation of EGCG by 
food proteins might be sufficient to largely reduce bitterness in green tea.  
The question whether bitter taste in black tea and oolong tea can be reduced by one of 
the two debittering methods applied in this thesis, is more complex. Due to the low amount 
of catechins, and the presence of thearubigins and theaflavins (oxidation products of 
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catechins), the answer to this question might dependent on the unclear taste effect of 
thearubigins and theaflavins. If they do not contribute to bitterness, as reported by (55), the 
bitter compounds are narrowed down to catechins and caffeine / theobromine, like in green 
tea. If thearubigins and theaflavins contribute to bitterness, as reported by (56), it should be 
investigated if they can be complexed with food proteins, or if they can activate bitter taste 
receptors, in order to identify the target receptor. As mentioned above, complex formation 
between caseins and flavonoids is favored in the presence of rotatable bonds and four or 
more rings in the flavonoid (43). Due to the presumed oligomeric character of thearubigins 
and theaflavins, complexation with food proteins seems thus likely. Therefore, also for 
oolong and black tea, complexation seems to be a good approach to reduce bitter taste.  
In conclusion, the choice of debittering strategies depends on the molecular structure of 
the bitter food compounds, as exemplified for soybean products and tea. Therefore, each 
food product needs its own tailor-made debittering solution. 
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Many flavonoids and isoflavonoids have been associated with beneficial health effects. 
Therefore, consumption of (iso)flavonoid-rich food products, and enrichment of foods with 
(iso)flavonoids is becoming increasingly popular. However, several (iso)flavonoids have 
been reported as bitter. Consequently, their incorporation in (or fortification of) foods can 
introduce (or enhance) bitterness. Hence, debittering strategies are demanded.  
Some (iso)flavonoids have unknown taste properties, as they have never been 
incorporated in high levels in food products. For other (iso)flavonoids, contradictory 
findings on bitterness have been made in sensory tests. Therefore, objective tests are 
necessary to identify which (iso)flavonoids contribute to bitterness of a food product. An 
objective tool to study bitterness is a cell-based bitter taste receptor assay. Twenty-five 
different bitter taste receptors (hTAS2Rs) occur on the human tongue, each of which has 
been introduced in a separate human embryonic kidney (HEK)293 cell line. With these, the 
“intrinsic bitterness” of a compound can be investigated in vitro. Intrinsic bitterness is the 
capacity of a compound to activate bitter taste receptors, uncoupled from cross-modal 
interactions and interactions with salivary proteins and oral mucosa. The aim of this 
research was to study the intrinsic bitterness of a large set of (iso)flavonoids and to 
investigate structural requirements for (iso)flavonoids to activate the bitter receptors 
identified. A subsequent aim was the investigation of different debittering strategies by the 
use of the bitter receptor assay.  
Chapter 1 provides an overview of flavonoids and isoflavonoids with respect to their 
structural classification, sensorial properties and occurrence as dietary compounds. Taste 
perception and the mode of action of bitter taste receptors are introduced. The measurement 
of bitter receptor activation in vitro is explained, as well as strategies to reduce bitter 
receptor activation, and bitter taste in general. A state-of-the-art overview of all 25 bitter 
taste receptors is given with respect to known agonists and antagonists. 
The aim of Chapter 2 was to identify the bitter receptor(s) that recognize the bitter 
taste of the soy isoflavone genistein. Screening of all 25 human bitter receptors revealed 
genistein as agonist of hTAS2R14 and hTAS2R39. Genistein displayed threshold values of 
4 and 8 µM on hTAS2R14 and hTAS2R39, and EC50 values of 29 and 49 µM, respectively. 
Besides, the behavior of structurally similar isoflavonoids was investigated. Although the 
two receptors are not closely related, the results for hTAS2R14 and hTAS2R39 were 
similar towards most isoflavonoid aglycones. Glucosylation of isoflavones seemed to 
inhibit activation of hTAS2R14, whereas four of five glucosylated isoflavones were 
agonists of hTAS2R39, namely glycitin, genistin, acetyl genistin, and malonyl genistin. A 
total of three hydroxyl substitutions of the A- and B-rings of the isoflavonoids seemed to be 
more favorable for receptor activation than less hydroxyl groups. The concentration of the 
trihydroxylated genistein in several soy foods exceeds the bitter receptor threshold values 
determined, whereas those of other soy isoflavones are around or below their respective 
threshold values. Despite its low concentration, genistein might be one of the main 
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contributors to the bitterness of soy products. Furthermore, the bioactive isoflavonoids 
equol and coumestrol activated both receptors, indicating that their sensory impact should 
be considered when used as food ingredients. 
In Chapter 3, the intrinstic bitterness of (iso)flavonoids, which can hamper their use as 
food bioactives, was investigated further. The effect of a large set of structurally similar 
(iso)flavonoids on the activation of bitter receptors hTAS2R14 and hTAS2R39 was tested, 
and their structural requirements to activate these receptors were predicted. In total, 68 
compounds activated hTAS2R14 and 70 compounds activated hTAS2R39, amongst which 
58 ligands were overlapping. Their activation threshold values varied over a range of three 
log units between 0.12 and 500 µM. Ligand-based 2D-fingerprint and 3D-pharmacophore 
models were created to detect structure activity relationships. The 2D-models demonstrated 
excellent predictive power in identifying bitter (iso)flavonoids and discrimination from 
inactive ones. The structural characteristics for an (iso)flavonoid to activate hTAS2R14 and 
hTAS2R39 were determined by 3D-pharmacophore models to be composed of two (for 
hTAS2R14) or three (for hTAS2R39) hydrogen bond donor sites, one hydrogen bond 
acceptor site, and two aromatic ring structures, of which one had to be hydrophobic. An 
additional hydrogen bond donor feature for hTAS2R39 ligands indicated the possible 
presence of another complementary acceptor site in the binding pocket, compared to 
hTAS2R14. Hydrophobic interaction of the aromatic feature with the binding site might be 
of higher importance in hTAS2R14 than in hTAS2R39. Together, this might explain why 
OH-rich compounds showed different behavior towards the two bitter receptors. The 
combination of in vitro data and different in silico methods created a good insight in 
activation of hTAS2R14 and hTAS2R39 by (iso)flavonoids and provided a powerful tool in 
prediction of their potential bitterness. By understanding the “bitter motif”, introduction of 
bitter taste in functional foods enriched in (iso)flavonoid bioactives might be avoided. 
Bitter receptor hTAS2R39 is activated by many different classes of bitter compounds, 
amongst which (iso)flavonoids. Nevertheless, several flavanones are known to mask bitter 
taste sensorially, and not all flavanones reported in Chapter 3 activated hTAS2R39. For 
that reason, in Chapter 4, fourteen flavanones were investigated for their potential to 
reduce activation of hTAS2R39 by epicatechin gallate (ECG), one of the main bitter 
compounds present in green tea. Three compounds showed inhibitory behavior towards the 
activation of hTAS2R39 by ECG: 4’-fluoro-6-methoxyflavanone, 6,3’-
dimethoxyflavanone, and 6-methoxyflavanone (in order of decreasing potency). The 6-
methoxyflavanones also inhibited activation of hTAS2R14 (another bitter receptor 
activated by ECG), though to a lesser extent. Dose-response curves of ECG at various 
concentrations of the most potent antagonist 4’-fluoro-6-methoxyflavanone and wash-out 
experiments indicated reversible insurmountable antagonism. The same effect was 
observed for the structurally different agonist denatonium benzoate, suggesting a non-
competitive orthosteric mechanism. The bitter receptor blockers identified might not be 
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applicable to food products. Nevertheless, they create insight into structural requirements, 
which might lead to other, more suitable, blockers. 
Chapter 5 investigates another strategy to reduce bitterness, namely complexation of 
bitter flavonoids with food proteins. The binding characteristics of the bitter tea compound 
epigallocatechin gallate (EGCG) to purified food proteins, and their equivalent food-grade 
preparations, were related to their effects on reducing bitter receptor activation by EGCG in 
vitro and their bitter-masking potential in vivo. β-Casein, in particular, and several gelatins, 
are known as strong binders of EGCG, contrary to β-lactoglobulin. Also in the bitter 
receptor assay, β-casein showed the strongest effect, with a maximum reduction of 
hTAS2R39 activation of about 93%. A similar potency was observed for Na-caseinate, 
which was applied as food-grade alternative for β-casein. β-Lactoglobulin had little effect 
on bitter receptor activation, as expected based on its low binding affinity for EGCG. The 
bitter-masking potential of Na-caseinate was confirmed in vivo using a trained sensory 
panel. β-Lactoglobulin also slightly reduced EGCG bitter perception, which could not be 
directly related to its binding capacity. The bitter receptor assay appeared to be a valid tool 
to evaluate in vitro the efficacy of food proteins as complexing agents for bitter-masking. 
Chapter 6 discusses the findings presented in this thesis, addresses prospects and 
limitations of the bitter receptor cell assay, presents additional results on testing 
(iso)flavonoids for possible antagonistic properties, and compares taste evaluation by 
sensory tests, receptor assays and modeling. Furthermore, it evaluates strategies for bitter 
taste reduction, and applies the findings to soy products and tea. 
The systematic investigation of (iso)flavonoid aglycones showed that the substitution 
pattern of (iso)flavonoids is of higher importance for bitter receptor activation than the 
backbone structure. In case of bitter receptor antagonists, the substitution pattern as well as 
backbone structure revealed to be crucial for functionality. The bitter receptor assay was 
shown to be an appropriate tool not only for identification of bitter receptor agonists and 
antagonists, but also for identification of reduced receptor activation by complexing agents. 
Based on the findings of this thesis, it was concluded that complexation with food proteins 
is the most promising strategy to reduce bitter taste of flavonoids in tea. On the other hand, 
for soybean isoflavones, debittering by use of bitter receptor blockers seemed to be a 
promising debittering strategy. Alternatively to the use of receptor blockers, processing 
conditions (leading to low isoflavone aglycone formation) or raw material choice (i.e. 
cultivars low in genistein forms) were recommended. In conclusion, the choice of 
debittering strategies depends on the molecular structure of the bitter food compounds, as 
exemplified for soybean products and tea. Therefore, each food product seems to require its 
own tailor-made debittering solution. 
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Veel flavonoïden en isoflavonoïden worden in verband gebracht met gezondheids-
bevorderende effecten. Om deze reden wordt de consumptie van voedingsmiddelen rijk aan 
(iso)flavonoïden en het verrijken van producten met (iso)flavonoïden steeds populairder. 
Verschillende (iso)flavonoïden worden echter als bitter ervaren. Als gevolg hiervan kan het 
toevoegen van of verrijken met (iso)flavonoïden voedingsmiddelen bitter maken of de 
bitterheid verhogen. Er is daarom behoefte aan methoden om producten te ontbitteren. 
Van sommige (iso)flavonoïden zijn de smaakeigenschappen onbekend, omdat ze nooit 
in hoge concentraties aan voedingsmiddelen zijn toegevoegd. Voor andere zijn 
tegenstrijdige resultaten gevonden in sensorisch onderzoek. Daarom zijn objectieve 
methoden nodig om te bepalen welke (iso)flavonoïden bijdragen aan de bitterheid van een 
product. Een objectief hulpmiddel om bitterheid te bestuderen is een cel-gebaseerde 
bitterreceptor-assay. Op de menselijke tong komen 25 verschillende bitterreceptoren 
(hTAS2Rs) voor, welke allemaal in een afzonderlijke HEK 293 cellijn zijn geïntroduceerd. 
Met behulp van deze cellijnen kan de “intrinsieke bitterheid” van een verbinding in vitro 
worden onderzocht. Intrinsieke bitterheid is de capaciteit van een verbinding om 
bitterreceptoren te activeren, losgekoppeld van cross-modale interacties en interacties met 
speekseleiwitten en mondslijmvlies. Het doel van dit onderzoek was het bestuderen van de 
intrinsieke bitterheid van een groot aantal (iso)flavonoïden en het identificeren van hun 
structurele eigenschappen, die het activeren van bitterreceptoren mogelijk maken. 
Daarnaast is door middel van de bitterreceptor-assay onderzocht welke verschillende 
strategieën er zijn voor ontbittering. 
In hoofdstuk 1 wordt een overzicht gegeven van flavonoïden en isoflavonoïden met 
betrekking tot hun structurele indeling, sensorische eigenschappen en voorkomen als 
dieetbestanddelen. Smaakperceptie en de werking van bitterreceptoren worden 
geïntroduceerd. Het in vitro meten van bitterreceptoractivatie wordt uitgelegd, evenals 
strategieën om bitterreceptoractivatie, en bittere smaak in het algemeen, te verminderen. Er 
wordt een actueel overzicht weergegeven van de bekende agonisten en antagonisten van 
alle 25 bitterreceptoren. 
Het doel van hoofdstuk 2 was het identificeren van de bitterreceptor(en) die de bittere 
smaak van het sojaisoflavon genisteïne herkennen. Screening van alle 25 humane 
bitterreceptoren maakte duidelijk dat genisteïne een agonist van hTAS2R14 en hTAS2R39 
is. Drempelwaarden van genisteïne waren 4 en 8 µM voor hTAS2R14 en hTAS2R39, EC50 
waarden waren respectievelijk 29 en 49 µM. Daarnaast werd het gedrag van structureel 
vergelijkbare isoflavonoïden onderzocht. Hoewel de twee receptoren hTAS2R14 en 
hTAS2R39 niet nauwverwant zijn, waren de resultaten met de meeste isoflavon aglyconen 
vergelijkbaar. Glucosylering van isoflavonen leek de activatie van hTAS2R14 te remmen, 
terwijl vier van de vijf geglucosyleerde isoflavonen, namelijk glycitine, genistine, 
acetylgenistine en malonylgenistine, agonisten waren van hTAS2R39. Een totaal aantal van 
drie hydroxylsubstituenten op de A- en B-ring van de isoflavonoïden leek meer 
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bevorderlijk voor receptoractivatie dan minder hydroxylgroepen. De concentraties van het 
trihydroxyl isoflavonoïd genisteïne in verschillende sojaproducten overschrijden de 
gevonden bitterreceptor drempelwaarden, terwijl die van andere soja-isoflavonen rond of 
onder hun respectievelijke drempelwaarden liggen. Ondanks zijn lage concentratie zou 
genisteïne een van de belangrijkste veroorzakers van bitterheid van sojaproducten kunnen 
zijn. Verder activeerden de bioactieve isoflavonoiden equol en coumestrol beide 
receptoren. Hetgeen suggereert dat hun sensorische invloed in acht moet worden genomen 
wanneer ze gebruikt worden als ingrediënt in voedsel. 
In hoofdstuk 3 werd de intrinsieke bitterheid van (iso)flavonoïden, wat hun toepassing 
als bioactieve ingrediënten kan bemoeilijken, verder onderzocht. Het effect van een grote 
set structureel vergelijkbare (iso)flavonoïden op de activatie van bitterreceptoren 
hTAS2R14 en hTAS2R39 werd onderzocht en hun structurele vereisten om deze receptoren 
te activeren werden voorspeld. 68 verbindingen activeerden hTAS2R14 en 70 verbindingen 
activeerden hTAS2R39, waarvan 58 liganden overlapten. Hun drempelwaarden voor 
activatie varieerden over een bereik van drie logeenheden tussen 0,12 en 500 µM. Ligand 
gebaseerde 2D-vingerafdruk en 3D-pharmocaphore modellen werden gemaakt om 
structuur-activiteit-relaties te vinden. De 2D modellen konden erg goed voorspellen of 
(iso)flavonoïden bitter zijn of niet. Met behulp van 3D-pharmacophoremodellen werd 
gevonden dat de structurele eigenschappen voor (iso)flavonoïden om hTAS2R14 en 
hTAS2R39 te activeren bestaan uit twee (voor hTAS2R14) of drie (voor hTAS2R39) 
waterstofbrugdonoren, één waterstofbrugacceptor en twee aromatische ringstructuren, 
waarvan één hydrofoob dient te zijn. Een additionele waterstofbrugdonor voor hTAS2R39 
liganden duidt op de mogelijke aanwezigheid van nog een complementaire acceptorplaats 
in de bindingsplaats, vergeleken met hTAS2R14. Hydrofobe interactie van de aromatische 
eigenschap met de bindingsplaats zou in hTAS2R14 belangrijker kunnen zijn dan in 
hTAS2R39. Tezamen zou dit kunnen verklaren waarom OH-rijke verbindingen een 
verschillend effect op de twee bitterreceptoren lieten zien. De combinatie van in vitro data 
met verschillende in silico methoden heeft geleid tot een goed inzicht in de activatie van 
hTAS2R14 en hTAS2R39 door (iso)flavonoïden en bleek een krachtig hulpmiddel te zijn 
bij het voorspellen van hun potentiële bitterheid. Door het begrijpen van het “bitter motief” 
kan het introduceren van bittere smaak in functional foods verrijkt met (iso)flavonoïden 
mogelijk voorkomen worden. 
Bitterreceptor hTAS2R39 wordt geactiveerd door veel verschillende klassen van bittere 
verbindingen, waaronder ook (iso)flavonoïden. Desalniettemin zijn er enkele flavanonen 
bekend die bittere smaak sensorisch maskeren, en niet alle in hoofdstuk 3 genoemde 
flavanonen activeerden hTAS2R39. Om deze reden werden in hoofdstuk 4 veertien 
flavanonen onderzocht op hun potentieel om de activatie van hTAS2R39 door epicatechine 
gallaat (ECG), een van de belangrijkste bittere verbindingen in thee, te verminderen. Drie 
verbindingen remden de activatie van hTAS2R39 door ECG: 4’-fluor-6-methoxyflavanone, 
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6,3’-dimethoxyflavanone en 6-methoxyflavanone (in volgorde van afnemende potentie). De 
6-methoxyflavanonen remden ook de activatie van hTAS2R14 (een andere bitterreceptor 
die wordt geactiveerd door ECG), maar in mindere mate. Dosis-respons curves van ECG 
met verschillende concentraties van de meest potente antagonist 4’-fluoro-6-
methoxyflavanone en wash-out experimenten wezen op omkeerbaar onoverkomelijk 
antagonisme. Hetzelfde effect werd gevonden voor de structureel verschillende agonist 
denatoniumbenzoaat, hetgeen een niet-competitief orthosterisch mechanisme suggereert. 
Hoewel de geïdentificeerde bitterreceptorblokkeerders mogelijk niet kunnen worden 
toegepast in levensmiddelen, geven ze inzicht in structurele vereisten welke tot andere, 
meer geschikte blokkeerders zouden kunnen leiden. 
Hoofdstuk 5 onderzoekt een andere strategie om bitterheid te verminderen, namelijk 
complexatie van bittere flavonoïden met voedingseiwitten. De karakteristieken van de 
binding van de bittere theeverbinding epigallocatechine gallaat (EGCG) met gezuiverde 
voedingseiwitten en hun vergelijkbare food-grade preparaten, werden gerelateerd aan hun 
effecten op de reductie van bitterreceptoractivatie door EGCG in vitro en hun 
bittermaskeringspotentieel in vivo. Van vooral β-caseïne en van verscheidene gelatines is 
bekend dat het sterke binders van EGCG zijn, dit in tegenstelling tot β-lactoglobuline. Ook 
in de bitterreceptor-assay had β-caseïne het grootste effect met een maximale reductie van 
hTAS2R39 activatie van ongeveer 93%. Een vergelijkbare potentie werd gevonden voor 
Na-caseïnaat, welke als food-grade alternatief voor β-caseïne werd gebruikt. β-
Lactoglobuline had weinig effect op bitterreceptoractivatie, zoals verwacht op basis van de 
lage bindingsaffiniteit voor EGCG. Het bittermaskerende effect van Na-caseïnaten werd in 
vivo bevestigd met behulp van een getraind sensorisch panel. β-Lactoglobuline verlaagde 
de bitterperceptie van EGCG ook enigszins, hetgeen niet direct gerelateerd kon worden aan 
de bindingscapaciteit. De bitterreceptor-assay bleek een goed hulpmiddel te zijn om in vitro 
de effectiviteit van voedingseiwitten als bittermaskeerder te onderzoeken. 
Hoofdstuk 6 bediscussieert de in dit proefschrift beschreven resultaten, behandelt 
kansen en beperkingen van de bitterreceptor-cel-assay, beschrijft aanvullende resultaten 
aangaande onderzoek naar mogelijke antagonistische eigenschappen van (iso)flavonoïden 
en vergelijkt smaakevaluatie door middel van sensorisch onderzoek, receptor-assays en 
modelleren. Daarnaast worden strategieën voor de reductie van bittere smaak geëvalueerd 
en worden de gevonden resultaten toegepast op sojaproducten en thee. 
Het systematische onderzoek van (iso)flavonoïde-aglyconen toonde aan dat het 
substitutiepatroon van (iso)flavonoïden belangrijker is voor het activeren van de 
bitterreceptoren dan de basisstructuur. In het geval van bitterreceptorantagonisten bleken 
zowel het substitutiepatroon als de basisstructuur cruciaal te zijn voor functionaliteit. 
Aangetoond werd dat de bitterreceptor-assay niet alleen een geschikt hulpmiddel is voor de 
identificatie van bitterreceptoragonisten en –antagonisten, maar ook voor het identificeren 
van verminderde receptoractivatie door complexerende verbindingen. Gebaseerd op de 
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resultaten in dit proefschrift wordt geconcludeerd dat complexatie van flavonoïden met 
voedingseiwitten de meest veelbelovende strategie is om hun bittere smaak in thee te 
verminderen. Voor isoflavonen uit soja bleek ontbittering door middel van 
bitterreceptorblokkeerders een veelbelovende strategie te zijn. Als alternatief voor het 
gebruik van receptorblokkeerders werden aangepaste verwerkingscondities (resulterend in 
een beperkte vorming van isoflavon aglyconen) en de keuze van grondstoffen (het 
gebruiken van cultivars met een lage concentratie van de verschillende vormen van 
genisteïne) aanbevolen. Geconcludeerd kan worden dat de keuze van geschikte 
ontbitteringsstrategieën afhankelijk is van de moleculaire structuur van de bittere 
verbindingen, zoals toegelicht is aan de hand van sojaproducten en thee. Op grond hiervan 
lijkt het dat elk voedingsmiddel een eigen, op maat gemaakte ontbitteringsstrategie vereist. 
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Die Aufnahme von Flavonoiden und Isoflavonoiden wird häufig mit gesundheitsfördernden 
Effekten assoziiert. Aus diesem Grund besteht sowohl für den Verzehr von (iso-)flavonoid-
reichen Lebensmitteln als auch für die Anreicherung von Lebensmitteln mit (Iso-) 
Flavonoiden wachsendes Interesse. Einige (Iso-)Flavonoide besitzen jedoch einen bitteren 
Geschmack. Daher kann ihre Zugabe (oder Anreicherung) Bitterkeit in Lebensmitteln 
verursachen (oder verstärken). Die Entwicklung von Entbitterungsstrategien ist daher nötig, 
um dieses Problem zu lösen.  
Die Geschmackseigenschaften vieler (Iso-)Flavonoide sind unbekannt, da sie noch nie 
in höheren Konzentrationen in Lebensmitteln angewandt wurden. Für andere (Iso-) 
Flavonoide ergaben sensorische Tests widersprüchliche Ergebnisse bezüglich ihres bitteren 
Geschmacks. Objektive Tests sind notwendig, um zu identifizieren, welche (Iso-) 
Flavonoide zum bitteren Geschmack von Lebensmitteln beitragen können. Ein objektives 
Instrument für Bitterkeitsstudien ist ein zellbasiertes Bitterrezeptor-Assay. Auf der 
menschlichen Zunge befinden sich 25 verschiedene Bittergeschmacksrezeptoren 
(hTAS2Rs). Jeder dieser Rezeptoren wurde individuell in Zellkulturen (HEK 293) 
eingebracht. Mit diesen Bitterrezeptor enthaltenden Zellen kann die „intrinsische Bitterkeit“ 
eines Stoffes in vitro untersucht werden. Intrinsische Bitterkeit ist ein Maß für die Fähigkeit 
eines Stoffes, Bitterrezeptoren zu aktivieren, unabhängig von anderen sensorischen 
Wahrnehmungen und von Wechselwirkungen mit Speicheleiweißen und der 
Mundschleimhaut. Das Ziel der vorliegenden Arbeit war es, die intrinsische Bitterkeit einer 
Vielzahl von (Iso-)Flavonoiden zu untersuchen und Strukturvoraussetzungen für die 
Aktivierung von Bitterrezeptoren durch (Iso-)Flavonoide zu erforschen. Anschließend 
wurden verschiedene Entbitterungsstrategien mit Hilfe des Bitterrezeptor-Assays getestet.  
Im ersten Kapitel wird eine Übersicht über Flavonoide und Isoflavonoide bezüglich 
ihrer Strukturklassifizierung, ihrer sensorischen Eigenschaften und ihres Vorkommens in 
Lebensmitteln gegeben. Außerdem werden Geschmackswahrnehmung und die 
Wirkungsweise von Bitterrezeptoren erklärt. Sowohl der Mechanismus von Bitterrezeptor-
Aktivierung in vitro als auch Strategien zur Verminderung von Bitterrezeptor-Aktivierung 
und Bittergeschmack im Allgemeinen werden beschrieben. Es wird ein aktueller Überblick 
über alle 25 Bitterrezeptoren in Bezug auf bekannte Agonisten und Antagonisten gegeben. 
Das Ziel der im zweiten Kapitel beschriebenen Studie war die Identifizierung der 
Bitterrezeptoren, die den bitteren Geschmack des Soja-Isoflavons Genistein erkennen. Das 
Screening aller 25 menschlichen Bitterrezeptoren ergab, dass Genistein einen Agonisten für 
hTAS2R14 und hTAS2R39 darstellt. Genistein-Wahrnehmungsschwellenwerte lagen bei 4 
und 8 µM für hTAS2R14 und hTAS2R39. Die jeweiligen EC50-Werte waren 29 und 49 
µM. Neben Genistein wurden außerdem Isoflavonoide mit einer genistein-ähnlichen 
Struktur untersucht. Obwohl die zwei Rezeptoren nicht eng verwandt sind, konnten 
ähnliche Resultate für hTAS2R14 und hTAS2R39 für die meisten Isoflavonoid-Aglykone 
erzielt werden. Für hTAS2R39 konnten vier von fünf glykosylierten Isoflavonen (Glycitin, 
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Genistin, Acetyl-Genistin, Malonyl-Genistin) als Agonisten identifiziert werden, 
wohingegen die Aktivierung von hTAS2R14 durch Glykosylierung von Isoflavonen 
verhindert zu werden schien. Eine dreifache Hydroxylierung des A- und B-Rings eines 
Isoflavonoids schien für eine Rezeptor-Aktivierung günstiger zu sein als eine geringere 
Hydroxylierung. Die Konzentration des dreifach-hydroxylierten Genistein liegt in vielen 
soja-basierten Lebensmitteln über dem in dieser Studie bestimmten Grenzwert. Die 
Konzentrationen anderer Soja-Isoflavone liegen dicht bei oder unter ihren 
Wahrnehmungsgrenzwerten. Trotz seiner niedrigen Konzentration könnte Genistein daher 
einer der Hauptverursacher des Bittergeschmacks von Soja-Produkten sein. Da auch die 
bioaktiven Isoflavonoiden Equol und Coumestrol beide Rezeptoren aktivierten, sollte vor 
ihrem Einsatz in Lebensmitteln ihr möglicher sensorischer Einfluss in Betracht gezogen 
werden. 
Im dritten Kapitel wird die intrinsische Bitterkeit, die den Einsatz von (Iso-) 
Flavonoiden als bioaktive Lebensmittelinhaltsstoffe einschränken könnte, genauer 
untersucht. Eine große Anzahl von (Iso-)Flavonoiden mit einander ähnelnden Strukturen 
wurde bezüglich ihres Effekts auf die Bitterrezeptoren hTAS2R14 und hTAS2R39 
untersucht und die strukturellen Voraussetzungen für die Aktivierung dieser Rezeptoren 
wurden vorausgesagt. Insgesamt aktivierten 68 Stoffe hTAS2R14 und 70 Stoffe 
hTAS2R39, wovon 58 Liganden identisch waren. Die Aktivierungsschwellenwerte lagen 
bis zu drei logarithmische Einheiten auseinander, nämlich zwischen 0.12 und 500 µM. 
Ligand-basierte 2D-Fingerprint- und 3D-Pharmakophor-Modelle wurden entwickelt, um 
Struktur-Aktivitäts-Beziehungen bestimmen zu können. Die 2D-Modelle zeigten 
hervorragende Voraussageeigenschaften für die Identifizierung von bitteren (Iso-) 
Flavonoiden und unterschieden diese von inaktiven (Iso-)Flavonoiden. Mit Hilfe der 3D-
Pharmakophor-Modelle konnte für hTAS2R14- und hTAS2R39-aktivierende (Iso-) 
Flavonoidmoleküle bestimmt werden, welche Elemente sie aufweisen müssen, nämlich: 
entweder zwei (hTAS2R14) oder drei (hTAS2R39) Wasserstoffdonoren, einen 
Wasserstoffakzeptor und zwei aromatische Ringstrukturen, wovon mindestens ein Ring 
hydrophobe Eigenschaften aufweisen muss. Ein zusätzliches Wasserstoffdonor-Element für 
hTAS2R39 (verglichen mit hTAS2R14) wies auf die mögliche Anwesenheit eines weiteren, 
komplementären Akzeptor-Elementes im aktiven Zentrum von hTAS2R39 hin. 
Hydrophobe Wechselwirkungen zwischen dem aromatischen Element und dem aktiven 
Zentrum könnten für hTAS2R14 von höherer Bedeutung sein als für hTAS2R39. 
Zusammengenommen können die beiden letzten Eigenschaften erklären, warum OH-reiche 
Stoffe sich gegenüber diesen zwei Bitterrezeptoren anders verhalten. Die Kombination von 
In-vitro-Daten und verschiedenen In-silico-Methoden erlaubten eine gute Einsicht in die 
Aktivierung von hTAS2R14 und hTAS2R39 durch (Iso-)Flavonoide und stellten ein 
leistungsstarkes Instrument für die Voraussage ihrer möglichen Bitterkeit dar. Durch das 
Begreifen des „Bitter-Motives“ könnte das Einbringen eines bitteren Geschmacks in 
funktionelle Lebensmittel durch (Iso-)Flavoinoide verhindert werden. 
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Der Bitterrezeptor hTAS2R39 kann durch viele verschiedene Klassen von 
Bitterstoffen, worunter auch (Iso-)Flavonoide fallen, aktiviert werden. Jedoch sind auch 
einige Flavanone bekannt, die einen bitteren Geschmack maskieren können und nicht alle 
im dritten Kapitel beschriebenen Flavanone aktivierten hTAS2R39. Aus diesem Grund 
wurde im vierten Kapitel für 14 Flavonone untersucht, ob sie die Aktivierung von 
hTAS2R39 durch Epicatechingallat (ECG), einem der Hauptbitterstoffe in grünem Tee, 
reduzieren können. Drei der getesteten Stoffe zeigten einen hemmenden Effekt auf die 
Aktivierung von hTAS2R39 durch ECG: 4’-Fluoro-6-methoxyflavanon, 6,3’-
Dimethoxyflavanon, und 6-Methoxyflavanon (in abnehmender Wirkungsstärke). Die 
getesteten 6-Methoxyflavanone hemmten auch die Aktivierung von hTAS2R14 (einem 
anderen Bitter-Rezeptor, der auch durch ECG aktiviert wird), jedoch in geringerem Maße. 
Sowohl die bei verschiedenen Konzentrationen des wirksamsten Antagonisten 4’-Fluoro-6-
methoxyflavanon gemessenen Dosis-Wirkungs-Kurven von ECG als auch 
Waschexperimente wiesen auf reversiblen unüberwindbaren Antagonismus hin. Da ein 
vergleichbarer Effekt auch für den strukturell anders aufgebauten Agonisten 
Denatoniumbenzoat beobachtet werden konnte, kann von einem nichtkompetitiven 
orthosterischen Mechanismus ausgegangen werden. Die hier identifizierten Bitterrezeptor-
Blocker können wahrscheinlich nicht in Lebensmitteln angewandt werden. Sie tragen 
jedoch zu einem besseren Verständnis von strukturellen Voraussetzungen für 
Bitterrezeptor-Blocker bei und können bei der Identifizierung von für den Einsatz in 
Lebensmitteln geeigneten Blockern helfen.  
Im fünften Kapitel wird eine andere Strategie zur Reduzierung von Bitterkeit 
untersucht: die Komplexbildung von bitteren Flavonoiden mit in Lebensmitteln 
vorkommenden Eiweißen. Der bittere Teeinhaltsstoff Epigallocatechingallat (EGCG) 
wurde bezüglich seiner Bindungseigenschaften zu aufgereinigten Lebensmitteleiweißen 
und ihren entsprechenden Zubereitungen in Lebensmittelqualität untersucht. Diese 
Bindungseigenschaften wurden sowohl zu reduzierter Bitterrezeptor-Aktivierung in vitro 
als auch zu ihren Bitterkeit-Maskierungseigenschaften in vivo in Beziehung gesetzt. Im 
Gegenteil zu β-Laktoglobulin sind vor allem β-Kasein und einige Gelatinearten für ihre 
starke Bindungsneigung mit EGCG bekannt. Auch im Bitterrezeptor-Assay zeigte β-Kasein 
die stärksten Bindungseigenschaften mit einer maximalen Abnahme der Aktivierung von 
hTAS2R39 von ungefähr 93%. Eine vergleichbare Wirkung konnte für Na-Kaseinat, die 
Alternative zu β-Kasein in Lebensmittelqualität, beobachtete werden. Wie bereits durch 
seine niedrige Bindungsaffinität zu EGCG zu erwarten, hatte β-Laktoglobulin einen 
geringen Effekt auf die Bitterrezeptor-Aktivierung. Das Bittermaskierungspotential von Na-
Kaseinat konnte in vivo durch ein sensorisch geschultes Expertenpanel bestätigt werden. 
Auch β-Laktoglobulin konnte die Bitter-Wahrnehmung leicht vermindern. Dieses Ergebnis 
konnte nicht direkt den Bindungskapazitätsergebnissen zugeordnet werden. Das 
Bitterrezeptor-Assay konnte als hilfreiches In-vitro-Instrument für die Einschätzung der 
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Wirkungskraft von Lebensmitteleiweißen als Komplexbildner zu 
Bittermaskierungszwecken eingesetzt werden. 
Im sechsten Kapitel werden sowohl die in der vorliegenden Arbeit beschriebenen 
Ergebnisse als auch die Möglichkeiten und Einschränkungen des Bitterrezeptor-Zell-
Assays diskutiert. Außerdem werden weitere Testergebnisse zu möglichen antagonistischen 
Eigenschaften von (Iso-)Flavonoiden präsentiert und Geschmacksbewertungen durch 
sensorische Tests, Rezeptor-Assays und Modellieren verglichen. Des Weiteren werden 
Strategien zur Reduzierung von Bitterkeit evaluiert und auf Soja-Produkte und Tee 
angewandt. 
Die systematische Untersuchung von (Iso-)Flavonoid-Aglykonen zeigte, dass ihr 
Substitutionsprofil von größerer Bedeutung für die Bitter-Rezeptor-Aktivierung ist als die 
Struktur ihres Molekülskeletts. Für die Funktion von Bitter-Rezeptor-Antagonisten sind 
jedoch sowohl ihr Substitutionsprofil als auch die Struktur ihres Molekülskeletts essenziell. 
Das Bitterrezeptor-Assay konnte als hilfreiches Instrument sowohl für die Identifizierung 
von Bitterrezeptor-Agonisten und -Antagonisten als auch die Identifizierung von 
reduzierter Rezeptor-Aktivierung durch Komplexbildner beschrieben werden. Basierend 
auf den Ergebnissen dieser Arbeit konnte die Komplexbildung mit Lebensmitteleiweißen 
als die erfolgversprechendste Strategie für die Reduzierung des bitteren Geschmacks von in 
Tee vorkommenden Flavonoiden identifiziert werden. Für in Sojabohnen vorkommende 
Isoflavone scheint jedoch die Entbitterung durch die Verwendung von Bitterrezeptor-
Blockern die erfolgversprechendste Strategie zu sein. Neben der Verwendung von 
Rezeptor-Blockern konnten auch Anpassung von Prozessmethoden (dergestalt, dass für 
eine nur geringe Bildung von Isoflavon-Aglykonen gesorgt wird) und die sorgfältige 
Auswahl von Rohstoffen (z.B. Sorten mit niedrigem Genisteingehalt) zur Vermeidung 
eines bitteren Geschmacks empfohlen werden. Abschließend kann festgestellt werden, dass 
die Wahl der Entbitterungsstrategien von der molekularen Struktur des bitteren 
Lebensmittelinhaltsstoffes abhängt. Dies wurde an Hand von soja-basierten Produkten und 
Tee gezeigt. Offensichtlich ist für jedes Lebensmittelprodukt eine maßgeschneiderte 
Entbitterungsstrategie nötig. 
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